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“You never change things by fighting the existing reality. 
To change something, build a new model that makes the existing model 
obsolete.”  
 
R. Buckminster Fuller 
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Abstract 
The purine nucleoside adenosine is an important intermediate metabolite, which 
is released from most cells. It mediates signaling through activation of four 
distinct adenosine receptors (ARs): A1, A2A, A2B, and A3. ARs have been 
recognized as therapeutic targets for a wide range of physiological processes 
and pathophysiological conditions, including epilepsy, chronic pain, ischemia, 
inflammation, and cancer. This has led to the development of various subtype-
specific AR antagonists. By screening a chemical library in vivo, we had 
previously recovered AR antagonists as inhibitors of blood and lymph vessel 
angiogenesis in Xenopus embryos [Kalin et al. 2009 Blood 114, 1110-1122]. 
Here, we assessed the role of adenosine signaling in vascular development in 
Xenopus embryos by testing a panel of subclass-selective AR antagonists for 
anti-(lymph) angiogenic activities. Compound-treated embryos were assessed 
phenotypically for evidence of edema formation, which is a reliable 
pathophysiological indicator of anti-angiogenic activity. Quantitative 
pharmacological parameters, such as EC50, ECmax, and LC50 values, were 
established for each compound. While antagonists selective for A2A, A2B, or A3 
ARs were typically inactive, all A1 AR antagonists were found to induce edema 
with EC50 values ranging from 0.3 to 6.7 µM. However, only two compounds, 7-
chloro-4-hydroxy-2-phenyl-1, 8-naphthyridine (7CN) and 1,3 Diethyl-8-
phenylxanthine (DEPX), had potent anti-angiogenic activities in vivo. 
Subsequently, structure-activity relationship studies led to the identification of 
two additional compounds, 7-methyl-2-phenyl-1, 8-naphthyridine (7MN) and 
1,3-dipropyl-8-phenylxanthine (DPPX), equally capable of disrupting vascular 
development in Xenopus embryos. Treatment of primary human endothelial cell 
cultures demonstrated that only 7CN and 7MN but not DEPX and DPPX disrupted 
cell proliferation and VEGF-induced sprouting in vitro. Gene expression and 
knockdown studies in Xenopus embryos failed however to provide evidence for a 
central role of A1 ARs in vascular development. This suggests that the 
antiangiogenic activities of 7CN and 7MN may be due to polypharmacology 
involving inhibition of other targets than A1 ARs alone. In fact, we found that 
7CN and 7MN induced destabilization of microtubules, mitotic arrest, and excess 
DNA replication in endothelial cell cultures. Taken together, phenotypic 
compound profiling in Xenopus embryos has led to the identification of 7CN and 
7MN as promising drug candidates that act as potent anti-angiogenic compounds 
interfering with essential endothelial cell functions.  
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Zusammenfassung 
Das Purinnukleosid Adenosin ist ein wichtiger Metabolit, der von vielen Zellen 
freigesetzt wird. Adenosin wirkt als Signalmolekül mittels Aktivierung von vier 
verschiedenen Adenosinrezeptoren (AR): A1, A2A, A2B und A3. AR dienen als 
vielversprechende Angriffspunkte für die Entwicklung von Arzneimitteln zur 
Modulation einer breiten Palette von physiologischen Prozessen und 
pathophysiologischen Zuständen, einschliesslich Epilepsie, chronischen 
Schmerzen, Ischämie, Entzündungen und Krebs. In der Folge wurden 
verschiedene subtypspezifische AR-Antagonisten entwickelt. Mittels eines In Vivo 
Screening-Verfahrens hatte unsere Arbeitsgruppe zuvor mehrere AR-
Antagonisten einer chemischen Bibliothek als Inhibitoren der Blut- und 
Lymphgefässangiogenese in Xenopus Embryonen identifziert [Kalin et al. 2009 
Blood 114, 1110-1122]. In der vorliegenden Arbeit untersuchten wir mittels 
einer Reihe von subklassenselektiven AR-Antagonisten die Rolle der 
Signalwirkung von Adenosin bei der Bildung des Gefässsystems in Xenopus 
Embryonen. Insbesondere wurde nach anti-lymphatischen bzw.                          
-angiogenetischen Aktivitäten in vivo gesucht. Wirkstoff-behandelte Embryonen 
wurden phänotypisch beurteilt und auf Ödembildung als zuverlässigen 
pathophysiologischen Indikator für anti-angiogenetische Aktivitäten untersucht. 
Für jede Verbindung wurden quantitative pharmakologische Parameter, wie EC50, 
ECmax und LC50, ermittelt. Typischerweise waren A2A-, A2B- oder A3-AR-selektive 
Antagonisten inaktiv. Hingegen waren alle A1 AR-Antagonisten aktiv und 
induzierten Ödeme mit EC50-Werten von 0.3 bis 6.7 µM. Allerdings besassen nur 
zwei Verbindungen, 7-Chloro-4-hydroxy-2-phenyl-1, 8-naphthyridin (7CN) und 
1,3 Diethyl-8-phenylxanthin (DEPX), starke anti-angiogenetische Aktivitäten in 
vivo. Anschliessend wurden Studien zur Struktur-Wirkungs-Beziehung 
durchgeführt. Diese führten zur Identifizierung von zwei zusätzlichen 
Verbindungen, 7-Methyl-2-phenyl-1, 8-naphthyridin (7MN) und 1,3-Dipropyl-8-
phenylxanthin (DPPX), die in der Lage waren, die Gefässbildung in Xenopus 
Embryonen zu stören. Die Behandlung von primären humanen 
Endothelzellkulturen zeigte dann, dass nur 7CN und 7MN, aber nicht DEPX und 
DPPX, in der Lage waren die Proliferation und das VEGF-induzierte Sprouting in 
vitro zu unterbinden. Umfangreiche Genexpressions- und Knockdown-Studien 
lieferten keine Hinweise für eine zentrale Rolle von A1 AR bei der vaskulären 
Gefässbildung in Xenopus Embryonen. Dies weist darauf hin, dass die anti-
angiogenetischen Aktivitäten von 7CN und 7MN vermutlich auf 
Polypharmakologie zurückzuführen sind und sich nicht durch die alleinige 
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Hemmung von A1 ARs erklären lassen. In der Tat fanden wir, dass die 
Behandlung von  endothelialen Zellkulturen mit 7CN und 7MN zu einer 
Destabilisierung des mikrotubulären Zytoskeletts, einer Blockierung der Mitose 
und zu übermässiger DNA Replikation führten. Zusammengenommen hat die 
phänotypische Charakterisierung von AR Antagonisten in Xenopus Embryonen 
zur Identifizierung von 7CN und 7MN als viel versprechende Wirkstoffkandidaten 
geführt. Beide Verbindugen haben potente anti-angiogenetische Aktivitäten, 
welche wesentliche endotheliale Zellfunktionen stören. 
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A chemical genetic screen in Xenopus embryos defines adenosine 
receptor antagonists as modulators of the vasculature 
The vasculature comprises of an extensively branched network, and is among 
the first organ systems to develop within the developing embryo. In vertebrates, 
two vascular systems exist, namely the blood vasculature and the lymphatic 
vasculature, which are hierarchical networks of vessels lined by endothelial cells 
(Schuermann et al., 2014, Neufeld et al., 2014). The blood vasculature is 
comprised of arterial vessels carrying oxygenated blood from the lungs via the 
heart to the periphery, whereas venous vessels return oxygen-depleted blood to 
the lungs to discharge CO2. The lymphatics represent a separate vessel system 
that permeates the body and communicates with the blood vasculatures via 
thoracic duct, which drains lymph into the blood circulation (Fig. 1). Besides the 
transport of oxygen and CO2, the physiological roles of the blood vasculature 
include the transport of nutrients, signaling molecules, and immune cells to all 
tissues and organs of the vertebrate body. Key functions attributed to the 
lymphatic vasculature include roles in immune regulation, tissue fluid 
homeostasis, the uptake of dietary fats, and the absorption of excess 
extravasated protein-rich fluids from the interstitial spaces and their return to 
the blood circulation (Stacker et al., 2014, Schuermann et al., 2014). 
 
 
 
Figure 1. Schematic illustration of the 
relationship between the blood circulation 
and the lymphatic system. The blood vessels 
form a closed circulatory system composed of 
arteries (red) and veins (blue). The lymphatic 
system (green) forms a one-way conduit for 
tissue fluidd and leukocytes. Tissue fluids are 
drained by lymph capillaries and transported by 
a series of larger lymphatic vessels into the 
venous blood circulation. Picture is modified 
from www.softchalk.com. 
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Unlike most other organs of the adult body, the vasculature has a remarkable 
capacity to grow and extend also in adult organism. This can occur as a natural 
process, for example as a response to hypoxia to meet increased needs for 
oxygenation, during the female menstrual cycle, or as part of the wound healing 
process (Guo and Dipietro, 2010, Demir et al., 2010). By contrast, misregulation 
of vessel growth is observed as a hallmark of several different pathological 
conditions and human diseases. For example, an involvement of blood and 
lymph vessel has been found in chronic inflammatory diseases, like psoriasis, 
inflammatory bowel disease, and rheumatoid arthritis (Carmeliet, 2003, 
Roudnicky et al., 2013). Furthermore, tumor growth is usually accompanied by 
the release of vascular endothelial growth factor (VEGF) triggering the sprouting 
of new blood vessels from existing vascular beds to fulfill the increased 
requirements for nutrients and oxygen in the expanding tumor tissue (Dome et 
al., 2007). Finally, the tumors induce lymphangiogenesis to promote tumor 
metastasis via lymph nodes by releasing vascular endothelial growth factors 
(VEGFB, VEGFC) and the activation of VEGF receptor signaling through VEGFR2 
and VEGFR3 (Makinen et al., 2001). The ability to influence or modulate blood 
and lymph vessel growth using small organic molecules or specific antibodies 
could therefore be beneficial in tumor therapy or any other disease, where 
pathological blood or lymph vessel growth is observed. For example, 
Bevacizumab, commercially known as Avastin, is a humanized anti-VEGF 
monoclonal antibody that was the first anti-angiogenic therapeutic agents 
approved for cancer treatment. Avastin inhibits all isoforms of VEGF to reduce 
angiogenesis, tumor growth, and metastasis. Avastin is currently used in 
chemotherapy against different types of cancers including colorectal, lung, 
breast, and brain cancer (Greillier et al., 2016, Shih and Lindley, 2006). 
A better understanding of vascular and lymphatic development may provide 
novel drug targets to treat various pathologies associated with dysregulated 
vascular growth and function. Over the years, different approaches have 
therefore been used to define molecular determinants and signaling pathways 
regulating angiogenesis and lymphangiogenesis (Corada et al., 2014). This 
includes the identification of genes underlying hereditary diseases of the 
vasculature and lymphatics in the human population, the study of candidate 
genes using reverse-genetics approaches, and genetic screens in model 
organisms, such as zebrafish (Habeck et al., 2002, Jin et al., 2007). Chemical 
genetics uses small organic molecules to perturb biochemical pathways and to 
identify potential drug targets with efficacy in modulating biological processes 
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(Schenone et al., 2013). Larvae of aquatic organisms, such as fish and 
amphibians, are particularly attractive for chemical genetic screening approaches 
(Wheeler and Brandli, 2009). First, they represent whole organisms with fully 
functional organs. Second, they are small enough to be cultured in multiwell 
dishes. Finally, they are sufficiently abundant to envisage the screening of 
thousands of chemical compounds for suitable bioactivity in vivo. Chemical 
genetics therefore represents an interesting alternative to the above-mentioned 
genetic approaches in order to define drug candidates targeting the vasculature 
in living organisms.  
Our laboratory had developed in the past an unbiased chemical genetic 
screening strategy to identify small organic molecules that could interfere with 
blood and/or lymph vessel development or function in vivo (Kalin et al., 2009). 
About 36 hours post fertilization, Xenopus embryos initiate the development of 
blood and lymphatic vessel systems, which subsequently become fully functional 
(Ny et al., 2005, Helbling et al., 2000). Edema formation, i.e. abnormal fluid 
accumulation in tissue and organs, was selected as a pathophysiological read-
out indicating an imbalance of fluid homeostasis caused by disruption of blood 
and/or lymphatic vessel functions. Edema formation is a simple phenotypic trait 
that can be easily scored in Xenopus embryos and tadpoles using a 
stereomicroscope. The whole-organism based screening strategy was comprised 
of two steps (Fig. 2).  
First, Xenopus embryos were arrayed in 48-well dishes and treated with 
compounds from a chemical library. Compounds inducing edema or late lethality 
were identified and selected for a secondary screen. In the secondary screen, 
whole-mount in situ hybridization was used to visualize the integrity of the blood 
and lymphatic vessel systems of compound-treated embryos. Using this 2-step 
screening strategy, a commercial chemical library of 1280 pharmacologically 
active compounds (LOPAC1280, Sigma-Aldrich) were tested at a concentration of 
20 µM. In total, 32 bioactive compounds emerged that interfered with 
angiogenesis and/or lymphangiogenesis in vivo from the chemical screen (Kalin 
et al., 2009). They could be grouped into three distinct categories. Compounds 
that affected blood vessel development only; compounds selectively interfering 
with lymph vessel formation; and those interfering with both blood and 
lymphatic vessel. Importantly, two known VEGFR inhibitors (SU4312, SU5416) 
were identified as bioactive compounds, which validated the phenotypic in vivo 
screening strategy. 
Introduction 
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Figure 2. Two-step whole-organism based chemical library screening strategy to identify 
modulators of vascular development in Xenopus embryos. In first step, embryos are cultured in 
multi-well dishes, which contain per well a single compound from a chemical library. Embryos are 
visually scored for late lethality or the presence of edema. In a second step, whole-mount in situ 
hybridization of compound-treated embryos was performed to identify those compounds interfering with 
vascular development. Figure taken from Kalin et al. (2009). 
 
The study also identified novel compounds, not previously known to interfere 
with blood and/or lymph vessel development. For example, this included two 
compounds (1, 3-Diethyl-8-Phenylxanthine, DEPX; 7-Chloro-4- hydroxy-2-
phenyl- 1,8-naphthyridine, 7CN) known as antagonists that disrupted signaling 
of G-protein coupled receptors (GPCRs) of the adenosine receptor (AR) 
subfamily. DEPX and 7CN were effective at disrupting both blood and lymphatic 
vessel development in Xenopus embryos. Furthermore, 7CN blocked proliferation 
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and tube formation of human endothelial cells in vitro. Finally, 7CN inhibited 
VEGF-induced angiogenesis and lymphatic vessel enlargement in the mouse 
(Kalin et al., 2009). Collectively, these findings indicate a role for members of 
the AR family of GPCRs in vascular development and function in Xenopus, 
mouse, and humans. The fact that the in vivo chemical screening strategy led to 
the identification of two chemically distinct AR antagonists (DEPX, 7CN) further 
strengthens this notion.  
Many open questions still remain. What are the half-effective doses of DEPX and 
7CN that cause edema formation in Xenopus embryos? Are there other than 
vascular defects observed in DEPX- or 7CN-treated embryos? What are the 
doses causing lethality in 50% of the treated embryos? What are the molecular 
targets of DEPX and 7CN? Are there other AR that antagonists disrupt vascular 
development in vivo? The present thesis is aimed at providing answers to the 
questions raised here.  
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G-protein coupled receptors constitute key mediators of cellular 
response 
The anti-angiogenic compounds DEPX and 7CN identified by phenotypic drug 
screening in Xenopus embryos (Kalin et al., 2009) target the adenosine receptor 
(AR) family of G protein-coupled receptors (GPCRs), which are important 
sensors of extracellular signals. In all living organisms, cell-cell communication 
represents a vital process for the regulation of various physiological functions. 
Cells respond to signals from the extracellular environment, through activation 
of membrane receptors. These receptors convert the external cues into 
intracellular signals that activate or suppress specific biochemical pathways. 
Ultimately, this will trigger cell-specific responses, such as morphological 
changes and differential gene expression. Guanylyl-nucleotide-binding protein-
coupled receptors, also known as G protein-coupled receptors (GPCRs), 
represent the largest superfamily of cell surface receptors present in vertebrate 
genomes (Fredriksson et al., 2003, Lagerstrom and Schioth, 2008). They are 
able to respond to a wide range of chemically diverse signals, which includes 
ions, amines, amino acids, hormones, lipids, peptides, organic odorants, and 
even photons. GPCRs play vital roles in regulating numerous aspects of human 
physiology such as vision, smell, and taste, the immune response, cellular 
metabolism, signal transmission in the nervous system, angiogenesis, endocrine 
signaling, reproduction, and many others. Given their central role in cellular 
signaling and in the regulation of important physiological functions of the human 
body, GPCRs have become important therapeutic targets (Salon et al., 2011, 
Overington et al., 2006). Currently, about 30-50% of all approved drugs act 
through modulating GPCR function (Lagerstrom and Schioth, 2008). 
The human genome encodes more than 800 distinct GPCR genes and they 
constitute the largest gene family of cell surface receptors (Jassal et al., 2010, 
Fredriksson et al., 2003). GPCRs are embedded in the cell membrane and they 
all share a common topology consisting of a seven transmembrane (7TM) alpha-
helical fold. The seven transmembrane (7TM) helices form a bundle that is 
interlinked by three extracellular (ECL) and three intracellular loops (ICL). The 
extracellular (EC) region, which may include a sizeable amino terminus, plays an 
important role in the activation of the receptor. It is responsible for the 
recognition and binding of ligands and participates in transmitting signals across 
the membrane (Schulte and Levy, 2007, Ji et al., 1998). Ligand binding induces 
conformational changes in the EC region and in the 7TM bundle. This will 
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subsequently lead to structural reorganizations affecting the three ICLs and the 
C-terminus on the cytoplasmic side enabling the binding of intracellular 
effectors, such as heterotrimeric G proteins (Unal and Karnik, 2012).  
 
Structural diversity of the GPCR superfamily 
More than 4% of all genes present in the human genome encode for GPCRs, 
which comprise the largest superfamily of integral membrane proteins. GPCRs 
are characterized by a similar 7TM topology and they share highest sequence 
homology in the TM domains. Structural diversity is mainly confined to the 
amino- and carboxy-terminal domains (Kobilka, 2007). The overall sequence 
identity between GPCRs is low and even for the TM domains it is typically less 
than 20%. On the basis of sequence and structural similarities, the GPCR 
superfamily is commonly divided into five major classes and numerous 
subfamilies (Cobanoglu et al., 2011, Fredriksson and Schioth, 2005, Fredriksson 
et al., 2003). A phylogenetic tree of the human GPCR superfamily is shown in 
Fig. 3. Class A, also known as Rhodopsin family, is the largest family of GPCRs 
comprising approximately 700 human receptor proteins (Krishnan et al., 2012, 
Jassal et al., 2010). They bind a diverse range of ligands, including amines, 
purines and peptides. Furthermore, they are targets for the majority of drugs in 
clinical use that interfere with GPCR functions (Tyndall and Sandilya, 2005). 
Class A is further divided in four subgroups: α, β, γ, and δ; and they consist of 
many prominent GPCR genes. Rhodopsin (RHO), cannabinoid (CNR) and 
adenosine receptors (ADORA) belong to subgroup α; endothelin (EDNRA, 
EDNRB) and neuropeptide Y (NPY1R, NPY2R, NPY5R) receptors are part of β 
group; subgroup γ contains chemokine receptors (CCR, CXCR), angiotensin 
receptors (AGTR) and melanin-concentrating hormone receptors (MCHR1, 
MCHR2); and δ group harbors follicle stimulating hormone receptor (FSHR) and 
purinergic receptors (P2Y) among others. With 388 distinct genes, olfactory 
receptors represent the biggest gene cluster in δ group of the Rhodopsin family 
of GPCRs (Lagerstrom and Schioth, 2008, Krishnan et al., 2012). Class B is the 
second largest GPCRs family and it contains two subfamilies: the Secretin and 
adhesion receptor families. The Secretin receptor family (15 genes) is 
characterized by an extracellular hormone-binding domain, which mainly 
recognizes peptides hormones. Adhesion receptor family is comprised of 33 
members, which contain GPCR proteolytic (GPS) domains. Secretin receptor 
family members do not have GPS domains and they differ in the N-termini from 
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Adhesion receptors. For these reasons, they are classified separately 
(Fredriksson et al., 2003).  
The classification of GPCRs put forward by Fredriksson et al. in 2003 has to date 
been largely upheld. With the improvements in annotating the human genome, 
the total number of human GPCRs has however increased to 836 genes (Cvicek 
et al., 2016). Furthermore, vomeronasal receptors (VNR) have been recognized 
as a separate class, since they have little similarity to other families of GPCRs. 
They appear to be distantly related to TAS2 and rhodopsin-like GPCRs. Table 1 
provides the current gene numbers by GPCR class.  
Table 1. Number of human GPCR genes by class 
Class Genes Class Genes 
A - alpha 88 B – Secretin 16 
A - beta 33 B – Adhesion 33 
A - gamma 57 C – Glutamate 22 
A - delta 58 Frizzled/TAS2 36 
A - other 51 Vomeronasal 5 
A - Olfactory 418 Other 11 
Class A and class B are comprised of 705 and 49 genes, respectively. “Other” refers to currently 
unclassified GPCRs. Table adapted from Cvicek et al. (2016).  
 
Introduction 
10 
 
 
Figure 3. Human GPCR superfamily sequence homology tree. The phylogenetic tree was 
constructed based on sequence similarity in the seven transmembrane domains. The tree shows the five 
major families of GPCRs: Rhodopsin family (class A); Secretin and Adhesion families (class B); 
Glutamate family (class C) and Frizzled/taste 2 receptors (TAS2) family. The Rhodopsin family is further 
divided into subfamilies: the α-group, the β-group, the γ-group, and the δ-group as indicated. The δ-
group also contains the olfactory receptors. Only four olfactory receptors are shown, but they comprise 
the largest distinct group with 388 receptors. Figure was adapted from Stevens et al. (2013).  
 
The class C or Glutamate receptor family is comprised of 22 human GPCR 
proteins, which includes GPRC6A, eight metabotropic glutamate receptors 
(GRMs), two GABBRs, seven orphan receptors and the calcium-sensing receptor 
(CASR) (Lagerstrom and Schioth, 2008). Most members of the Glutamate family 
have long N-termini with contain cysteine rich domains (CRD), which distinguish 
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them from other GPCR families. The Frizzled/Taste 2 receptor (TAS2) family 
includes two distinct clusters, the frizzled receptors and the TAS2 receptors. The 
frizzled branch contains the smoothened receptor (SMO) and the ten frizzled 
receptors (FZD1-10). SMO acts in a ligand-independent manner in the regulation 
of the hedgehog signaling pathway (Amakye et al., 2013). By contrast, the 
binding of Wnt glycoprotein family members activates FZD signaling (MacDonald 
and He, 2012). Finally, the Taste2 receptor (TAS2) family embraces 25 distinct 
TAS2 genes in human genome; with all of them confined to chromosomes 9 and 
12. Fig. 4 provides an overview of the key structural features of the different 
GPCR families and their ligands. Diversity is associated with the extracellular 
domains, while the characteristic arrangement of the TM domains is shared. The 
ability of their extracellular domains to interact with small organic molecules has 
rendered GPCRs the targets of a substantial proportion of the currently approved 
drugs on the market (Tesmer, 2016, Wise et al., 2002). 
 
Figure 4. GPCR subfamilies and their ligands. The diversity of extracellular domains is evident, 
whereas the topology of the TM domains is conserved. Numbers in parentheses correspond to the 
number of GPCR genes identified for each family shown in the human genome. Olfactory GPCRs are 
included in the rhodopsin family. Members of the TAS2 and vomeronasal families are not shown, as they 
lack analogous extracellular domains (ECD). Complete listing of the human GPCR gene numbers is 
provided in Table 1. The Venus fly trap domains (VFD) mediate dimerization of glutamate receptors. 
Adhesion receptors contain GPCR autoproteolysis-inducing domains (GAIN) that cleave the ECD. The 
mature receptors exist therefore as two non-covalently associated subunits. GPCR ligands are shown in 
blue and the location of their binding sites are shown. Wnts are ligands for GPCRs of the Frizzled 
subfamily. These ligands are modified covalently by palmitoylation (jagged line) and bind to the 
cysteine-rich domains (CRD) of the receptors. Figure adapted and modified from Tesmer (2016). 
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Guanosine nucleotide-binding proteins 
GPCRs transduce signals by activating effector proteins, called guanosine 
nucleotide-binding proteins or G proteins, which are members of a group of 
enzymes known as GTPases (Ross and Wilkie, 2000, Oldham and Hamm, 2008). 
G proteins are heterotrimeric protein complexes containing three subunits: Gα, 
Gβ, and Gγ. Typically, mammalian genomes harbor genes for 16 distinct Gα 
subunits, 7 Gβ subunits, and 11 Gγ subunits (Hurowitz et al., 2000). The Gα 
subunit genes encode for GTP-binding proteins and comprise the biggest family 
of G protein subunits (Fig. 5). They are further divided into four classes: Gαs, 
Gαi/Gαo, Gαq/Gα11, and Gα12/Gα13. They are widely expressed through out the 
body and interfere with different signaling pathways and ion channels. Gαs is 
responsible for the stimulation of adenylyl cyclase. Gαi inhibits adenylyl cyclase 
and is also responsible for the activation of G-protein-coupled inwardly rectifying 
potassium (GIRK) channels. Gαq acts by regulating phospholipase C (PLC), which 
converts phosphatidylinositol bisphosphate (PIP2) into diacylglycerol and inositol 
triphosphate (IP3). Finally, Gα12 activates Rho guanine-nucleotide exchange 
factors (GEFs). The biochemical functions and primary gene expression domains 
of α subunits of trimeric G proteins are compiled in Fig. 5. The G protein β and γ 
subunits are important for the formation of the heterotrimeric protein complex 
(Smrcka, 2008, Worzfeld et al., 2008). After GPCR activation, the Gα subunit 
harboring the GTPase activity dissociates from heterotrimeric complex, but Gβγ 
remains composed and is called the Gβγ complex. Gβγ complexes do not contain 
catalytic activity, they exert their downstream effects through regulation of ion 
channels by protein-protein interaction. Furthermore, they regulate second 
messenger signaling.  
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Name Expression Effector  
 
Gαs class 
Gαs Ubiquitous AC↑ 
Gαolf Olfactory epithelium, brain AC↑ 
 
Gαi/Gαo class   
Gαi1 Widely distributed 
} AC↓ (directly regulated) Gαi2 Ubiquitous 
Gαi3 Widely distributed 
   
Gαo Neuronal, neuroendocrine VDCC↓, GIRK ↑    
Gαz Neuronal, platelets AC↓, Rap1GAP 
   
Gαgust Taste cells, brush cells Unknown 
Gαt-r Retinal rods, taste cells PDE ↑  
Gαt-c Retinal rods PDE ↑ 
   
Gαq/Gα11 class   
Gαq Ubiquitous 
} PLC-β↑ Gα11 Almost ubiquitous 
Gα14 Kidney, lung, spleen 
Gα15/16 Hematopoietic cells 
   
Gα12/Gα13 class   
Gα12 Ubiquitous PDZ-RhoGEF/LARG, others 
Gα13 Ubiquitous Lsc, PDZ-RhoGEF/LARG, others 
Figure 5. Classification, expression, and function of G protein α subunit family members. The 
primary expression domains of the different α subunits and the key effectors are listed. Abbreviations: 
AC, adenylyl cyclase; GIRK, G-protein-regulated inward-rectifier potassium channel; PDE, 
phosphodiesterase; PDZ, PSD95–Disc-large–ZO-1; PLC, phospholipase C; RhoGEF, Rho guanine 
nucleotide exchange factor; VDCC, voltage-dependent Ca2+-channel. The figure is taken from Worzfeld 
et al. (2008). 
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GPCR activation and signaling 
GPCRs are activated by ligand binding (Dorsam and Gutkind, 2007, Conn et al., 
2009, Kenakin, 2010). While the endogenous GPCR ligands can come in many 
different flavors, such as ions, biogenic amines, amino acids, peptides, 
hormones, and lipids (Fig. 4), they all activate GPCR signaling by occupying a 
receptor-specific extracellular ligand-binding pocket, known as the orthosteric 
site. This causes subtle conformation changes in the GPCR structure triggering 
activation of trimeric G protein signaling on the intracellular side. GPCR ligands 
can work in two ways (Wootten et al., 2013). As classical agonists, they 
stimulate GPCR signaling by binding to the orthosteric binding site. In contrast, 
the binding of antagonists blocks GPCR activation. Antagonists that do so by 
binding to the orthosteric site, where they may displace the activating agonist, 
are known as inverse agonists. The detailed knowledge about the interaction of 
GPCR ligands with their orthosteric binding sites has been essential for the 
development of therapeutics targeting GPCR signaling  (Katritch et al., 2012).  
A single GPCR can couple to one or more distinct trimeric G proteins. In their 
resting stage, trimeric G proteins interact with GPCRs and they have GDP bound 
to the Gα subunit. Agonist-induced GPCR activation triggers the exchange of 
GDP for GTP and the dissociation of the Gα subunit from the Gβγ subunits. After 
dissociation, Gα-GTP and the Gβγ heterodimers have the capability to interfere 
with different effectors to regulate intracellular signaling pathways. This is 
achieved by regulating enzymatic effectors, like phoshopholipase C (PLC) 
isoforms, adenylate cyclase or ion channels, which in turn triggers the 
generation or release of small molecules (cAMP, Ca2+) referred to as second 
messengers. They control intermediary metabolism by modulating the activities 
of protein kinases, such as PKA (via cAMP) and PKC (via Ca2+) (Luttrell, 2008). 
Typically, Gαs family members cause an increase in intracellular cAMP 
concentration by stimulation of adenylyl cyclase, whereas members of Gαi /Gαo 
class lower cAMP levels by inhibition of adenylyl cyclase or stimulation of 
phosphodiesterases (PDE) (Fig. 5, 6).  The Gαq/Gα11 class activates 
phospholipase C, which cleaves PIP2 to diacylglycerol and IP3, ultimately 
increasing intracellular Ca2+ levels. Besides the regulation of the classical 
second-messenger generating pathways, members of the Gα12/Gα13 class and 
Gβγ subunits control key intracellular signal-transducing effectors, including 
small GTP-binding proteins of the Ras and Rho classes, guanine nucleotide 
exchange factors (GEF) and various serine-threonine kinases (MAPK, ERK, JNK), 
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which remain to be fully elucidated. Ultimately, the activation of GPCR-regulated 
signaling networks controls many cellular functions, such proliferation, 
differentiation, migration, and survival. Importantly, disregulation of GPCR 
signaling can contribute to pathophysiological processes, such as cancer 
progression and metastasis (Dorsam and Gutkind, 2007).  
 
Figure 6. Diversity of GPCRs activation and signaling. Various ligands use GPCRs to transmit 
extracellular signals into the cell to regulate membrane, cytoplasmic, and nuclear targets. This will elicit 
a wide range of biological responses, such as cell proliferation, survival, differentiation, and migration. 
Abbreviations: 5-HT, 5-hydroxytryptamine; ECM, extracellular matrix; ERK, extracellular signal-
regulated kinase; JNK, c-jun N-terminal kinase (JNK); GABA, gamma-aminobutyric acid; GEF, guanine 
nucleotide exchange factor; GRK, G protein receptor kinase; IP3, inositol triphosphate; LPA, 
lysophosphatidic acid; PI3K, phophatidylinositol 3-kinase; PIP, phosphatidylinositol bisphosphate; PKA, 
protein kinase A; PKC, protein kinase C; PLC, phospholipase C; S1P, sphingosine-1-phosphate. Figure 
taken from Dorsam and Gutkind (2007).  
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Adenosine 
The endogenous purine nucleoside adenosine is an important intermediate 
metabolite, composed of adenine and ribose. It is a component of the biological 
energy currency ATP and serves as building block for nucleic acids (Chen et al., 
2013, Borea et al., 2016). In addition, extracellular adenosine acts as a signaling 
molecule to mediate various physiological and pathological effects through 
activation of a family of GPCRs, known as adenosine receptors (AR). Intracellular 
adenosine is primarily produced by ATP breakdown to AMP followed by 
hydrolysis, which can occur during physical exercise and ischemic conditions. 
ATP can be released from cells via multiple processes, where it can activate its 
own receptors, such as P2X ionotropic ion channels and P2Y metabotropic 
GPCRs. Furthermore, it serves as an important source for extracellular 
adenosine. ATP release mechanisms include vesicular exocytosis, passage 
through channels, and cell lysis. Fig. 7 shows the pathway of ATP and ADP 
breakdown to adenosine (Roberts et al., 2014, Chen et al., 2013). In a first step, 
the extracellular enzyme ectonucleoside triphosphate diphosphohydrolase 1 
(ENTPD1, CD39) breaks ATP as well as ADP down to AMP. The final critical step 
is the conversion of AMP to adenosine by ecto-5’ nucleotidase (NTSE, CD73). 
The action of these enzymes will rapidly and efficiently shift signaling of released 
adenine nucleotides to adenosine-mediated GPCR signaling. An alternative 
source of extracellular adenosine is the release of intracellularly generated 
adenosine via the equilibrative nucleoside transporters ENT1 and ENT2. Once 
generated, adenosine can be removed from extracellular spaces by adenosine 
deaminase (ADA) to form inosine. Typically, reasonable high levels of adenosine 
are present in cells because of its involvement in several different metabolic 
pathways, and therefore intracellular concentrations of adenosine can never 
reach zero (Chen et al., 2013). 
 
 
Introduction 
17 
 
 
Figure 7. Structures and extracellular degradation of ATP to adenosine. (A) Structures of ATP 
and the breakdown products leading to adenosine and inosine. (B) Schematic representation of 
extracellular ATP catabolism. See main text for abbreviations. Panel B is a modified version a figure 
taken from Roberts et al. (2014).  
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The adenosine receptor family of GPCRs 
Adenosine serves as a signaling molecule by exerting its influence through the 
activation of four distinct GPCRs of the adenosine receptor (AR) subfamily: A1, 
A2A, A2B, and A3 (Fredholm et al., 2011). Each AR has a unique ligand selectivity, 
activation profile, tissue distribution, and G protein binding preference. The 
corresponding human genes encoding the four ARs are denoted ADORA1, 
ADORA2A, ADORA2B, and ADORA3, respectively. All vertebrate genomes, 
including amphibians, harbor a complement of four AR genes. The key properties 
and biochemical features of the human AR subtypes are summarized in Table 2. 
ARs, as GPCRs, share the structural motif of a single polypeptide chain forming 
seven transmembrane (7TM) helices, with the N-terminus being extracellular 
and the C-terminus located in the cytoplasm. The primary sequence lengths vary 
between 318 to 412 amino acids and they share a relatively high degree of 
overall amino acid sequence identity ranging between 31 to 46% (Piirainen et 
al., 2011). For example, the A1 AR has higher sequence identity to A3 (46%) 
than to either A2B (42%) or A2A (37%). Three intracellular (ICL) and three 
extracellular (ECL) loops connect the seven TM helices, consisting of 25-30 
residues each. Helix 8 is located on the cytoplasmic side and does not cross the 
membrane. The variation in sequences length between ARs can be attribute to 
differences in the length of the C-terminal segment. The A2A AR has C-terminus 
of more than 120 amino acids. The C-terminal domain is not required for 
coupling to trimeric G proteins, but may serve as a binding site of accessory 
proteins modulating AR-subtype specific activities (Zezula and Freissmuth, 
2008). All ARs harbor potential N-linked glycosylation sites located in the ECLs, 
but the glycosylation state does not appear to alter the ligand binding properties 
(Piirainen et al., 2011). Furthermore, several tyrosine and serine/threonine 
phosphorylation sites have been predicted in both the cytoplasmic domains and 
the C-termini of all four ARs. Apart from A2A, all ARs have potential 
palmitoylation sites at the end of helix 8. Removal of palmitoylation sites by 
mutagenesis appears to influence receptor degradation and phosphorylation, 
whereas no effects were seen with G protein binding (Piirainen et al., 2011). For 
example, depalmitoylation of A1 AR increases the phosphorylation of the 
receptor by GPCR kinases (GRKs) resulting in rapid desensitization of receptor 
(Gao et al., 1999).  
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Table 2. Primary sequence and key properties of human ARs 
Subtype Gene Chromosomal 
location 
G protein 
α subunits 
Length 
[Residues] 
Predicted 
MW [Da] 
Adenosine 
Potency* 
[nM] 
A1 ADORA1 1q32.1 Gi, Go 326 36,512 1-10 
A2A ADORA2A 22q11.23 Gs, Golf 412 44,707 30 
A2B ADORA2B 17p12-p11.2 Gs, Gq 332 36,333 1000 
A3 ADORA3 1p13.2 Gi, Go, Gq 318 36,185 100 
*Adenosine potency is approximately EC50. Table adapted from Piirainen et al. (2011), Chen et al. 
(2013) and Jacobson & Müller (2016).  
 
AR signaling and biological functions 
The basal physiological levels of extracellular adenosine have been estimated to 
range between 30-200 nM (Ballarin et al., 1991). From the baseline levels, 
adenosine concentrations can vary substantially as a consequence of many 
biological variables, such as tissue type and stress experienced, which can affect 
adenosine production from intracellular adenosine sources, adenosine 
metabolism to inosine or AMP, extracellular adenosine production or adenosine 
transport (Smrcka, 2008, Jacobson and Gao, 2006, Chen et al., 2013). Extreme 
physiology, such as strenuous exercise, will raise extracellular adenosine to the 
low micromolar range and under pathological conditions of ischaemia they can 
increase to 30 µM (Chen et al., 2013, Jacobson, 2009). The affinity of ARs for 
their natural ligand adenosine varies with the subtype (Table 2). In addition, 
inosine can also act as a partial agonist for A1 and A3 ARs (Fredholm et al. 
2011). Highest affinities for adenosine (1-30 nM) are observed for the A1 and the 
A2A ARs. For A3 AR, adenosine affinity is intermediate (100 nM) and A2B has the 
lowest at about 1 µM. Basal extracellular adenosine levels would therefore only 
be sufficient to partially activate the ARs present. Apart from varying affinities, 
the ability of adenosine to stimulate ARs is dependent on the number of ARs 
present on the cell surface, and this number can change depending on the 
circumstances (Chen et al. 2013; Jacobson & Müller 2016).  
ARs participate in many normal physiological functions, which include the 
regulation of renal blood flow, immune functions, blood circulation, cardiac 
rhythm, angiogenesis, sleep, and neuromodulation. On the other hand they also 
play important roles in pathological processes, such as neurodegenerative 
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disorders, inflammatory diseases, ischemia-reperfusion, and tumor growth 
(Chen et al., 2013, Fredholm et al., 2005, Eltzschig, 2009, Hasko et al., 2008). 
Given the differences in adenosine affinities, tissue distribution, and gene 
expression levels, it is likely that AR subtypes participate to various degrees in 
the different physiological and pathological effects of ARs. Importantly, ARs also 
exert subtype-specific intracellular effects (Fig. 8).  
A1 AR 
The A1 AR is the most conserved AR subtype across different vertebrate species 
(Chen et al., 2013). The highest expression levels of A1 AR are found in brain, 
particularly at excitatory nerve endings (Yamaguchi et al., 2014). A1 AR signaling 
has traditionally been linked to Gi-mediated inhibition of adenylyl cyclase 
activity. It also stimulates potassium channels, such as KATP channels in neurons 
and myocardium. Furthermore, it blocks transient calcium channels, which raises 
intracellular calcium levels. Finally, the activation of phospholipase C (PLC) 
elevates intracellular inositol-triphosphate (IP3) concentrations (Smrcka, 2008, 
Chen et al., 1999, Jacobson and Gao, 2006).  
A2A AR 
A2A ARs are highly expressed in immune cells, blood platelets, thymus, and the 
striatum of the brain. Intermediate levels of A2A AR expression are found in 
heart, lungs, and blood vessel (Fredholm et al., 2001). A2A ARs stimulate the 
AMP-protein kinase pathway, and interact with Gs and Golf proteins to upregulate 
the PKA pathway. Furthermore, A2A ARs regulate various processes in the central 
nervous system, such as motor activities, neuronal cell death, the sleep-awake 
cycle, and psychiatric behaviors by interacting with a number of 
neurotransmitters in the brain. Apart from brain activities, A2A ARs play vital 
roles in peripheral tissues, where they modulate angiogenesis, inflammation, 
and coronary blood flow, and they are implicated in the control of cancer 
progression (Eltzschig et al., 2012, Jacobson and Gao, 2006, Chen et al., 2013).  
A2B AR 
A2B ARs are widely expressed in many tissues of the body, but the expression 
levels are generally low when compared to other AR family members (Smrcka, 
2008, Chen et al., 2013). A2B AR stimulation triggers adenylate cyclase 
activation via Gs and PLC activation via Gq. Furthermore, stimulatory effects on 
mitogen-activated protein kinase (MAPK) activities are observed. Among all ARs, 
A2B AR receptors are most insensitive to adenosine concentration requiring 
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micromolar adenosine concentrations for activation (Table 2). Such 
concentrations of extracellular adenosine are typically only encountered under 
pathological conditions, like ischemia, inflammation or hypoxia. It is believed 
that A2B ARs play vital roles in attenuating acute inflammation, increasing 
ischemia tolerance, and adaptation to hypoxia (Rosenberger et al., 2009, Eckle 
et al., 2012, Eckle et al., 2008, Hart et al., 2011).  
A3 AR 
In humans, A3 ARs are expressed at very low levels under normal physiological 
conditions. This can however change dramatically under pathological conditions. 
For example, the blood cells of patients suffering from rheumatoid arthritis, 
Crohn’s disease, or colon cancer, express elevated levels of A3 ARs when 
compared to healthy individuals. The functional significance of these 
observations remain however still elusive. Among different vertebrate species, 
the pharmacology and distribution of A3 ARs is subject to considerable variation. 
In mice, for example, A3 AR signaling has been implicated in the degranulation 
of mast cells, but the situation may be different in humans. The classical 
signaling pathways associated with A3 AR activation comprise Gi-mediated 
inhibition of adenylate cyclase and Gq-mediated stimulation of PLC. Despite the 
apparent species-specific differences, A3 ARs are considered as significant drug 
targets and some A3AR-specific agonists have entered clinical testing for anti-
tumor and anti-inflammatory indications (Ochaion et al., 2009, Gessi et al., 
2004). 
With regard to intracellular signaling, the following picture emerges. After 
stimulation AR subtypes have shared and divergent effects on second messenger 
pathways (Fig. 8). All ARs play a central role in the regulation of cyclic AMP 
(cAMP) levels by modulating the activity of adenylyl cyclase through distinct sets 
of G proteins (Table 2). In general, A1 and A3 ARs are coupled with G proteins of 
the Gi, Gq, and Go families to exert an inhibitory effect on adenylate cyclase 
activity (Ardura and Friedman, 2011, Sheth et al., 2014). The activation of A1 
and A3 ARs will also increase activity of PLC raising intracellular Ca2+ levels, 
which will stimulate PKC. A1 ARs also modulate voltage-sensitive K+ and Ca2+ 
channels. In contrast, the canonical signaling mechanisms activated by A2a and 
A2B ARs rely on the stimulation of adenylate cyclase activity by Gs and Golf to 
raise intracellular cAMP levels and activate PKA (Borea et al., 2016, Headrick et 
al., 2013). Furthermore, A2B but not A2A ARs activate PLC though Gq. Finally, all 
four subtypes of ARs can couple to mitogen-activated protein kinase (MAPK), 
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giving them a role in cell growth, survival, death and differentiation (Jacobson 
and Gao, 2006, Eisenstein and Ravid, 2014). 
 
 
Figure 8. Overview of the intracellular signaling pathways activated by ARs. ARs have common 
and subtype-specific effects on intracellular second messenger pathways. Figure adapted from Borea et 
al. (2016).  
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Crystal structures of adenosine receptors 
Until 2007, the structural information on GPCRs was limited to crystal structures 
of rhodopsin, which were used to infer the structures of other GPCRs 
(Rosenbaum et al., 2009, Katritch et al., 2013, Salon et al., 2011). 
Breakthrough developments in protein engineering and microcrystallography 
have resulted in the exponential growth of reported crystal structures for GPCRs. 
By 2013, structures of 16 GPCRs had been determined covering a range of 
different GPCR subfamilies with distinct ligand recognition and functional 
characteristics. They include the structures of the beta-adrenergic, A2A 
adenosine, chemokine CXCR4, dopamine D3, histamine H1, muscarinic, and 
opioid receptors (Katritch et al., 2013). In addition, several GPCRs have been 
co-crystallized in complexes with different ligands: agonists, inverse agonists 
and antagonists. The intrinsic structural flexibility of GPCRs, which had been a 
major source for the problems encountered in GPCR crystallography, was 
overcome by a number of protein engineering strategies with the aim of 
decreasing protein heterogeneity and trapping a stable GPCR confirmation 
(Katritch et al., 2013, Salon et al., 2011). For example, the third intracellular 
loop (ICL3) was replaced with a highly crystallizable protein, such as T4 
lysozyme or apocytochrome B562RIL. Alternatively, monoclonal antibodies were 
used to assist the crystallization process by mimicking Gα interactions on the 
intracellular loop domains of GPCRs. In the thermostabilization approach, point 
mutations would be introduced to improve the thermostability and to trap stable 
agonist or antagonist-bound GPCR confirmations. Importantly, all non-rhodopsin 
GPCR structures reported to date have truncated or modified N- and C-termini, 
and frequently lack glycosylation sites. Despite these modifications, the 
engineered GPCRs were shown to retain ligand-binding properties similar to their 
unmodified counterparts. Furthermore, the conformational differences between 
multiple structures of the same receptor obtained with different engineering 
approaches were found to be rather minor (Xu et al., 2011). While corroborating 
the common seven transmembrane α-helical GPCR fold, the structures provide 
first insights into the scope of structural diversity in the GPCR superfamily. 
Diversity is observed mainly in the extracellular and intracellular loops. 
Furthermore, size, shape and amino acid composition of the ligand binding 
pockets are unique for each GPCR type. Finally, there is growing evidence that 
GPCRs can adopt multiple confirmations that include more than one active state 
(Katritch et al., 2013). In the simplest model, there is an equilibrium between 
inactive (R) and active (R*) states. The inactive R state represents the ground 
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state and binds inverse agonists. The activated state R* signals by coupling and 
activation of trimeric G proteins. Various biochemical studies and the structural 
information gained from the crystallization of GPCRs indicate a more complex 
situation supporting the existence of intermediate conformational states. 
Katritich et al. (2013) suggest a more refined model with five distinct 
conformational states: R (inactive, inverse agonist-bound state), R’ (inactive, 
agonist-bound state), R’’ (active, agonist-bound state), R* (active, with Gα 
mimic), and R*G (active, G protein signaling state). To date, there is however, 
no representative series of crystal structures supporting all five confirmational 
states for a given GPCR. Overall, the GPCR crystal structures have been crucial 
for improving our understanding of the mechanisms by which various ligands 
induce conformational changes leading to GPCR activation, G protein coupling, 
and cytoplasmic signal transduction.  
With regard to X-ray crystallography, ARs are currently among the most 
comprehensively covered GPCR family members enabling detailed structure-
based studies and in-depth understanding of ligand-binding pockets (Lebon et 
al., 2015, Yuan et al., 2015). The crystallization efforts have focused so far 
solely on the human A2A AR. Since 2008, a total of 15 structures of A2A ARs 
cocrystallized in complex with a variety of natural and artificial ligands have 
been reported (Table 3).  
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Table 3. Crystal structures of the A2A adenosine receptor 
Ligand Type Comments 
Engineering 
strategy 
Activation 
state 
PDB 
ID 
Reference 
ZM241385 Inverse agonist 
A2A selective 
non-xanthine 
derivative 
ICL3 
replacement by 
T4L  
R 3EML 
Jaakola et al. 
2008 
Point mutations R 3PWH 
Dore et al. 
2011 
Antibody 
complex 
R 
3VGA 
3VG9 
Hino et al. 
2012 
ICL3 
replacement by 
BRIL 
R 4EIY 
Liu et al. 
2012 
UK-432097 Agonist 
A2A selective 
xanthine 
derivative 
ICL3 
replacement 
T4L fusion  
R’’ 3QAK 
Xu et al. 
2011 
Adenosine  Agonist 
Nonselective 
endogenous 
xanthine 
derivative  
Point mutations R’’ 2YDO 
Lebon et al. 
2011 
NECA Agonist 
Nonselective 
xanthine 
derivative 
Point mutations 
R’’ 2YDV 
Lebon et al. 
2011 
R* 5G53 
Carpenter et 
al. 2016 
CGS21680 Agonist 
A2A selective 
xanthine 
derivative 
Point mutations R” 
4UG2 
4UHR 
Lebon et al. 
2015 
XAC Antagonist 
Nonselective 
xanthine 
derivative 
Point mutations R 3REY 
Dore et al. 
2011 
Caffeine Antagonist 
Low affinity, 
nonselective 
xanthine 
derivative 
Point mutations R 3RFM 
Dore et al. 
2011 
Compound 4e Antagonist 
A2A selective 
non-xanthine 
derivative 
Point mutations R 3UZC 
Congreve et 
al. 2012 
Compound 4g Antagonist  
A2A selective 
nonxanthine 
derivative 
Point mutations R 3UZA 
Congreve et 
al. 2012 
Abbreviations: BRIL, apocytochrome b562RIL; ICL3, intracellular loop 3; PDB ID, Protein Data Bank ID; R 
(inactive state); R’’ (active state); T4L, T4 lysozyme. 
At present, the A2A AR structures represent three (R, R”, R*) of the five proposed 
confirmation states of GPCRs (Katritch et al., 2013). The structure of the A2A AR 
bound to an engineered G protein, mini-Gs, is the most recent entry (Carpenter 
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et al., 2016). The mini-Gs is a truncated variant containing point mutations to 
stabilize the protein in absence of the fully assembled trimeric G protein. The 
A2AR-mini-GS structure was obtained after co-crystallization with the agonist 
NECA and GDP bound to the mini-Gs. The transition to an active G-protein bound 
state affects primarily the cytoplasmic end of TM helix 6 without affecting the 
extracellular domains of the receptor around the ligand-binding domain. The 
structure of the fully activated receptor coupled to the trimeric G protein is still 
lacking and may provide additional insights. Surprisingly, the use of different 
protein engineering strategies had no significant impact on the obtained crystal 
structures overall (Yuan et al., 2015, Lebon et al., 2015). Collectively, the 
different A2A AR structures confirm the canonical membrane topology of GPCRs 
with seven transmembrane α–helix domain (7TM) spanning the lipid bilayer 
(Massink et al., 2015). The extracellular regions include the N-terminus and 
three extracellular loops (ECL 1-3), which are responsible for ligand recognition 
and binding. The cytoplasmic side consists of three intercellular loops (ICL 1 - 
3), which interact with G-proteins and other downstream effectors. Furthermore, 
the helix 8 and the C-terminus are also present (Fig. 9A).  
 
Figure 9. Agonist bound crystal structure of A2A AR. (A) Structure of A2A AR in complex with the 
inverse agonist ZM241385. The visible extracellular and intracellular loops are labeled. The disordered 
portion of ECL2 is shown as a dashed line. Dotted lines denote the boundaries of the lipid bilayer. (B) 
Close-up view of the superimposed orthosteric ligand binding sites for ZM241385 (blue) and the agonist 
NECA (green). Transmembrane helices are shown as green discs. The black arrows show 
transmembrane helical movements occurring on A2A AR activation. Pictures is taken and modified from 
Dore et al. (2011).  
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Agonist binding to the A2A AR appears to induce a series of stereotypical 
movements of the TM helices in the lipid bilayer. More specifically, the helices 1, 
3, 5, 6 and 7 go through following conformational changes: TM7 and TM1 shift 
towards the center of the receptor, TM3 moves upward in the direction of 
extracellular region of the receptor, and the inward movement of TM5 leads to 
the rotational movement of TM4 (Fig. 9B). At the same time, it is believed that 
the IC regions undergo large conformation changes as part of the A2A AR 
activation mechanism. This will allow for interactions with trimeric G proteins 
and intracellular signaling. Precise structural insights will require cocrystalization 
of activated A2A AR with trimeric G protein complexes (Dore et al., 2011).  
A comparison of the different A2A crystal structures has revealed details on the 
orthotopic ligand-binding pocket and the binding mode of the core adenosine 
moieties of A2A AR agonists (Fig. 10). While remarkable similarity in the binding 
mode was observed, the shape of the binding pocket at the extracellular surface 
differs significantly between the different ligand-bound structures. These 
changes can be mainly attributed to the differences in the length of the side 
groups extending from the core structure occupying the adenosine-binding 
pocket. For example, the (2-carboxyethyl) phenylethylamino extension of 
CGS21680, an agonist protrudes into a pocket formed by ECL2, ECL3 and the 
extracelluar portions of TM2 and TM7. As these regions are the most divergent 
between different ARs, they may help to determine subtype-specific ligand 
binding. Furthermore, the entrance to the ligand-binding pocket appears to be 
very open as the inverse agonist ZM241385 can bind in two different manners.   
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Figure 10. Comparison of the ligand binding sites of A2A adenosine receptors bound to 
various ligands. The PDB IDs are shown in parentheses. The PBD ID for CGS21680 is 4UG2. The 
receptor is viewed as a slice perpendicular to the membrane plane through the binding pocket. The 
surfaces are shown in color and water molecules are represented as red spheres. The figure was 
taken from Lebon et al. (2015).  
 
The recently reported 1.8-Å high-resolution structure of the inactive A2A AR has 
revealed structured water molecules, sodium ions, lipids, and cholesterol bound 
to the receptor (Liu et al., 2012). Importantly, the allosteric regulatory site, 
which binds a sodium ion and 10 water molecules, was identified (Fig. 11). It is 
localized deep in the middle of 7TM bundle. Upon receptor activation, the inward 
movement of TM7 collapses the pocket and does not provide sufficient space for 
the sodium ion. 
 
Figure 11. General structural architecture of A2A adenosine receptors highlighting the binding 
sites for orthosteric and allostric ligands. Figure taken and adapted from Yuan et al. (2015). 
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The various crystal structures of A2A AR have provided information at atomic 
resolution about orthosteric and allosteric ligand binding sites, which will guide 
the rational design of novel compounds targeting the A2A AR. Many questions, for 
example about the precise structural determinants for ligand affinity, specificity 
and stability, remain however unresolved. Further insights into AR function will 
require the determination of the structures of the closely related A1, A2B, and A3 
ARs. 
Expression of adenosine receptors  
Adenosine is ubiquitously present throughout the human body and involved in 
various physiological and pathological processes as outlined above. The effects 
of extracellular adenosine are mediated via four distinct AR subtypes, which are 
generally widely expressed in various tissue and organs of the body. 
Nevertheless, each AR subtype has its own characteristic gene expression 
profile. Table 4 provides an overview of main expression domains for the four AR 
subtypes in human and two model organisms (zebrafish embryos; adult mice). It 
is evident that there is extensive overlap in gene expression of AR subtypes in 
different organs of the vertebrate body. This is particularly true for brain, heart, 
kidney, and liver. While AR subtypes may share gene expression in the same 
organ, expression of each AR subtype may be confined to distinct structures or 
tissues of the organ. These differences are at present poorly understood. The 
main expression domains for each AR subtype are similar across species, but 
there also appear to be species-specific differences. For instance, the brain is 
one of the main organs expressing A3 AR in humans, whereas this is not the 
case for mice (Table 4). These apparent differences warrant a more systematic 
comparative analysis of AR gene expression across model organisms in the 
future.  
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Table 4. Expression domains of AR subtypes in zebrafish, mouse, and human 
AR 
subtype 
Main expression domains 
 Zebrafish Mouse Human 
A1 - Brain (hippocampus, 
cerebellum), Spinal 
cord, Eye, Adrenal 
gland, Atria  
Brain (hippocampus, striatum, 
thalamus), Spinal cord, 
Kidney, Muscle, Adrenals, 
Atria, Heart, Liver, Bladder, 
Testis, Lung 
A2A Heart, Brain (hindbrain, 
hypothalamus), Ventral 
hematopoietic mesoderm  
Brain (cerebellum, 
cortex), Spleen, 
Thymus, Heart, 
Leukocytes, Lung, 
Blood vessels 
Brain (cerebellum, prefrontal 
cortex, temporal lobe), Lung, 
Olfactory tubercle, Heart, 
Kidney, Liver, Vasculature, 
Testis, Spleen 
A2B Vasculature, Brain 
(telencephalon, hindbrain, 
neurons), Eye (retina), Yolk 
syncytial layer 
Intestine (colon, 
cecum), Bladder, 
Blood vessels, Brain, 
Kidney, Liver, Adrenal 
gland, Pituitary gland 
Brain (cerebellum, prefrontal 
cortex, frontal lobe, temporal 
lobe), Intestine, Heart, 
Kidney, Liver, Testis 
A3 - Lung, Liver, Spleen, 
Testis, Thyroid, Heart, 
Arteries, Mast cells 
Brain, Heart, Kidney, Lungs, 
Eyes, Adrenal gland, Blood, 
Muscle, Liver 
Table summarizes gene expression data for zebrafish embryos (Boehmler et al. (2009), adult mice (Wei 
et al. 2011), and humans (Fredholm et al. 2001; Jacobson & Müller 2016). Abbreviations: -; unknown.   
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Genetic analysis of adenosine receptor functions 
Adenosine signaling has been implicated in many physiological processes, such 
as neuromodulation, immune regulation, vascular functions, and metabolic 
control. Over the last twenty years, various mouse strains deficient in the four 
AR subtypes have been generated by targeted mutagenesis in embryonic stem 
cells with the aim of uncovering the normal physiological roles of ARs. The 
phenotypes have been extensively reviewed elsewhere (Fredholm et al., 2011, 
Chen et al., 2013, Wei et al., 2011, Jacobson and Muller, 2016). The most 
striking finding from the loss of function experiments is the fact that none of the 
AR subtype knockouts had lethal effects and all the mutant mouse strains were 
viable and fertile. In line with the findings in AR knockout mice, there are 
presently also no reports of AR mutations causing disease phenotypes in the 
human population (Online Mendelian Inheritance in Man; www.omin.org; 
November 2016). This indicates that there is extensive functional redundancy of 
AR gene functions in mice and probably also in humans, which is not surprising 
given the broad and extensive overlap of gene expression domains of AR 
subtypes (Table 4). Many organs, such as brain, heart and kidney, express at 
least two or more AR subtypes. Alternatively, the lack of severe phenotypes in 
the AR knockout mouse strains could indicate the existence of compensation 
mechanisms. Indeed, up-regulation of A2B AR expression was observed in 
coronary arteries of A2A AR knockout mouse (Teng et al., 2008). In future, it will 
be important to generate double, triple and quadruple knockout mouse lines of 
the four AR subtypes. For example, A1 AR and A2A AR double knockout mice have 
a lower body temperature than wild-type mice (Yang et al., 2009). The 
systematic and coordinated generation of mutant mouse lines carrying multiple 
AR gene mutation may reveal further insights into physiological processes 
regulated by AR signaling.   
While general phenotypes of the single AR knockout mice are not significantly 
different to wild-type mice, minor differences have been observed, particularly 
under special physiological and/or pathologic conditions. This encompasses 
behavioral abnormalities (aggression, anxiety), cardiovascular changes, 
alteration in homeostasis, and immune system deficiencies (Wei et al., 2011, 
Belikoff et al., 2011, Yaar et al., 2005). A selection of these subtle phenotypes 
are shown in Table 5. Given the mild and modest phenotypes seen in AR-
deficient mice, it will be important that mutant and control mice share the same 
genetic background.  
Introduction 
32 
 
Table 5. Selection of phenotypes observed in AR knockout mice 
A1 AR A2A AR A2B AR A3 AR 
Hyperalgesia 
Blood pressure and 
renin activity ↑ 
Anxiety ↑ 
Heart rate ↓ 
Tubuloglomerular 
feedback ↓ 
Acute pain response ↓ 
Anxiety ↑ 
Aggression ↑ 
Heart rate ↑ 
Blood pressure ↑ 
Focal brain ischemia 
damage ↓ 
Neonatal brain 
ischemia damage ↑ 
Leukocyte adhesion to 
blood vessels ↑ 
Inflammation ↑ 
Vascular leakiness ↑ 
Myocardial 
preconditioning 
Airway responsiveness ↓ 
Mast cell degranulation ↓ 
Intraocular pressure ↓ 
Resistance to cardiac 
ischemia-reperfusion 
injury 
Table adapted from Fredholm et al. (2011), Chen et al. (2013) and Jacobson & Müller (2016).  
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Roles for adenosine receptors in angiogenesis and lymphangiogenesis 
Adenosine is an ubiquitous and endogenous purine nucleoside which controls 
several physiological processes, including angiogenesis and vasculogenesis. 
During metabolic stress such as hypoxia and cancer, the secretion of adenosine 
is increased. Furthermore, adenosine has been reported as a master regulator of 
angiogenesis during (Lenoir et al., 2014, Escudero et al., 2014). In the 
vasculature, adenosine induces vasodilation of preexisting vasculature and it 
stimulates angiogenesis in order to increase blood flow and thereby increasing 
nutrient and oxygen delivery (Feoktistov et al., 2009, Adair, 2005). First 
evidence for a role of adenosine in the stimulation of angiogenesis was provided 
by experiments using the chicken chorioallantoic membrane (CAM) system 
(Dusseau and Hutchins, 1988, Dusseau et al., 1986). Administration of 
adenosine led to a dose-dependent increase in vascular density supporting an 
angiogenic role for adenosine. In Xenopus tadpoles, long-term treatment with 
the adenosine agonist NECA causes dilation of brain blood vessels and increased 
blood flow (Jen and Rovainen, 1994). The effect of adenosine on angiogenesis 
appears to involve the modulation of multiple steps, including vascular 
endothelial cell proliferation, migration, and tube formation (Feoktistov et al., 
2009, Adair, 2005). Adenosine activates all AR subtypes (A1, A2A, A2B, A3) and 
endothelial cells are known to express ARs. Table 6 provides a summary of the 
postulated involvement of AR subtypes in the modulation of angiogenesis. There 
are however conflicting reports on the presence of specific AR subtypes in 
endothelial cells. For example, human umbilical vein endothelial cells (HUVEC) 
express preferentially A2A ARs, whereas microvascular endothelial cells (HMEC) 
have a preference for A2B ARs (Feoktistov et al., 2002).  
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Table 6. Summary of AR involvement in angiogenesis using human cell cultures 
AR Angiogenic process Cell type 
A1 Migration ↑ EPC 
A2A VEGF expression ↑ Macrophages 
Thrombospondin 1 expression ↓ HMVEC 
sFlt-1 release ↓ Macrophages 
mFlt-1 expression ↑ Macrophages 
Proliferation/migration and VEGF expression ↑ HUVEC 
A2B Permeability ↑ HUVEC-PMN 
VEGF expression↑ HMVEC 
Migration ↑ HREC 
VEGF, IL-8 and bFGF expression ↑ HMEC-1 
IL-8 secretion ↑ Melanoma cells, HT29 
VEGF expression ↑ HUVEC under hypoxia 
Proliferation/migration and tube formation and VEGF 
expression ↑ 
HREC 
A3 Migration and tube formation ↓ HUVEC 
VEGF and IL-8 expression ↑ Melanoma cells 
VEGF expression ↑ HT29 
Angiopoietin-2 expression ↑ HMEC-1 
VEGF, vascular endothelial growth factor; sFlt-1, soluble Flt1; mFlt-1, membrane-linked Flt1; IL-8, 
Interleukin 8; bFGF, basic fibroblast growth factor; HMVEC, human microvascular endothelial cells; 
HUVEC, human umbilical vein endothelial cells; PMN, polymorphonuclear leukocyte; HREC, human 
retinal endothelial cells; HMEC-1, human microvascular endothelial cell line 1; EPC, endothelial 
progenitor cells; HT-29, human colon adenocarcinoma. Increase (↑) and decrease (↓) of pro-or 
anti-angiogenic processes; AR, adenosine receptor. Table adapted from Escudero et al. (2014), 
where the primary references can be found. 
 
Multiple pieces of evidence suggests that the proangiogenic activities of 
adenosine can be furthermore attributed to its ability to modulate the release of 
pro- and anti-angiogenic factors (Feoktistov et al., 2009). During ischemia or 
hypoxia, the heart produce adenosine as negative feedback signal to retain 
oxygen supply. The released adenosine activates A2A ARs, which will inhibit 
production of the antiangiogenic factor thrombospondin-1. At the same time 
adenosine activates A2B ARs on endothelial cell, which will stimulate the release 
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of vascular endothelial growthfactors (VEGF), fibroblast growth factor (bFGF), 
and interleukin-8 (IL-8) (Feigl, 2004, Feoktistov et al., 2002, Linden, 2005). 
During wound repair and in inflammation, adenosine stimulates angiogenesis by 
activation of A2A ARs on macrophages resulting in the production of VEGF instead 
of IL-6 and tumor necrosis factor (Olah and Caldwell, 2003). Expression of ARs 
in different types of leukocytes, such as macrophages, mast cells, and 
neutrophils, has been demonstrated in the past (Feoktistov et al., 2003, Thiele 
et al., 2004, Salmon and Cronstein, 1990). Taken together, the indirect 
stimulation of angiogenesis via adenosine involves two distinct mechanisms: the 
increased production and release of proangiogenic factors, like VEGF and 
angiopoietin 2 (Ang2), and downregulation of the production of antiangiogenic 
factors, like thrombospondin-1 (Tsp1). Overall, the effects of adenosine signaling 
on blood vessels is complex as it involves direct and indirects modes of action. 
Direct effects are mediated by endothelial ARs, whereas in the indirect effects 
are triggered by ARs on smooth muscle cells and different leucocytes. Figure 12 
shows the model of Clark et al. (2007) describing the complex involvement of 
ARs in angiogenesis.  
 
Figure 12. Model explaining the functions of different AR subtypes in the stimulation of 
angiogenesis. In monocytes and macrophages, extracellular adenosine (Ado) activates A1 and 
A2A ARs to stimulate the release of VEGF. Lipopolysaccharides (LPS) or interferon γ (INFγ) 
synergize with adenosine to activate A2A ARs. Stimulation of mast cells by adenosine blocks 
degranulation (via A2A AR) and promotes release of interleukin-8 (IL-8) and angiopioetin-2 (Ang2) 
via A2B and A3 ARs, respectively. In smooth muscle cells (SMC), A2A AR activation stimulates VEGF 
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release. In endothelial cells, A2A AR activation inhibits thrombospondin 1 (Tsp1) and promotes 
VEGF synthesis. Furthermore, hypoxia-induced upregulation of endothelial A2A and A2AB ARs 
triggers IL-8 and VEGF release. The role of A1 ARs, which is present in endothelial cells remains 
unclear. Figure taken from Clark et al. (2007).   
 
While there is ample evidence supporting a role for adenosine signaling in 
regulating blood vessel angiogenesis, the effects of adenosine on 
lymphangiogenesis remain poorly understood. Kalin et al. (2009) provided first 
evidence indicating a role for adenosine signaling in modulating 
lymphangiogenesis. The A1 AR-selective antagonists 7-chloro-4-hydroxy-2-
phenyl-1,8-naphthyridine (7CN) and 1,3-diethyl-8-phenylxanthine (DEPX) were 
identified as chemical agents not only affecting blood vessel formation, but also 
causing hypoplasia of lymphatics in Xenopus embryos. 7CN inhibited both cell 
proliferation and tube formation of human lymphatic endothelial cells in vitro. 
Furthermore, 7CN was found to cause a reduction of lymphatic vessels in a 
murine neovascularization model (Kalin et al., 2009). 7CN was subsequently also 
identified in a phenotypic in vitro screen as an effective inhibitor of 
lymphangiogenic sprouting (Schulz et al., 2012). More recently, it was 
demonstrated that human adult dermal microvascular lymphatic endothelial cells 
express A2A and A2B AR, but apparently not A1 and A3 ARs (Lenoir et al., 2014). 
The use of different in vitro and in vivo models failed however to resolve the role 
of extracellular adenosine unequivocally. Adenosine was found to inhibit 
proliferation and migration of lymphatic cells in vitro, but to stimulate 
lymphangiogenesis in vivo (Lenoir et al., 2014). Given these discrepancies, 
further studies to explore the role of adenosine signaling in lymphangiogenesis 
are warranted. Overall, the exact roles of the four AR subtypes in the 
development and maintenance of blood and lymphatic vessels remains to be 
elucidated.  
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Adenosine receptors as therapeutic targets 
The prospect of therapeutically targeting ARs emerged almost 90 years ago 
when adenosine administration was reported to lower body temperature and 
contribute to vasodilation (Bennet and Drury, 1931, Drury and Szent-Gyorgyi, 
1929). It was believed that vasodilation is caused by the release of adenosine 
and/or AMP after tissue trauma (Chen et al., 2013). Clinically, the generic drugs 
adenocard and adenoscan use adenosine as a short-lived, non-selective AR 
agonist for the treatment of superventricular tachycardia (Delacretaz, 2006). 
The therapeutic benefit of interfering with AR signaling is also very powerfully 
illustrated by the methylxanthines that include caffeine (from coffee beans), 
theophylline (from tea leafs), and theobromine (from cocoa beans). They are 
ingested on regularly basis by billions of people worldwide and therefore they 
are considered the most widely consumed stimulants in the world. The effects of 
methylxanthines are mediated primarily via blockade of ARs (Snyder et al., 
1981). AR action may not only be modulated by agents that directly interact 
with ARs, but also by compounds that stimulate adenosine release, inhibit the 
metabolism of extracellular adenosine, or block its cellular uptake (Jacobson and 
Gao, 2006). Overall, there is growing evidence that therapeutic agents 
interfering with AR signaling could be beneficial in treating a wide range of 
conditions, including cerebral and cardiac ischaemic diseases, sleep disorders, 
immune diseases, inflammatory disorders, and cancer (Jacobson and Gao, 2006, 
Chen et al., 2013). Numerous selective AR agonists and antagonists have been 
developed in recent years and several have entered clinical testing (Chen et al., 
2013, Jacobson and Muller, 2016). Fig. 13 provides an overview of current 
disease areas for selective AR ligands. Chen et al. (2013) have reviewed ongoing 
or recently completed Phase II-III clinical trials targeting ARs.  
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Figure 13. Proposed disease targets for selective adenosine receptor ligands. The figure 
illustrates disease areas that could benefit from AR subtype-specific antagonists (left) and agonists 
(right) as therapeutic agents. Figure taken from Jacobson et al. (2006). 
 
However, to date only two AR-specific agents targeting A2A ARs have gained 
approval by regulatory medicinal agencies. Regadenoson (CVT-3146; Lexiscan, 
Astellas Pharma) is a selective agonist of the A2A AR. Given its coronary 
vasodilator activities, it is used as adjunctive pharmacological stress agent for 
radionuclide myocardial perfusion imaging in patients with suspected coronary 
artery disease (Ghimire et al., 2013). By contrast, the caffeine analog 
istradefylline (KW-6002; Kyowa Hakko Kirin) is a selective antagonist of the A2A 
AR. It is approved in Japan as a useful alternative to dopaminergic drugs in the 
treatment of Parkinson’s disease (Lewitt, 2008). Despite the established 
therapeutic potential of adenosine and agents targeting ARs, the design of 
effective and safe drugs with validated clinical applications is still a challenge. 
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For example, a phase III clinical trial to determine the efficacy of the promising 
A1 AR-selective antagonist rolofylline in treating patients with acute heart failure 
had a disappointing outcome (Massie et al., 2010). Increased seizure rates and 
worsening renal function were among the major side effects of rolofylline. The 
complexity of adenosine signaling in the human body remains a continuing 
source for unexpected adverse side effects in clinical applications. ARs are widely 
distributed throughout the body, with target tissues frequently expressing 
multiple AR subtypes. Furthermore, the ligand adenosine itself is present 
ubiquitously. Finally, ARs are involved in or contribute to a wide range of 
pathophysiological and physiological functions (Fredholm et al., 2005). Despite 
these many challenges, the potential therapeutic benefits of drugging ARs calls 
for the development of more sophisticated AR modulators (Massie et al., 2010, 
Jacobson and Gao, 2006).  
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Hypothesis and Aims 
In a chemical library screen using Xenopus embryos, our laboratory had 
previously identified adenosine receptor (AR) antagonists that acted as inhibitors 
of blood vascular and lymphatic development (Kalin et al. 2009). In a proof-of-
principle study, the adenosine receptor antagonist 7-chloro-4-hydroxy-2-phenyl-
1,8-naphthyridine (7CN) was shown to disrupt VEGFA-induced adult 
neovascularization in mice. These initial results suggested that AR antagonists 
could act as potent inhibitors of vascular development and angiogenesis. 
Therefore, the aim of the present thesis was to characterize in detail the effects 
and specificities of AR antagonists on vascular development using Xenopus 
embryos and mammalian test systems. Towards this end, the following specific 
aims were formulated:  
1. To define the spectrum and subclass specificity of AR antagonists that are 
effective in disrupting blood and/or lymph vessel development in Xenopus 
embryos; 
2. To perform dose-response studies of bioactive AR antagonists in order to 
establish key pharmacological parameters, i.e. EC50 and LC50 values, in 
Xenopus embryos; 
3. To assess the tissue specificities of AR antagonists in vivo; 
4. To establish the structure-activity relationship for selected bioactive AR 
antagonists by changing their chemical structures; 
5. To test whether selected AR antagonists affect blood and/or lymph 
endothelial cells in vitro; and  
6. To elucidate the mechanisms of action of selected AR antagonists. 
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Obtaining Xenopus embryos 
The Xenopus studies were conducted under protocols approved by the Regierung 
von Oberbayern, Munich, Germany (permits 55.2-1-54-2532.6-3-10 and 55.2-1-
54-2532.0-95-14). Adult Xenopus laevis frogs were obtained from commercial 
suppliers (Xenopus Express; NASCO) and they were held at temperatures 
ranging between 18°-22°C. Xenopus embryos were obtained by performing in 
vitro fertilization as previously described (Helbling et al., 1998, Brandli and 
Kirschner, 1995). In brief, testicles were harvested from adult males that were 
terminally anesthetized with 0.5% tricaine (MS-222; #A5040, Sigma-Aldrich). 
The isolated testicles were cultured in testis medium [1x MMR, 10% fetal calf 
serum, 0.01% gentamycin] at 4°C for at least 7 days. 1x MMR refers to Marc's 
Modified Ringer’s Solution: 0.1 M NaCl, 2 mM KCl, 1 mM MgSO4, 2 mM CaCl2, 5 
mM Hepes and pH was adjusted to 7.8. The dorsal lymph sacs of sexually 
mature female frogs were injected with 600 units of human chorionic 
gonadotropin (#CG10, Sigma-Aldrich; Ovogest 300 I.E. /ml, Intervet 
Deutschland GmbH) to induce ovulation and egg laying. Injected females were 
kept overnight in tap water at 20°C. Typically, egg laying began 14 – 16 hours 
after hormone injection. Females were gently squeezed and the freshly released 
eggs were collected in to glass Petri dishes. A sperm-containing solution was 
generated by cutting a piece of tissue from the testicle and macerated in 1x 
MMR. To initiate in vitro fertilization, the sperm solution was added to the freshly 
obtained eggs. Subsequently, 0.1 x MMR was added to the fertilized eggs and 
they were kept at 22°C until the first few cleavages had occurred. Blastula stage 
embryos were dejellied with 2% cysteine (#7352, Sigma-Aldrich) solution 
(adjusted with 10 M NaOH to pH 7.8) and washed 3 times with 0.1x MMR to 
remove cysteine. The dejellied embryos were raised at 22°C. Unfertilized eggs, 
dead or malformed embryos were regularly removed from the embryo cultures. 
The embryos were staged according to Nieuwkoop & Faber (Nieuwkoop PD, 
1994).  
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Pharmacological treatments of Xenopus embryos 
Table 7 provides a list of all AR antagonists used in the present study. For each 
compound, a 10 mM stock solution was prepared in dimethyl sulfoxide (DMSO; 
#D8418, Sigma-Aldrich) and stored at 4°C. For dose-response studies, the stock 
solutions were serially diluted to: 5 mM, 2 mM, 1 mM, 0.5 mM, 0.2 mM, 0.1 mM, 
0.05 mM, 0.02 mM, and 0.01 mM. Each AR antagonist was tested at final 
concentrations ranging between 0.01 µM to 100 µM in 0.1x MMR containing 1% 
DMSO. Compound testing was performed with Xenopus embryos at embryonic 
stage 31 (37 hours post fertilization, hpf). Polystyrene flat-bottom 48-well tissue 
culture plates (BD Falcon #353078) were used to array 5 embryos per well. 
Each well contained 1 ml of screening solution (0.1× MMR, AR antagonist 
dissolved in DMSO). Two negative controls were used for each pharmacological 
test; one well contained 0.1x MMR only and a second well contained 0.1x MMR 
plus 1% DMSO. Pharmacological treatments were performed in a humidified 
incubator at 22°C for the duration of 5 days. Embryo phenotypes were manually 
scored by visual inspection using a dissecting microscope (SV6; Carl Zeiss). The 
embryos were scored for morphological defects, primarily edema formation and 
lethality. Typically, scoring was done once the embryos reached the following 
stages: 33 (45 hpf), 37-38 (53 hpf), 39 (56 hpf), 41 (76 hpf), 42 (80), 43 (87 
hpf), 45 (98 hpf), 46 (110 hpf), and 47 (120 hpf). Fluid evaporation was 
compensated daily by the addition of water and dead embryos were removed 
from the cultures. The AR antagonists were considered bioactive when at least 
60% of the treated embryos showed a consistent phenotype; edema, 
morphological defects and/or lethality. AR antagonists were considered inactive, 
if 30% or less of the treated embryos displayed phenotype at 100 μM, the 
highest concentration tested. For each compound at least six independent 
experiments were performed to obtain consistent results and to confirm the 
observed phenotypes. Xenopus embryos were anesthetized with 0.05% tricaine 
in 0.1x MMR at stage 45 and pictures were taken for documentation. The images 
were taken using a stereo microscope (M205 FA, Leica Microsystems) equipped 
with a digital camera. The following pharmacological parameters were 
established at stage 45: EC50 (effective concentration, where 50% of the treated 
embryos present with edema and/or die), LC50 (lethal concentration, causing 
lethality in 50% of the treated embryos), and ECmax (effective concentration, 
where maximal incidence of edema was observed).  
 
Materials and methods 
 
44 
 
Table 7. AR antagonists selected for the pharmacological studies 
  
Compound name 
(CAS Number) 
AR 
selectivity 
Supplier 
(Catalog number) 
1,3-Diethyl-8-phenylxanthine  
(75922-48-4) 
A1 Sigma-Aldrich  
(A003) 
1,3-Dimethyl-8-phenylxanthine  
(961-45-5) 
A1 Sigma-Aldrich 
(P2278) 
1,3-Dipropyl-8-phenylxanthine  
(85872-53-3) 
A1 Tocris Bioscience 
(0486) 
1,3-Dipropyl-8-(p-sulfophenyl) xanthine  
(89073-57-4) 
A1 Sigma-Aldrich  
(A022) 
7-Chloro-4-hydroxy-2-phenyl-1,8-naphthyridine (No CAS 
number assigned) 
A1 Angene International Ltd.  
(AG-I-03578) 
7-Methyl-2-phenyl-1,8-naphthyridin-4(1H)-one (No CAS 
number assigned) 
A1 Angene International Ltd.  
(AG-I-03577) 
7-Chloro-4-hydroxy- [1,8] naphthyridine  
(286411-21-0) 
A1 Synchem UG & Co. KG 
(cdp194fp2vp3) 
PSB 36 
(524944-72-7) 
A1 Tocris Bioscience 
(2019) 
SLV 320 
(251945-92-3) 
A1 Tocris Bioscience  
(3344) 
CGS 15943 
(104615-18-1) 
A2A Sigma-Aldrich  
(C199) 
SCH 442416 
(316173-57-6) 
A2A Tocris Bioscience  
(2463) 
SCH 58261 
(160098-96-4) 
A2A Tocris Bioscience  
(2270) 
ZM 241385 
(139180-30-6) 
A2A Tocris Bioscience  
(1036) 
MRS 1706 
(264622-53-9) 
A2B Tocris Bioscience  
(1584) 
MRS 1754 
(264622-58-4) 
A2B Tocris Bioscience  
(2752) 
PSB 1115 
(152529-79-8) 
A2B Tocris Bioscience  
(2009) 
MRS 3777 hemioxalate 
(1186195-57-2) 
A3 Tocris Bioscience  
(2403) 
PSB 11 hydrochloride 
(453591-58-7) 
A3 Tocris Bioscience  
(2012) 
VUF 5574 
(280570-45-8) 
A3 Tocris Biosciences  
(1359) 
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Secondary pharmacological testing 
Secondary pharmacological tests were performed with bioactive A1 AR 
antagonists to investigate if the compounds were interfering with angiogenesis 
and/or lymphangiogenesis in vivo. Xenopus embryos at stage 31 (37 hpf) were 
treated with A1 AR antagonists at the EC50 concentrations. The treated embryos 
were raised to stages 35/36 (50 hpf) or 40-41 (76 hpf). Embryos were fixed with 
MEMFA fixative (0.1 M MOPS pH 7.4, 2 mM EGTA, 1 mM MgSO4, 3.7% 
formaldehyde) for 2 hours at room temperature (RT) or overnight at 4°C. 
MEMFA fixative was replaced twice with 100% ethanol and the embryos were 
kept at -20°C in ethanol for whole mount in situ hybridization.  
Whole mount in situ hybridizations 
Control Xenopus embryos and those treated with AR antagonists were stained by 
whole mount in situ hybridization according to the current lab protocol shown in 
Table 8. It is based on the standard protocol for whole mount in situ 
hybridizations of Xenopus embryos (Harland, 1991). The following alterations 
were introduced. Methanol was replaced with ethanol, digestion of RNase was 
skipped, and buffers did not contain CHAPS. For blocking and antibody 
incubation maleic acid buffer (100 mM maleic acid, 150 mM NaCl, pH 7.5) with 
2% blocking reagent (#11 096 176 001, Roche Diagnostics;) and 20% sheep 
serum (S2263, Sigma-Aldrich) was used. Antisense digoxigenin-labeled RNA 
probes were created by using digoxigenin RNA labeling mix (#11 277 073 910, 
Roche Diagnostics). The linearized plasmids were purified using PCR purification 
kit (#28106, Qiagen). Then following transcription reaction was made for 
digoxigenin-labeled RNA synthesis: 
1 µg Linearized template DNA 
2.5 µl 10x reaction buffer 
2.5 µl UTP labeling mix 
1 µl RNA polymerase (SP6/T3/T7) 
Up to 25 µl ddH20 
The reaction mix was incubated at 37°C for 4 hours. Subsequently, 1 µl DNase 
was added for 15 min at 37°C. The reaction was terminated by adding 2 µl 4.9 
M LiCl2 and 62.5 µl 100% ethanol. The solution was mixed and incubated for 1 
hour at -20°C. Dig-labeled RNA was pelleted by centrifugation at 13,000 rpm at 
30 min at 4°C. Pellet was washed with 70% ethanol and pelleted by 
centrifugation for 15 min at 13,000 rpm.  Finally, Dig-labeled RNA was dissolved 
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in 20 µl 2x saline-sodium citrate (SSC)/50% formamide (FA) and stored at        
-20°C.  
For the detection of digoxigenin-labeled RNA probes sheep anti-digoxigenin Fab 
fragments conjugated to alkaline phosphatase ((#11 093 274 910, Roche 
Diagnostics) were used. BM purple (#11 442 074 001, Roche Diagnostics) was 
used for the color development and embryos were protected from light during 
color reaction. Embryos were bleached under cold light for 2 hours in bleaching 
solution (1% hydrogen peroxide, 5% formamide 0.5x SSC) (Helbling et al., 
1998). The pictures of stained embryos were taken using a stereo microscope 
(M205 FA, Leica Microsystems). 
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Table 8. Protocol for whole mount in situ hybridization of Xenopus embryos 
Day 1 
Time 
(min) 
Temperature 
(°C) 
100% Ethanol 5 RT 
75% Ethanol+ 25% PTW 5 RT 
50% Ethanol+ 55% PTW 5 RT 
25% Ethanol + 75% PTW 5 RT 
PBS-Tween (PTW) 5 RT 
PTW 5 RT 
PTW 5 RT 
PTW 5 RT 
10 µg/ml Proteinase K in PTW 15 RT 
0.1 M Triethanolamine (TEA) 5 RT 
0.1 M TEA 5 RT 
TEA + Acetic anhyride 15 RT 
PTW 5 RT 
PTW 5 RT 
Formaldehyde + PTW 20 RT 
PTW 5 RT 
PTW 5 RT 
PTW 5 RT 
PTW 5 RT 
25% Hybridization buffer (HB) 15 65 
50% HB 15 65 
75% HB 15 65 
100% HB 300 65 
HB + Dig-RNA Probe (1 µg/ml) overnight 65 
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Day 2 
   
 HB 15 60 
Day 3 
2x SSC 15 60 
2x SSC 15 60 
2x SSC 15 60 
RNase + 2x SSC 30 37 
2x SSC 5 RT 
2x SSC 5 RT 
0.2x SSC 30 60 
0.2x SSC 30 60 
1x MAB (Maleic acid buffer) 15 RT 
1x MAB 15 RT 
1x MAB + Blocking reagent (BR) 15 RT 
MAB + BR + 20% Sheep serum (SS) 60 RT 
MAB + BR + SS+ Digoxigenin antibody 
(1:2000) 
240 RT 
1x MAB 15 RT 
1x MAB 15 RT 
1x MAB 15 RT 
1x MAB o/n 4 
   
 1x MAB 15 RT 
 1x MAB 15 RT 
 1x MAB 15 RT 
 1x MAB 15 RT 
 AP buffer 5 RT 
 AP buffer 5 RT 
 BMP purple - RT 
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Marker genes for antisense probe synthesis 
To analyze the expression of ARs during embryogenesis, the following cDNAs 
were used for antisense probe synthesis: adora1 (GenBank. Acc. No. 
BC169511), adora2a (BC074202), adora2b (CX806531), and adora3 
(EL821975). Note that cDNAs for adora2b and adora3 were from Xenopus 
tropicalis. The gene expression patterns for adora2b and adora3 for Xenopus 
tropicalis and Xenopus laevis embryos were identical (not shown). The plasmids 
were linearized and antisense RNA transcribed using the appropriate restriction 
enzymes and RNA polymerases, respectively: adora1, NotI/T3; adora2a, 
SalI/T7; adora2b, SalI/T7; and adora3, SalI/T7. To analyze the organ 
morphology of compound-treated embryos, the following marker genes were 
used: MyoD (X16106), SCL/tal1 (AF060151), αT3 globin (X02796.1), APJ-b 
(XL025B17), VEGFR3 (BM2611245), and Fxyd (BU903987). The plasmids were 
linearized and antisense RNA transcribed using the appropriate restriction 
enzymes and RNA polymerases, respectively: MyoD, Asp 718/T7; SCL/tal1 
Xho/T7; αT3 globin HindIII/T7; APJ-b, EcoRI/T7; VEGFR3 SalI/T7; and Fxyd, 
SalI/T7.  
Microinjection of morpholino oligonucleotides 
Two translation-blocking antisense morpholino oligonucleotides (MO) targeting 
the AUG initiation codons, adora1-MO (GGATTCCCATGCTGCTTCAGTCCAA) and 
adora2a-MO (ATTTGACACCGTTACCATGGTAATG), were designed and purchased 
from Gene Tools, Inc (Philomath, Oregon, USA). For knockdown experiments, 
Xenopus embryos at the 2-cell stage were placed into glass Petri dishes 
containing 1x MMR. Each embryo was injected with 20 ng of adora1-MO or 
adora2a-MO (10 ng per blastomere). After MO injection, embryos were 
transferred to Petri dishes containing fresh 1x MMR and placed into an incubator 
at 20°C for 3 hours. Afterwards 1x MMR was replaced by 0.1x MMR and embryos 
were incubated at 20°C until further analysis.  
Mammalian cell culture 
Human umbilical vein endothelial cells (HUVEC) were purchased from PromoCell 
GmbH (#C-12203). HUVECs were cultured in Endothelial Cell Growth Medium 
(ECGM) (#C-22010, PromoCell) according to the manufacturer’s instructions in 
100-mm tissue culture plates (#430293, Corning). Cells were used for 
compound treatments at passages 4 and 5. 
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Chemical treatments and immunostaining of cell cultures  
The source of the test compounds is provided with Table 7. Nocodazole (# 
M1404, Sigma Aldrich) was used as a positive control as it disrupts the 
microtubule-based cytoskeleton. For chemical treatments, HUVECs (2 x 106 cells 
in 2 ml ECGM/well) were seeded into six-well plates (#35 3224, BD Falcon) 
containing glass cover slips (#H-875, Carl Roth). The plates were incubated at 
37°C for 3 hours to allow the cells to settle and adhere to the cover slips. 
Subsequently, A1 AR antagonists or nocodazole dissolved in DMSO were added 
to the culture media at the following final concentrations: 1 µM, 3 µM, 10 µM; 
0.1% DMSO. The cells were incubated at 37°C for either 2 hours or 16 hours. 
The cells were washed with phosphate buffered saline (PBS), and fixed with 2% 
para-formaldehyde (PFA). Fixed cells were washed three times with PBS 
contained 0.15% Triton X-100 (PBS-Triton). Then blocking solution (PBS with 
1% BSA and 0.15% glycine) was added to cells for 10 minutes. The blocking 
step was repeated 3 times. The mouse anti-α-tubulin monoclonal antibody (1 
mg/ml; #A11126, Life Technologies) was diluted in blocking solution to 1 µg/ml, 
and cells were treated with the antibody solution for 2 hours at room 
temperature and then overnight at 4°C. Subsequently, the cells were washed 
with PBS (1x), PBS-Triton (1x), and blocking solution (1x). Secondary anti-
mouse IgG conjugated with Alexa Fluor 448 (#A11001, Life Technologies) was 
diluted (1:200) in blocking solution. Cells were incubated with secondary 
antibody for one hour at room temperature. Cells were washed with PBS (1x) 
and PBS-Triton (1x). The washed coverslips containing the stained cells were 
carefully mounted on microscopy slides with VECTASHIELD antifade mounting 
medium containing 1.5 µg/ml DAPI (#H-1200, Vectorlabs). Fluorescence 
imaging was performed using a Zeiss Axiophot microscope with Carl Zeiss 
AxioCan MRm camera and Axiovison 4.6 Software.  
FACS analysis of A1 AR antagonist treated cells  
Fluorescence-activated cell sorting (FACS) was performed with propridium iodide 
stained HUVECs treated either with A1 AR antagonists or nocodazole. HUVECs 
were cultured in ECGM and split in 6 well plates. The plates were incubated 
overnight at 37°C. The next day, compounds were added to the medium at 0.1 
µM, 0.3 µM, 1 µM, 3 µM, and 10 µM in the presence of 0.1% DMSO. The cells 
were incubated with compounds at 37°C for 48 hours. The medium was 
removed and the cells were detached from culture wells by addition of 200 µl of 
trypsin solution (#59427C, Sigma-Aldrich) for 5 minutes at 37°C. 2 ml of ECGM 
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was added and the released cell suspension was collected in 15-ml conical 
Falcon tubes. The cells were fixed by addition of 5 ml 95% ethanol at room 
temperature for 30 minutes. Then cells were centrifuged at 3000 rpm for 5 
minutes, ethanol was replaced, and the cells were resuspended in 1 ml of 
Propidium Iodide (PI) working solution (propidium iodide, 100 ng/ml; RNase-A, 
10 µg/ml; NP40, 0.05%). The cells were incubated with PI staining solution at 
37°C for 30 minutes. The cells were analyzed for mitotic arrest with a flow 
cytometer (FCM) from Beckman Coulter (GalliosTM Instrument Fluorochrome). 
Yellow fluorescence channel containing 575BP/26 filter (range 562-588nm) was 
used for analysis. 
Proliferation and sprouting assays 
Proliferation and sprouting experiments using HUVECs and lymphatic endothelial 
cells (LECs) were performed by our collaborators Dr. Adriana Primorac and Prof. 
Dr. Michael Detmar (Institute of Pharmaceutical Sciences, ETH Zürich, 
Switzerland). In brief, HUVECs were purchased from Promocell GmbH. Primary 
human dermal lymphatic endothelial cells (LEC) were isolated from neonatal 
human foreskins by immunomagnetic purification as described previously 
(Nakatsu et al., 2007). Cells were cultured in endothelial basal medium (EBM; 
Lonza) supplemented with 20% fetal bovine serum (FBS; Invitrogen), antibiotic-
antimycotic solution (Invitrogen), 2 mM L-glutamine (Invitrogen), 10 μg/ml 
hydrocortisone (Sigma-Aldrich) and 25 μg/ml N-6,2’-Odibutyryladenosine 3’,5’-
cyclicmonophosphate (cAMP; Sigma-Aldrich) for up to 11 passages. Cells were 
grown on plastic dishes coated with type I collagen (50 μg/ml in PBS; Advanced 
Biomatrix). All cells were grown in a humidified atmosphere at 37°C and 5% 
CO2.  
Cell proliferation assays were performed as follows. Cells (1.5 – 3 x 103) were 
seeded on type I collagen coated 96-well black, clear-bottom plates (Costar 
3603, Corning) and incubated with 0.1% DMSO (Sigma-Aldrich) as solvent 
control, VEGFA (20 ng/ml), A1 AR antagonists at different concentrations in EBM 
containing 2% fetal bovine serum. After 2 days of incubation at 37°C, cells were 
incubated with 4-methylumbelliferylheptanoate (Sigma-Aldrich). The intensity of 
fluorescence, proportional to the number of viable cells, was measured using a 
microplate reader (SpectraMax Gemini EM, Molecular Devices). Eight replicates 
per condition were analyzed. To investigate cell sprouting, cytodex microcarriers 
were coated with LECs or HUVECs (Schulz et al., 2012). For HUVECs, the 
microcarriers were coated with fibronectin (10 μg/ml in PBS; Merck Millipore). 
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Then, the cell-coated microcarriers were embedded in a collagen type I gel and 
were incubated for 24 hours in 0.1% DMSO, a mixture of VEGFA (40 ng/ml) and 
basic fibroblast growth factor (bFGF, 40 ng/ml) or different concentrations of 
test compound. The induced sprouts were imaged at 4x magnification (Molecular 
Devices ImageXpress Micro HCS microscope MD2, Photometrics CoolSNAP HQ 
camera; Photometrics). Image analysis was performed using NIH Image J (64-
bit) software. The number of sprouts per microcarrier were counted and plotted. 
Three replicates per condition were performed. For all in vitro studies, three 
independent experiments were performed. Figures show results of one 
representative experiment. Statistical analyses were performed using one-way 
ANOVA (Prism 5, Graph Pad). 
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Reanalysis of an in vivo chemical library screen defines AR-subtype 
specific antagonists for testing in Xenopus embryos 
A two-step in vivo chemical library screen was developed in our laboratory to 
identify small organic molecules that would disrupt blood and/or lymph vessel 
development in Xenopus embryos (Kalin et al., 2009). The primary screening 
procedure led to the identification of 66 compounds representing different 
pharmacological classes that either induced edema formation or late lethality in 
Xenopus embryos. Three of the 66 compounds were AR-specific antagonists: 7-
Chloro-4-hydroxy-2-phenyl-1,8-naphthyridine (7CN), 1,3-Diethyl-8-
phenylxanthine (DEPX); and 9-Chloro-2-(2-furyl) [1,2,4] triazolo [1,5-c] 
quinazolin-5-amine (CGS 15943). A secondary in situ hybridization screen 
revealed that treatment of Xenopus embryos with the A1 AR-specific antagonists 
7CN and DEPX caused vascular defects. This however was not the case in 
embryos treated with the AR antagonist CGS 15943 (Kalin et al., 2009). These 
pharmacological findings suggest a role for A1 ARs in blood and lymph vessel 
formation in Xenopus embryos, which warrants further investigation and 
characterization.  
Given that, adenosine treatment stimulates the formation of new blood vessels 
in the chick chorioallantoic membrane and in other test systems (see 
Introduction for details); we first asked whether agonists of ARs were present in 
the LOPAC chemical library screened by Kalin et al. (2009) and whether they 
had any effect. Table 9 compiles all AR agonists according to their reported AR 
selectivity. In total 22 AR agonists were present in the LOPAC library. Adenosine 
and N6-Methyladenosine were non-selective AR agonists, whereas the other 20 
agonists are classified as AR-selective agonists. Importantly, treatment of 
Xenopus embryos with any of the 22 AR agonists at a concentration of 20 µM 
neither caused edema formation nor premature lethality. For these reasons, this 
class of organic compounds were not further investigated in the context of the 
present thesis.  
Table 10 lists the 25 AR antagonists with their reported AR-subtype selectivities 
that were present in the LOPAC chemical library examined in the study by Kalin 
et al. (2009). Importantly, we noticed that the specificity of CGS 15943 was 
misrepresented in the manufacturer’s information accompanying the LOPAC 
chemical library. CGS 15943 acts as a potent and selective antagonist for human 
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A2A AR with a Ki of 1.2 nM (Fredholm et al. 2011; Müller & Jacobsen 2011). It is 
however only modestly A2A AR-selective given that its Ki for human A1 AR is 3.5 
nM. The Ki values for A2B and A3 ARs are at least 10-fold higher.  
We conclude, in line with the findings of Kalin et al. (2009), that in vivo testing 
of 22 agonists and 25 antagonists targeting AR signaling in Xenopus embryos 
resulted in the identification of two A1 AR antagonists, 7CN and DEPX, that are 
effective at disrupting blood and lymph vessel formation. To explore the AR-
subtype specificity in greater detail, we selected a panel of AR antagonists with 
high affinity and AR-subtype selectivity (Table 11). For each AR subtype, at least 
3 antagonists were chosen for testing alongside of 7CN and DEPX. This panel of 
compounds will also be employed for in vivo dose-response studies, which had 
not been performed to date. 
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Table 9. AR agonists tested in Xenopus embryos by Kalin et al. (2009) 
Name Secondary Name Cas Number 
Molecular 
weight 
Selectivity 
Adenosine  58-61-7 267.25  
N6-Methyladenosine 
6-Methylaminopurine-9-
ribofuranoside 
1867-73-8 281.27  
N6-2-Phenylethyladenosine  20125-39-7 371.40 A1 
N6-Phenyladenosine   343.34 A1 
R(-)-N6-(2-Phenylisopropyl) 
adenosine 
R (-)-PIA 38594-96-6 385.43 A1 
(S)-ENBA 
PD-126280; ((2S)-N6-[2-
endo-Norbornyl] adenosine 
 361.40 A1 
N6-Cyclohexyladenosine CHA 36396-99-3 349.39 A1 
N6-Cyclopentyladenosine CPA 41552-82-3 335.37 A1 
5'-N 
ethylcarboxamidoadenosine 
NECA 35920-39-9 308.30 A1  / A2 
2-Chloroadenosine 2-CADO 146-77-0 301.69 A1  / A2 
5'-N-
Methylcarboxamidoadenosine 
MECA 35788-27-3 294.27 A2 > A1 
2-Phenylaminoadenosine CV-1808  358.36 A2 > A1 
5'-(NCyclopropyl) 
carboxamidoade nosine 
CPCA 50908-62-8 320.31 A2 
PD-125944 DPMA 120442-40-2 521.58 A2 
HE-NECA 
2-Hexynyl-5'- 
ethylcarboxamidoadenosine 
 388.43 A2 
Metrifudil 
N-[(2-Methylphenyl) methyl]-
adenosine 
 371.40 A2 
CGS-21680 hydrochloride 
2-p-(2-Carboxyethyl) 
phenethylamino 5'-
thylcarboxamidoadenosine 
124182-57-6 535.99 A2A 
N6-2-(4-Aminophenyl) 
ethyladenosine 
APNEA 89705-21-5 386.41 A3 
AB-MECA 
N6-(4-Aminobenzyl)-9-[5-
(methylcarbonyl)-beta-
Dribofuranosyl] adenine 
 399.41 A3 
N6-Benzyl-5'-
Nethylcarboxamidoadenosine 
N6-Benzyl-NECA  398.42 A3 
Chloro-IB-MECA 
 
2-Chloro-N6-(3-iodobenzyl)-
adenosine-5'-
Nmethyluronamide 
163042-96-4 544.74 A3 
1-Deoxy-1-[6-[(3-iodophenyl) 
methyl] amino]-9H-purin-9-
yl]-Nmethyl-beta- 
Dribofuranuronamide 
IB-MECA 152918-18-8 510.29 A3 
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Table 10. AR antagonists tested in Xenopus embryos by Kalin et al. (2009) 
Name Secondary Name 
Cas 
Number 
Molecular 
weight 
Selectivity 
Caffeine 1,3,7-Trimethylxanthine 58-08-2 194.19  
1,3-Diethyl-8-phenylxanthine DEPX 75922-48-4 284.32 A1 
8-Cyclopentyl-1,3-
dipropylxanthine 
DPCPX; PD 116,948 102146-07-6 304.40 A1 
Xanthine amine congener 
8-[4-[[[[(2- Aminoethyl) amino] 
carbonyl] met hyl]oxy]phenyl]-
1,3- dipropylxanthine 
 428.50 A1 
7-Chloro-4-hydroxy-2-
phenyl-1,8-naphthyridine 
7CN  256.69 A1 
8-Cyclopentyl-1,3- 
dimethylxanthine 
CPT; 8-Cyclopentyltheophylline 35873-49-5 248.29 A1 
FSCPX 
8-Cyclopentyl-N3-[3-(4- 
(fluorosulfonyl)benzoyloxy)propy 
l]-N1-propylxanthine 
156547-56-7 506.56 A1 
1,3-Dimethyl-8- 
phenylxanthine 
8-Phenyltheophylline; DMPX 961-45-5 256.27 A1 
N6-Cyclopentyl-9- 
methyladenine 
N-0840 109292-91-3 217.28 A1 
Aminophylline 
Ethylenediamine 
Theophylline ethylenediamine 317-34-0 420.43 A1  / A2 
Theophylline 1,3-Dimethylxanthine 58-55-9 179.18 A2 > A1 
Theobromine 3,7-Dimethylxanthine 83-67-0 180.17 A2 > A1 
1,7-Dimethylxanthine Paraxanthine 611-59-6 180.17 A2 > A1 
3-n-Propylxanthine Enprofylline 41078-02-8 194.19 A2 > A1 
8-(p-Sulfophenyl) 
theophylline 
 80206-91-3 336.33 A2 > A1 
1,3-Dipropyl-8-
psulfophenylxanthine 
DPSPX 89073-57-4 392.44 A2 > A1 
1,3-Dipropyl-7-
methylxanthine 
 31542-63-9 250.30 A2 
3,7-Dimethyl-
Ipropargylxanthine 
 14114-46-6 218.22 A2 
1-Allyl-3,7-dimethyl-8-
psulfophenylxanthine 
 149981-25-9 376.39 A2 
CGS 15943 
9-Chloro-2-(2-furyl) [1,2,4] 
triazolo[1,5-c] quinazolin -5-
amine 
104615-18-1 285.69 A2A > A1 
8-(3-Chlorostyryl) caffeine CSC 147700-11-6 330.78 A2A 
Alloxazine Isoalloxazine  214.18 A2B 
MRS 1754 
8- [4-[(4- Cyanophenyl) 
carbamoylmethyl) oxy]phenyl]-
1,3-di(npropyl) xanthine 
 486.53 A2B 
VUF 5574 
N-(2-methoxyphenyl)-N'-[2-(3- 
pyridinyl)-4-quinazolinyl]-urea 
 371.40 A3 
MRS 1523 
3-propyl-6-ethyl-5- 
[(ethylthio)carbonyl]-2-phenyl-
4- propyl-3-pyridine carboxylate 
212329-37-8 399.56 A3 
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Table 11. AR-subtype selective antagonists chosen for in vivo testing in Xenopus 
embryos 
Ki values refer to studies with human ARs unless noted. Abbreviations: AR, adenosine receptor; n.a., not 
available; b, bovine; r, rat. 
  
Compound 
name 
 
AR 
selectivity 
Ki Values (nM) Reference 
A1 A2A A2B A3 
DEPX 
 
A1 44.5 (r) 863 (r) 341 n.a. 
(Phelps et al., 2006, 
Bruns et al., 1987) 
7CN A1 
0.15 (b) 
300 
100 (b) 
400 
n.a. 
2100 (b, 
r) 
(Ferrarini et al., 
2000, Ferrarini et 
al., 2004)  
PSB 36 A1 0.7 980 187 2300 
(Fredholm et al., 
2011) 
SLV 320 A1 1 398 3981 200 
(Fredholm et al., 
2011) 
CGS 15943 A2A 3.5 1.2 32.4 35 
(Fredholm et al., 
2011) 
SCH 442416 A2A 1110 4.1 >10,000 >10,000 
(Fredholm et al., 
2011) 
SCH 58261 A2A 725 5 1110 1200 
(Fredholm et al., 
2011) 
ZM 241385 A2A 774 1.6 75 743 
(Fredholm et al., 
2011) 
MRS 1706 A2B 157 112 1.39 230 (Kalla et al., 2009) 
MRS 1754 A2B 403 503 1.97 570 
(Fredholm et al., 
2011) 
PSB 1115 A2B >10,000 24,000 (r) 53.4 >10,000 
(Fredholm et al., 
2011) 
MRS 3777  A3 >10,000 >10,000 >10,000 47  
(Jacobson and Gao, 
2006) 
 
PSB 11  A3 1640 1280 2100 2.34 
(Fredholm et al., 
2011) 
VUF 5574 A3 ≤10,000(r) ≤10,000 n.a. 4  
(Fredholm et al., 
2011) 
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Widespread expression of ARs in Xenopus embryos 
Given the potential role for AR signaling in vascular development and/or function 
uncovered by our previous chemical library screening strategy, we decided to 
assess first the expression of ARs in Xenopus embryos. The genomes of Xenopus 
tropicalis and Xenopus laevis harbor genes for all four AR genes (see 
xenbase.org for details). AR gene expression in Xenopus embryos from stage 25 
to stage 40 was determined by whole-mount in situ hybridization using 
antisense probes generated from AR cDNAs (Figure 14). All four ARs were 
expressed in the developing eyes and the central nervous system, particularly 
throughout the brain and spinal cord. Furthermore, AR subtype specific gene 
expression domains were observed. For example, A1 ARs was expressed in the 
cement gland and pronephric kidney. Pronephric expression was present along 
the entire nephron. Cement gland expression was also observed for A3 ARs, but 
this was confined to stage 25 embryos only. A2A and A2B ARs were also 
prominently expressed in somites. Furthermore, A2B ARs were widely expressed 
in the intermediate mesoderm, and moderate A2B AR gene expression could be 
detected in the distal pronephric kidney of stage 40 embryos. The renal 
expression of ARs in Xenopus embryos mirrors remarkably the situation in the 
adult kidneys of rodents, where A1 and A2B ARs are the primary AR genes with 
expression in the nephron (Vitzthum et al., 2004). Importantly however, none of 
the four Xenopus ARs were expressed in the developing embryonic blood or 
lymph vasculature at levels detectable by whole mount in situ hybridization. 
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Figure 14. Expression of AR genes in Xenopus embryos. AR gene expression was determined by 
whole mount in situ hybridization. Embryos are shown in lateral views. Besides common expression in 
the brain and eyes, the characteristic expression domains of the different ARs are as follows: A1 AR, the 
cement gland (arrowhead), spinal cord (sc), and the pronephric kidney (arrows); A2A AR, somites 
(arrows); A2B AR, somites (arrows) and intermediate mesoderm (arrowheads); and A3 AR, the cement 
gland (arrowhead) and spinal cord (sc).  
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Antagonists with selectivity for A1 ARs are effective at inducing edema 
in Xenopus embryos  
Selected AR antagonists (Table 11) were tested in vivo to determine their anti-
lymphatic/angiogenic potential by scoring their ability to induce edema in a 
dose-dependent manner. Xenopus embryos at embryonic stage 31 (37 hours 
post fertilization, hpf), which is prior to the onset of vascular and lymphatic 
vessel development (Kalin et al., 2009), were arrayed in 48-well dished and 
treated with the selected antagonists. Each AR antagonist was tested at final 
concentrations ranging between 0.01 µM to 100 µM in the culture media (0.1x 
MMR; 1% DMSO). Negative controls included embryos treated with 0.1x MMR 
alone and those with 0.1x MMR plus 1% DMSO alone. Pharmacological 
treatments were performed for a period of 5 days until embryos reached stage 
47 (Fig. 15). The embryonic phenotypes, particularly the appearance of edemas, 
were scored twice daily by visual inspection using a dissecting microscope. The 
following pharmacological parameters were established once embryos reached 
stage 45: EC50 (effective concentration, where 50% of the treated embryos 
present with edema and/or die), LC50 (lethal concentration, causing lethality in 
50% of the treated embryos), and ECmax (effective concentration, where 
maximal incidence of edema was observed) (see Material and Methods for 
details). 
 
Figure 15. Procedure to assess the potency of AR antagonists to induce edema formation 
in Xenopus embryos. The phenotypic screening procedure was performed in 48-well plates with 
five Xenopus embryos (E) per well. The embryos were scored twice daily for the presence of 
edema or lethality.  
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The results obtained from the in vivo treatments with subtype-specific AR 
antagonist were unambiguous. First, none of the antagonists selective for A2B 
and A3 ARs induced edema or caused lethality even at 100 µM, the highest dose 
tested (not shown). Secondly, CGS 15943 was the only A2A AR-selective 
antagonist that induced edema and embryonic lethality. Finally, all A1 AR-
selective antagonists showed edema and followed by embryonic lethality.  
Fig. 16 shows the edema phenotypes observed at stage 45 after treatment with 
the bioactive AR antagonists. Embryos treated with 7CN and DEPX were 
characterized by the presence of pericardial and pronephric edema. By contrast, 
CGS 15943 showed strong pericardial edema without pronephric edema. Finally, 
PSB 36 and SLV 320 treatments caused the formation of generalized ventral 
edema.  
 
Figure 16. Distinct edema phenotypes induced by subtype-specific AR antagonists in Xenopus 
embryos. The embryos were treated with the indicated AR antagonists at concentrations equivalent to 
ECmax (see Table 12) and incubated until stage 45. Control embryos were treated with 0.1x MMR and 
0.1x MMR with 1% DMSO. Representative embryos are shown in lateral views with enlargements below 
depicting head and trunk of the respective embryo. Primary areas of edema formation are marked by 
arrowheads for pericardial, arrows for pronephric, and asterisks for generalized ventral edema.  
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The dose-response relationships for the primary phenotypes (edema, lethality) 
observed in stage 45 embryos treated with bioactive AR antagonists are shown 
in Fig. 17. At the stage 45 endpoint, the percentage of normal, edema-
harboring, and dead embryos were determined. The obtained graphs were used 
to calculate EC50, ECmax, and LC50 values for each AR antagonist tested (Table 
12). Furthermore, we defined the therapeutic index (TI) as the ratio of LC50 over 
EC50. Our findings demonstrate that the compound concentration (ECmax) need to 
induce maximal edema frequency in the embryos was always lower than the one 
causing half-maximal lethality (LC50). The TI values ranged between 2.2 (for 
DEPX) and 11 (for SLV 320) indicating that SLV 320 was most optimal in that 
robust edema formation could be induced at concentrations, where no or 
minimal lethality was observed. With regard to the EC50 values, PSB 36 was the 
least potent compound with an EC50 value of 6.7 µM. By contrast, 7CN was the 
most potent compound with an EC50 value of 0.3 µM. It was therefore the only 
AR antagonist with edema-inducing efficacy at nanomolar compound 
concentrations in the media. However, 7CN was also the only AR antagonist with 
an LC50 value in the high nanomolar range. PSB 36, the least toxic compound, 
had an LC50 value of 23 µM.  
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Figure 17. Dose-response relationships of phenotypes induced in Xenopus embryos by AR 
antagonist treatment. Xenopus embryos were treated with the indicated AR antagonists at 
concentrations ranging from 0.1 µM to 100 µM. The phenotypes (edema, death) were scored once 
embryos reached stage 45. The black line shows the percentage of normal embryos observed with 
increasing doses of the AR antagonist. The blue line shows the percentage of embryos with edema. The 
dose-dependence of embryonic lethality shown with red lines. The graphs shown are compiled from at 
least six independent experiments. The error bars indicate standard deviations.  
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Table 12. Compilation of pharmacological parameters obtained from Xenopus embryos 
after AR antagonist treatment 
Compound Selectivity 
In vivo 
phenotype 
EC50 
[µM] 
ECmax 
[µM] 
LC50 
[µM] 
TI 
DEPX A1 Edema 2.4 4.9 5.3 2.2 
7CN A1 Edema 0.3 0.5 0.9 3 
PSB 36 A1 Edema 6.7 10 23 3.4 
SLV 320 A1 Edema 2 10 22 11 
CGS 
15943 
A2A Edema 2 5.1 21 10.5 
 
 
Combination treatments with antagonists targeting A2A, A2B or A3  ARs 
were ineffective at inducing edema formation  
Pharmacological profiling of subtype-specific AR antagonists indicates that 
selectivity for A1 ARs is a requirement for the induction of edema formation in 
Xenopus embryos. We next asked whether edema formation could be achieved 
by simultaneously inhibiting two AR subtypes in vivo. Xenopus embryos were 
treated with all possible combinations of subtype-specific AR antagonists, who 
by themselves had no edema-inducing potential (Fig. 18; Table 13). Each 
compound was present at a concentration of 20 µM in the culture media. The 
embryos were treated with the AR antagonist combinations from stage 31 to 
stage 45 as in the previous experiments. With one exception, all AR antagonist 
combinations tested failed to induce edema efficiently in Xenopus embryos. 
Typically, less than 10% of the embryos displayed a phenotype (edema or 
lethality) and many combinations had no effect at all. Similarly, we found that 
treatment of embryos with single A2A selective antagonists even at a 
concentration of 40 µM were ineffective at inducing edema at frequencies higher 
than 15%. By contrast, 80% of the embryos treated with a combination of SCH 
442416 and SCH 58261 had a phenotype: 45% manifested with edema, and 
35% had died (Table 13). However, concentrations of at least 20 µM of each 
antagonist were required to elicit these phenotypes, whereas A1 selective AR 
antagonists were alone effective at lower concentrations. Overall, the 
combination experiments indicate that co-inhibition of any two A2A, A2B or A3 AR 
is not sufficient to cause edema formation in Xenopus embryos.  
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Figure 18. Summary of the phenotypes observed after treatment of Xenopus embryos with AR 
antagonist combinations. The matrix shows all tested compound combinations. The pie charts 
visualize the relative frequencies of the observed main phenotypes (normal, edema, lethality). MMR and 
DMSO denote negative control experiments, where embryos were treated with the culture medium 0.1x 
MMR and 0.1x MMR containing 1% DMSO. The pie charts were generated from the primary data shown 
in Table 13.  
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Table 13. Frequencies of phenotypes observed in Xenopus embryos treated with AR 
antagonist combinations 
AR antagonist Normal 
[%] 
Edema 
[%] 
Lethality 
[%] 
SCH 442416 + SCH 442416 85 15 0 
SCH 442416 + SCH 58261 20 45 35 
SCH 442416 + ZM 241385 75 20 5 
SCH 442416 + MRS 1706 85 15 0 
SCH 442416 + MRS 1754 85 5 0 
SCH 442416 + PSB 1115 90 10 0 
SCH 442416 + MRS 3777 95 5 0 
SCH 442416 + PSB 11 98 2 0 
SCH 442416 + VUF 5574 85 15 0 
SCH 58261 + SCH 58261 100 0 0 
SCH 58261 + ZM 241385 100 0 0 
SCH 58261 + MRS 1706 90 10 0 
SCH 58261 + MRS 1754 100 0 0 
SCH 58261 + PSB 1115 98 0 2 
SCH 58261 + MRS 3777 90 10 0 
SCH 58261 + PSB 11 98 2 0 
SCH 58261 + VUF 5574 98 2 0 
ZM 241385 + ZM 241385 100 0 0 
ZM 241385 + MRS 1706 98 0 2 
ZM 241385 + MRS 1754 100 0 0 
ZM 241385 + PSB 1115 100 0 0 
ZM 241385 + MRS 3777 100 0 0 
ZM 241385 + PSB 11 98 2 0 
ZM 241385 + VUF 5574 100 0 0 
MRS 1706  + MRS 1706 100 0 0 
MRS 1706 + MRS 1754 100 0 0 
MRS 1706 + PSB 1115 100 0 0 
MRS 1706 + MRS 3777 100 0 0 
MRS 1706 + PSB 11 100 0 0 
MRS 1706 + VUF 5574 98 0 2 
MRS 1754 + MRS 1754 100 0 0 
MRS 1754 + PSB 1115 98 2 0 
MRS 1754 + MRS 3777 100 0 0 
MRS 1754 + PSB 11 98 2 0 
MRS 1754 + VUF 5574 100 0 0 
PSB 1115 + PSB 1115 95 5 0 
PSB 1115 + MRS 3777 85 5 10 
PSB 1115 + PSB 11 95 0 5 
PSB 1115 + VUF 5574 98 2 2 
MRS 3777 + MRS 3777 93 2 5 
MRS 3777 + PSB 11 100 0 0 
MRS 3777 + VUF 5574 98 2 0 
PSB 11 + PSB 11 100 0 0 
PSB 11 + VUF 5574 98 0 2 
VUF 5574 + VUF 5574 100 0 0 
Note: The final concentration of each compound in the culture media was 20 µM. The results listed per 
compound combination were compiled from 6 independent experiments with a total of 60 embryos. No 
abnormalities were observed when embryos were cultured in 0.1x MMR or 0.1x MMR with 1% DMSO.      
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AR antagonists affecting blood and lymph vessel morphogenesis  
Four A1 AR antagonists and the A2A AR-selective CGS 15943 antagonist were 
found to be capable of inducing edema in Xenopus embryos (Table 12). The 
appearance of edema in compound-treated embryos may be attributed to 
dysfunction of the cardiovascular system, the lymphatics, and/or the kidneys. 
Therefore, compound-treated embryos were analyzed by whole mount in situ 
hybridization for any alterations in tissue and organ morphology using organ-
specific molecular markers. The embryos were treated with the AR antagonists 
at concentrations equivalent to previously established EC50 values (Table 12). 
The embryos were raised to stages 35/36 (50 hpf) for the analysis of blood 
vessels and pronephric kidneys, and to stage 40-41 (76 hpf) for the lymphatics, 
respectively.  
A comparison of blood vessel development revealed nicely established vascular 
structures with vitelline vein networks and sprouting intersomitic vessels (ISVs) 
in embryos raised under control conditions (0.1x MMR; 0.1x MMR with 1% 
DMSO) (Fig. 19). By contrast, vascular abnormalities were evident in DEPX- and 
7CN-treated embryos (Fig. 19). VVN formation and ISV sprouting was impaired, 
particularly in 7CN-treated embryos. These findings are consistent with those 
reported by us previously (Kalin et al., 2009). Surprisingly, the blood vascular 
system appeared largely unaffected in embryos treated with PSB 36, SLV 320, 
and CGS 15943 (Fig. 19). Abnormal blood vessel morphogenesis is therefore 
unlikely to be the underlying defect causing edema formation in the embryos 
treated with this set of compounds.  
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Figure 19. AR antagonists interfering with blood vessel morphogenesis. Embryos were treated 
with the indicated AR antagonists at concentrations equivalent to the EC50 values (see Table 12) and 
raised until they reached stage 35/36. Subsequently, the embryos were fixed and the expression of the 
blood vessel marker aplnr (msr, apj-b) was determined by whole mount in situ hybridization. 
Arrowheads and arrows indicate disrupted VVN networks and impaired ISV sprouting, respectively. 
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DEPX and 7CN treatments disrupt lymph vessel morphogenesis 
To determine possible defects in lymphatic vessel development, compound-
treated embryos were raised to stages 40 and 41, when they were subjected to 
whole mount in situ hybridization to visualize the expression of lymphatic 
marker vegfr3 (Kalin et al., 2009). At these stages the lymphatic system 
includes the bilateral anterior lymph hearts (ALH), posterior lymph vessels 
(PLVs), and the anterior lymph sacs (ALS). Besides lymphatic endothelia, vegfr3 
is also expressed in the VVNs (Fig. 20).  
The embryos treated with DEPX and 7CN showed large-scale deficiencies of their 
lymphatic systems (Fig. 20). The ALHs were devoid of afferent lymph vessels, 
the ALSs appear to be underdeveloped, and the VVNs were disorganized. 
Patches of vegfr3-expressing cell clusters suggest the presence of endothelial 
cells, which failed to assemble into vessel and capillary networks. The absence of 
VVNs is consistent with previous results (compare with Fig. 19). Embryos 
treated with the other AR antagonists did not show overtly abnormal lymphatic 
structures (Fig. 20). For example, ALHs, ALSs, and VVNs were well established 
and comparable to control embryos. Taken together, DEPX and 7CN disrupted 
both blood and lymph vessel morphogenesis, whereas the edema-inducing 
activities of PSB 36, SLV 320 and CGS 15943 cannot be attributed to defects in 
the morphogenesis of these vessel systems.  
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Figure 20. AR antagonists interfering with lymph vessel morphogenesis. Embryos were treated 
with the indicated AR antagonists at concentrations equivalent to the EC50 values (see Table 12) and 
raised until they reached stage 40/41. Subsequently, the embryos were fixed and the expression of the 
lymph vessel marker vegfr3 was determined by whole mount in situ hybridization. Abnormalities in 
lymphatics feeding to the ALH (arrows), underdeveloped ALSs (asterisks) and disrupted VVNs 
(arrowheads) are indicated. Note that VVNs are normal in PSB 36, SLV 320 and CGS 15943 treated 
embryos. 
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Normal pronephric kidney morphogenesis in embryos treated with AR 
subtype-selective antagonists  
The pronephros marker fxyd 2 (γ subunit of Na+ K+ ATPase) was used to assess 
possible defects in pronephric kidney morphogenesis in AR antagonists-treated 
embryos at stage 35/36. At this stage the pronephric nephron is comprised of 
four main segments (proximal tubule, intermediate tubule, distal tubule, and 
connecting tubule) expressing fxyd2 (Raciti et al., 2008). The morphologies of 
the pronephric kidneys of control and compound-treated embryos are shown in 
Fig. 21. The pronephric kidneys of compound-treated embryos were comparable 
to controls, and no defects in nephron segment development were apparent. 
Edema formation in 7CN- and DEPX-treated embryos may therefore be 
attributed to arrested or disrupted blood and lymph vessel development, without 
affecting pronephric kidney development. With regard to PSB 36, SLV 320, and 
CGS 15943, the morphogenesis of pronephric kidneys and blood and lymphatic 
vessels appears to be normal suggesting the other mechanisms cause edema 
formation in embryos treated with these compounds. Of all the AR antagonists 
tested by us to date in Xenopus embryos, only 7CN and DEPX were able to 
disrupt vascular and lymphatic vessel development.  
 
Figure 21. AR antagonist treatments do not affect pronephric kidney development. Embryos 
were treated with the indicated AR antagonists at concentrations equivalent to the EC50 values (see 
Table 12) and raised until they reached stage 35/36. Subsequently, whole mount in situ hybridization 
was performed to visualize expression of the pronephric marker fxyd2. Compound-treated embryos 
retain normal pronephric kidneys, which were comparable in morphology to control embryos (0.1x MMR; 
0.1x MMR with 1% DMSO).  
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7CN and DEPX specific antagonists did not affect hematopoiesis, 
erythrocyte dispersal and muscle differentiation 
Next, we asked whether treatment of 7CN and DEPX interfered with the 
development of other organ systems in Xenopus embryos. Whole mount in situ 
hybridizations were performed on compound-treated stage 40 embryos to 
visualize the expression of hemoglobin αT3 subunit (hba3, αT3 globin) for 
erythrocytes, tal1 (scl) for hemangioblasts, and myod1 (myoD) for myoblasts 
(Fig. 22).  
Unlike mammalian erythrocytes, erythrocytes in Xenopus are nucleated and 
therefore they can be traced by visualizing globin gene expression (Kelley et al., 
1994). Stage 40 embryos have a functional cardiovascular system with 
circulating erythrocytes present in blood vessels, including PCVs, ISVs and VVNs 
(Fig. 22A,B). By contrast, erythrocyte dispersal was strongly reduces or blocked 
in compound-treated embryos (Fig. 22C,D). The erythrocytes were largely 
confined to the ventral blood islands indicating that specification and 
differentiation of erythrocytes is not affected by 7CN or DEPX treatment. As 
these compounds disrupt VVNs formation (Fig. 19), the erythrocytes remain 
trapped in the ventral blood islands and are unable to circulate.  
The transcription factor tal1 (scl) is initially expressed in the ventral blood island 
and the dorsal lateral plate (DLP), where it is crucial for the development of 
hemangioblasts in Xenopus embryos (Ciau-Uitz et al., 2013). The 
hemangioblasts of the DLP migrate to the midline, where they coalesce to form 
the dorsal aorta and, subsequently will give raise to the hemogenic endothelium 
and hematopoietic stem cells (Ciau-Uitz et al., 2013, Ciau-Uitz et al., 2000). As 
expected, the tal1-expressing hemangioblasts of stage 40 embryos are found in 
the ventral blood islands and in blood vessels of the DLP (Fig. 22 E,F). In 
compound-treated embryos, tal1-expressing hemangioblasts are confined the 
ventral blood islands, where they appear to be more abundant than in control 
embryos (Fig. 22G,H). No tal1-expressing hemangioblasts were detected in the 
DLP. This suggests that 7CN and DEPX interfere with the formation or 
differentiation of hemangioblasts in the DLP, where they would normally 
contribute to blood vessels and adult HSCs.  
In stage 40 embryos, the myoblast marker myod1 is expressed primarily in the 
somites and in migrating myoblasts, which will contribute to the hypaxial 
muscles of the abdomen (Maczkowiak et al., 2010). We observed that compound 
treatment of Xenopus embryos did not interfere with myod1 expression and 
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clusters of migrating myoblasts were present in normal numbers (Fig. 22I-L). 
Therefore, myogenesis is not affected by DEPX or 7CN treatment. Overall, the 
effects of DEPX and 7CN treatment in Xenopus embryos appear not to be of 
pleiotropic nature, disrupting the morphogenesis of multiple tissues or organs. 
Rather, the effects appear to be limited to interfering with blood and lymph 
vessel formation.  
 
Figure 22. Effects of DEPX and 7CN treatments on erythropoiesis, hemangiopoiesis, and 
myogenesis in Xenopus embryos. Embryos were treated with the DEPX and 7CN from stages 31 to 
40. Whole mount in situ hybridizations were performed to detect the expression of marker genes for 
erythrocytes (hba3/αT3 globin; a-d), hemangioblasts (tal1/scl; e-h), and myoblasts (myod1; i-l). (a-d) 
Erythrocytes remain largely confined to the ventral blood islands (arrowheads) in compound-treated 
embryos. (e-h) Hemangioblasts expressing tal1 present in ventral blood islands (arrows), but absent 
from the DLP regions (arrowheads). (i-l) Expression of myod1 in the somites and migrating myoblasts 
(arrowheads) is not affected by DEPX or 7CN treatment.  
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Effects of DEPX and 7CN on endothelial cell proliferation and sprouting 
in vitro  
The AR antagonists DEPX and 7CN were found to specifically disrupt blood and 
lymphatic vessel development in Xenopus embryos. We therefore asked whether 
these compounds are also active in mammals and whether they exert their 
effects directly or indirectly on blood vascular and lymphatic endothelial cells. 
Furthermore, we wondered whether they interfere with endothelial cell 
proliferation and/or sprouting. To address these points, experiments in cell 
cultures using human umbilical vein endothelial cells (HUVECs) and lymphatic 
endothelial cells (LECs) were carried out by our collaborator Dr. Adriana 
Promorac in the laboratory of Prof. Dr. Michael Detmar (Institute of 
Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland). 
Cell proliferation assays were performed by treating endothelial cells with the 
compounds in a dose-dependent manner. The compound concentrations tested 
ranged from 0.1 to 10 µM in presence of 0.1% DMSO. The cells were treated 
with VEGFA to enhance cell proliferation and compound treatments werecarried 
out for 48 hours. The control compound SU 4312, a VEGFR antagonist, served as 
a potent inhibitor of endothelial cell proliferation. DEPX appears to suppress in a 
dose-dependent manner VEGFA-dependent cell proliferation to control levels, but 
this effect was not statistically significant (Fig. 23). This was the case for 
HUVECs as well as for LECs. By contrast, 7CN inhibited HUVEC and LEC 
proliferation stronger and brought down cell proliferation below the control levels 
in a statistically significant manner. A 10 µM, proliferation was reduced to levels 
comparable with those obtained in the presence of 10 µM SU 4312. The half-
maximal inhibitory concentration (IC50) for 7CN were 2.09 µM and 2.42 µM for 
HUVECs and LECs, respectively.  
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Figure 23. Effects of DEPX and 7CN on endothelial cell proliferation. The compounds were tested 
in vitro on LEC and HUVEC cultures at the concentrations indicated. SU 4312 concentration was 10 µM. 
After 48 hours, live cells were stained with 4-methylumbelliferyl heptanoate (4-MUH) and fluorescence 
intensities were measured. Data is expressed as mean values ± standard error of mean (SEM) with n=8. 
Results are representative for 3 independent experiments. * p<0.05, ** p<0.01, *** p<0.001. 
 
Microcarrier beads coated with endothelial cells were used to assess the effects 
of DEPX and 7CN on sprouting (Fig. 24). The process was induced in vitro by 
treating HUVECs with basic fibroblast growth factor (bFGF) and VEGFA for 48 
hours. For LECs, sprouting was initiated with bFGF, VEGFA, and sphingosine-1-
phosphate (S1P). The concentrations of DEPX and 7CN ranged from 0.1 to 10 
µM in presence of 0.1% DMSO. The control compound SU 4312 inhibited LEC 
and HUVEC sprouting with IC50 values of 1.55 µM and 2.27 µM, respectively (Fig. 
23, data not shown). DEPX treatment had marginal effects on sprout formation 
by LECs (Fig. 24C, D, G), and for HUVEC sprouting, there were not significant 
effects (Fig. 24J, K, N). 7CN however was a potent inhibitory of both LEC and 
HUVEC sprouting with IC50 values of 0.20 µM and 0.37 µM, respectively (Fig. 
24).  
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Figure 24. Effects of DEPX and 7CN on endothelial cell sprouting. (A-F) Images of collagen gel-
embedded microcarriers coated with LEC after treatment with 0.1% DMSO (A), VEGFA/bFGF/S1P (B), 
0.1 µM or 10 µM DEPX (C, D), and 0.1 µM or 10 µM 7CN (E, F). (G) Results of the LEC sprouting 
experiments. (H-M) Images of collagen gel-embedded microcarriers coated with HUVEC after treatment 
with 0.1% DMSO (H), VEGFA/bFGF (I), 0.1 µM or 10 µM DEPX (J, K), and 0.1 µM or 10 µM 7CN (L, M). 
(N) Results of the HUVEC sprouting experiments. Examples of endothelial sprouting are indicated with 
arrowheads. SU 4312 concentration was 10 µM. The data are shown as mean values ± SEM, n=3. 
Results are representative for 3 independent experiments. *p < 0.05, **p < 0.01, *** p<0.001. 
In summary, the in vitro experiments with HUVECs and LECs indicate that 7CN 
was a strong inhibitor of endothelial cell proliferation and sprouting, whereas the 
effects of DEPX were at best marginal.  
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Structure-activity relationship studies  
Structure-activity relationship (SAR) studies were carried out to determine the 
relationship between the chemical structures of our two lead compounds, DEPX 
and 7CN, and their biological activity, i.e. their ability to induce edema and 
disrupt blood and lymph vessel development. Database searches were 
performed to identify commercially available derivatives of DEPX and 7CN, which 
would be then tested in vivo for bioactivity in Xenopus embryos.  
The in vivo activity of DEPX is influenced by side chain length 
Three derivatives of DEPX (1,3-Diethyl-8-phenylxanthine) were identified, which 
were commercially available: 1,3-Dimethyl-8-phenylxanthine (DMPX); 1,3-
Dipropyl-8-phenylxanthine (DPPX); and 1,3-Dipropyl-8 (p-sulfophenyl) xanthine 
(DPSPX). The chemical structures of the selected compounds in comparison to 
DEPX are shown in Fig. 25. DMPX contains methyl groups in place of the ethyl 
groups at positions 1 and 3 of the xanthine moiety. In DPPX, the side chains are 
extend to propyl groups. Finally, DPSPX is essentially identical to DPPX, but its 
phenyl ring is sulfonated. DMPX and DPPX are useful as we can determine 
whether the length of the 1,3 substitutes (methyl, ethyl and propyl) of 8-
phenylxanthine influence compound activity in vivo. With DPSPX, we could 
assess whether sulfonation of the phenol group provides a benefit. The selected 
DEPX derivatives have been shown in the past to act as antagonists of AR 
signaling (Table 14). On the basis of the available data, DEPX and its derivatives 
appear to preferentially target A1 ARs, with DMPX having the highest affinity.  
 
Figure 25. Selected derivatives of DEPX. The chemical structures of DMPX, DEPX, DPPX, and DPSPX 
were downloaded from ChemSpider (chemspider.com) 
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Table 14. DEPX derivatives and their AR subtype selectivities 
Ki values refer to studies with human ARs unless noted otherwise. Abbreviations: n.a., not available; b, 
bovine; r, rat. 
 
Dose-response studies with DMPX, DPPX, and DPSPX were performed in vivo to 
assess their ability to induce edema in Xenopus embryos and to establish 
pharmacological parameters. Fig. 26 compares the dose-response profile of 
DEPX with those obtained for the DEPX derivatives for the standard 5-day 
treatment assay. Neither DMPX nor DPSPX had significant effects on Xenopus 
embryos. At none of the concentrations tested did they induce edema formation 
and limited lethality was observed at 100 µM, the highest compound 
concentration tested. By contrast, DPPX was essentially indistinguishable from 
DEPX with regard to its ability to induce edema and cause lethality. 
Consequently, the pharmacological values (EC50, ECmax, LC50, TI) for DPPX were 
very similar to those of DEPX (Table 15).  
Compound name Ki Values (nM) Reference 
A1 A2A A2B A3 
DEPX 
 
44.5 (r) 863 (r) 341 n.a. (Phelps et al., 2006, 
Bruns et al., 1987) 
DMPX 1.2  (b) n.a. n.a. n.a. (Bruns et al., 1983) 
DPPX 10 (r) 190 (r) 18.9  n.a. (Yan and Muller, 2004) 
DPSPX 210 (r) 1400 (r) 250  183  (Yan and Muller, 2004) 
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Figure 26. Dose-response relations of phenotypes induced by AR antagonists in Xenopus 
embryos. Xenopus embryos were treated with DMPX, DPPX, and DPSPX at concentrations ranging from 
0.1 µM to 100 µM. Embryos were scored at stage 45 for phenotypes (edema, death). The black line 
shows the percentage of normal embryos, blue line shows the percentage of edema observed with 
increasing doses of the AR antagonist. Dose-dependency for embryonic lethality is shown with red lines. 
The graphs shown are compiled from at least six independent experiments. The error bars indicate 
standard deviations. Panel A was taken from Fig. 17 and is shown for comparative purposes.  
 
Table 15. Pharmacological values obtained from Xenopus embryos after treatment with 
DEPX derivatives 
Compound 
In vivo 
phenotype 
EC50  
[µM] 
ECmax  
[µM] 
LD50  
[µM] 
TI 
DMPX - n.a. n.a n.a n.a 
DEPX Edema 2.4 4.9 5.3 2.2 
DPPX Edema 2.7 4.8 5.7 2.1 
DPXS - n.a n.a n.a n.a 
Abbreviations: n.a., not available.  
 
Results 
 
81 
 
Interestingly, DPPX shared with DEPX a similar pattern of edema induction that 
was characterized by the appearance of pericardial and pronephric fluid 
accumulations (Fig. 27). The shared anatomy of edema formation provides 
further evidence that DPPX acts in vivo similarly to DEPX.   
 
 
Figure 27. Edema phenotypes induced by DPPX in Xenopus embryos. The embryos were treated 
with DPPX at concentrations equivalent to EC50 (see Table 15) and incubated until stage 45. Control 
embryos were treated with 0.1x MMR and 0.1x MMR with 1% DMSO. Representative embryos are shown 
in lateral and dorsal views with enlargements below depicting head and trunk of the respective embryo. 
Primary areas of edema formation are marked by arrowheads for pericardial, arrows for pronephric 
kidney edema. 
 
Since DPPX was found to be a potent inducer of edema in Xenopus embryos, we 
assessed by whole mount in situ hybridization whether compound treatment 
affected blood and lymph vessel development (Fig. 28). The abnormalities with 
blood vessels and the lymphatics in DPPX-treated embryos were very 
reminiscent of those seen with DEPX (compare Figs. 19 & 20 with Fig. 28). 
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Figure 28. DPPX disrupts vascular development in developing embryos. Embryos were treated 
with the DPPX and expression of the blood vessel marker aplnr and the lymph vessel marker vegfr 3 
were determined by whole mount in situ hybridization. (C) Disrupted VVNs and impaired ISVs sprouting 
are indicated by arrowheads and arrows, respectively. (F) Impaired ALHs, ALSs and disrupted VVNs are 
indicated by arrow, asterisks and arrowheads, respectively. 
 
DPPX-treated embryos were also stained for expression of fxyd2, hba3, tal1 and 
myod1 by performing whole mount in situ hybridization (Fig. 29). As with DEPX, 
the distribution of hemangioblasts and erthrytrocytes was altered as a 
consequence of the vascular defects caused by compound treatment (Fig. 29A-
F). DPPX treatment had no apparent effect on the morphology and development 
of pronephric kidney (Fig. 29G-H). Furthermore, we observed that DPPX did not 
interfere with myogenesis and myoblast migration (Fig. 29J-L). In summary, 
DEPX and its derivative DPPX are indistinguishable in their bioactivities in 
Xenopus embryos suggesting that they interact with the same molecular targets.  
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Figure 29. Effects of DPPX on selected tissues and organs of Xenopus embryos. Embryos were 
treated with DPPX and the expression of hemangioblasts marker tal1 (A-C), erythrocyte marker hba3 
(D-F), pronephros marker fxyd2 (G-I) and myoblast marker myod1 (J-L) were determined by whole 
mount in situ hybridization. (A-C) DPPX did not affect the production of hemangioblasts and they were 
present in ventral blood island (arrows) and DLP region (arrowheads). (D-F) Erythrocytes were normally 
generated in ventral blood island (arrowheads) of DPPX-treated embryos but did not disperse due to the 
absence of VVNs. DPPX did not interfere with the morphology and development of pronephric kidney (G-
I) and neither with the differentiation and migration of myoblasts (J-L). 
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Endothelial cell proliferation is not affected by DEPX derivatives 
As for DEPX (Fig. 23), possible effects of DPPX, DMSP and DPSPX treatments on 
human vascular and lymphatic endothelial cell proliferation were assessed (Fig. 
30). Each compound was tested at three concentrations: 0.1 µM, 1 µM, and 10 
µM. However, under most of the conditions tested no effect of the compounds on 
HUVECs or LECs proliferation was observed. DPPX, at the highest concentration 
tested, moderately inhibited VEGFA-induced proliferation of HUVECs and LECs, 
which is reminiscent of DEPX.  
 
 
Figure 30. DEPX derivatives did not affect endothelial cell proliferation. The compounds 
were tested in vitro on HUVEC and LEC cultures at the concentrations indicated. SU 4312 
concentration was 10 µM. After 48 hours, live cells were stained with 4-methylumbelliferyl 
heptanoate (4-MUH) and fluorescence intensities were measured. Data is expressed as mean 
values ± standard error of mean (SEM) with n=8. Results are representative of four or five 
independent experiments for LECs and HUVECs, respectively. * p<0.05, ** p<0.01, *** p<0.001. 
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The in vivo activity of 7CN requires the presence of a phenyl ring 
Two commercially available compounds structurally related to 7CN (7-chloro-4-
hydroxy-2-phenyl-1, 8-naphthyridine) were identified: 7-Methyl-2-phenyl-1, 8-
naphthyridin-4(1H)-one (7MN), and 7-Chloro-4-hydroxy- [1, 8] naphthyridin 
(7CH). The chemical structures of 7CN derivatives are shown in Fig 31. 7CH 
lacks the phenyl group present in 7CN. In 7MN, the chloro group of 7CN is 
replaced by a methyl group. 7MN and 7CH are therefore useful to determine the 
functional significance of the chloro and phenyl moieties in 7CN, respectively. 
Based on available data, selected derivatives appear to preferentially target the 
A1 ARs (Table 16). 
 
Figure 31. Compound structurally related to 7CN. The chemical structures of 7CN, 7MN, and 7CH 
shown were downloaded from ChemSpider (chemspider.com). 
 
Table 16. 7CN derivatives and their AR subtype selectivities 
Ki values refer to studies with human ARs unless noted otherwise. Abbreviations: n.a., not available; b, 
bovine; r, rat. 
 
Xenopus embryos were treated with 7MN and 7CH to assess their potential to 
induce edema in dose-dependent manner. The compounds were tested from a 
concentrations ranging from 0.1 µM to 100 µM concentrations. 7CH did not show 
any effect on Xenopus embryos even at 100 µM, the highest concentration 
tested (data not shown). Neither edema nor lethalities were observed, which 
suggest that phenyl ring is essential for the edema-inducing activity of 7CN. By 
Compound name Ki Values (nM) Reference 
A1 A2A A2B A3 
7CN 
 
0.15 (b) 100 (b) n.a. 2100 (b,r) (Ferrarini et al., 2000) 
7MN 5.3 (b) 460 (b) n.a. 8800 (b,r) (Ferrarini et al., 2000) 
7CH n.a. n.a. n.a. n.a.  
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contrast, 7MN induced edema and led to lethality at submicromolar 
concentrations (Fig. 32, Table 17). The obtained pharmacological parameters 
were very similar to 7CN, but 7MN had a lower LC50 and TI values.  
 
Figure 32. Dose-response relationship of phenotypes induced by 7MN. Xenopus embryos were 
treated with 7MN and pharmacological values were established as described before. Embryos were 
phenotypically analyzed at stage 45 and normal (black), edema formation (blue), and lethality (red) was 
scored. The graphs shown are compiled from at least six independent experiments (n = 10). The error 
bars indicate standard deviations. Panel A with 7CN was taken from Fig. 17 and is shown for 
comparative purposes. 
 
Table 17. Pharmacological values of 7CN derivatives obtained from the treatment of 
Xenopus embryos 
Compound 
In vivo  
Phenotype 
EC50 
[µM] 
ECmax 
[µM] 
LC50 
[µM] 
TI 
7CN Edema 0.3 0.5 0.9 3 
7MN Edema 0.3 0.38 0.4 1.3 
7CH None n.a. n.a. n.a. n.a. 
  Abbreviations: n.a., not available.  
 
As previously observed with DEPX and DPPX, we noted that the pattern of 
edema induction seen after 7MN treatment was essentially identical to the one 
observed with 7CN (Fig. 33; compare with Fig. 16). This is consistent with the 
notion that the two compounds act on the same pathway(s).  
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Figure 33. Edema phenotypes induced by 7MN in Xenopus embryos. The embryos were treated 
with 7MN at concentrations equivalent to EC50 (see Table 17) and incubated until stage 45. Control 
embryos were treated with 0.1x MMR and 0.1x MMR with 1% DMSO. Representative embryos are shown 
in lateral and dorsal views with enlargements below depicting head and trunk of the respective embryo. 
Primary areas of edema formation are marked by arrowheads for pericardial, and arrows for pronephric 
kidney edema. 
As 7MN was found to be a potent inducer of edema in Xenopus embryos, we 
assessed by whole mount in situ hybridization whether compound treatment 
affected vascular development (Fig. 34). Blood vessel and lymphatic defects 
were extensive in 7MN-treated embryos and they were comparable with those 
observed after 7CN treatment (compare Figs. 19 & 20 with Fig. 34).  
 
Figure 34. 7MN interfered with vasculature development in Xenopus embryos. 7MN-treated 
embryos analyzed for possible defects in blood and lymphatic vessel development. (A-C) Arrowheads 
and arrows indicate (C) disrupted VVNs and impaired ISVs sprouting, respectively. (D-F) Impaired ALH, 
abnormal ALSs, and disrupted VVNs are indicated by arrows, asterisks, and arrowheads, respectively. 
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7MN-treated embryos were also stained for expression of fxyd2, hba3, tal1 and 
myod1 by performing whole mount in situ hybridization (Fig. 35). The 
distribution of hemangioblasts and erythrocytes was affected as a result of the 
vascular defects caused by 7MN-treatment (Fig. 35A-F). 7MN treatment did 
however not alter pronephric kidney morphology (Fig. 35 G-H), myogenesis, and 
myoblast migration (Fig. 35J-L). Overall, 7MN and 7CN were comparable in their 
ability to induce edema and to interfere with vascular development in Xenopus 
embryos. The substitution of the methyl group in the naphtyridine moiety for 
chloride was beneficial as this correlated with less toxicity for 7CN compared to 
7MN.  
 
Figure 35. Effects of 7MN treatment on selected organs in Xenopus embryos. 7MN-treated 
embryos were fixed and the expression of hemangioblast (tal1; A-C), erythrocyte (hba3; D-F), 
pronephric kidney (fxyd2; G-I) and myoblasts (myod1; J-L) markers were determined by whole mount 
in situ hybridization. (A-C) 7MN treatment showed abundance of hemangioblasts in ventral blood island 
(arrows) but hemangioblasts were not present in DLP region (arrowheads). (D-F) Erythrocytes were 
restricted to ventral blood island (arrowheads) of 7MN-treated embryos. Morphology and development 
of pronephric kidney (G-I) and differentiation and migration of myoblasts (J-L) were not affected by 
treatment with 7MN. 
Results 
 
89 
 
7MN inhibits endothelial cell proliferation and sprouting 
The similarities in bioactivities between of 7CN and 7MN observed in Xenopus 
embryos extended also to human endothelial cell cultures. Cell proliferation and 
sprouting assays were performed with HUVEC and LEC treated with 7MN. Fig. 36 
shows the effect of 7MN on HUVECs and LECs proliferation, respectively. 7MN 
significantly inhibited VEGFA-induced proliferation of HUVECs at concentrations 
as low as 0.3 µM. For LEC proliferation, 7MN concentrations as low as 1 µM were 
sufficient.  
 
 
Figure 36. Human endothelial cell proliferation is inhibited by 7MN. 7MN was tested in vitro for 
48 hours on LEC and HUVEC cultures, respectively, at the concentrations indicated. SU 4312 
concentration was 10 µM. Cell proliferation was assessed by fluorescent dye labeling and 
photospectrometric quantitation. The data is expressed as mean values ± standard error of mean (SEM) 
with n=8. Results are representative for 3 independent experiments. ** p<0.01, *** p<0.001. 
 
Cell sprouting assays using microcarriers coated with HUVECs and LECs, 
respectively, demonstrated that 7MN was as potent as 7CN (Fig. 37). Minimal 
effective concentrations of 7MN for inhibition of sprout formation were 0.3 µM 
for HUVECs and 0.1 µM for LECs, respectively. These findings mirror the 
situation observed with 7CN (see Fig. 24).  
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Figure 37. 7MN inhibited on endothelial sprout formation. Sprouting of collagen gel-embedded 
microcarriers coated with HUVECs or LECs was induced by VEGFA/bFGF or VEGFA/bFGF/S1P, 
respectively. 7MN concentration tested ranged from 0.1 to 10 µM. SU 4312 concentration was 10 
µM.The data are shown as mean values ± SEM, n=3. Results are representative of 3 and 4 independent 
experiments for HUVECs and LECs, respectively. *p < 0.05, **p < 0.01, *** p<0.001. 
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7MN and 7CN cause mitotic arrest in vitro 
Our in vivo and in vitro studies demonstrated that 7MN and 7CN, but not DEPX, 
inhibited proliferation of blood vascular and lymphatic endothelial cells. We next 
wanted to understand how these compounds interfere with the cell division 
cycle. Therefore, we employed fluorescence-activated cell sorting (FACS) of 
propridium iodide (PI) stained cells after compound treatment to assess their 
DNA content. The experiments were performed with HUVECs and they were 
treated with 7MN, 7CN, and DEPX for 48 hours prior to FACS analysis. 
Nocodazole was used as a positive control as it arrests the cell cycle in M-phase 
(Cooper, 2003). HUVECs were treated with compound concentrations ranging 
from 0.1 to 10 µM in presence of 0.1% DMSO. The results of the flow cytometric 
analysis are shown in Figure 38. On the basis of DNA content, three distinct cell 
populations were identified; 2N (cells with diploid DNA content), 4N (tetraploid 
cells) and >4N (polyploid cells); and their relative abundancies were 
quantitated. The histograms of the FACS analysis of HUVECs after treatment 
with 1 µM of the test compounds are shown to illustrate the profound changes 
observed (Fig. 38A). In the DMSO control, 68% of the cells had DNA content of 
2N and 25% were of 4N. As expected, nocodazole-treated cells were arrested in 
mitosis with increased DNA content: 2% (4N) and 95% (>4N). The DNA content 
of DEPX treated cells was indistinguishable from controls with 67% (2N) and 
27% (4N). For 7CN and 7MN, the numbers were 58% (4N) and 40% (>4N) and 
7% (4N) and 90% (>4N), respectively. This indicates that both compounds 
induce mitotic arrest, but 7MN was moderately more potent than 7CN. The 
observed effects were dose-dependent as shown in Figure 38B. Two peaks in the 
histogram of 7MN and nocodazole represent 8N and 16N DNA contents. At 
concentrations of 3 µM and higher, typically 95-98% of the nocodazole-, 7MN- 
and 7CN-treated cells failed to progress in the cell cycle and they were arrested 
with DNA contents >4N. 7MN and 7CN were therefore comparable with 
nocodazole in their ability to arrest the cell cycle.  
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Figure 38. 7MN and 7CN induce mitotic arrest with increased DNA content. HUVECs were 
treated for 48 hours with the indicated compounds and the DNA contents were measured by FACS. (A) 
FACS analysis of HUVECs treated with test componds at a concentration of 1 µM. The histograms of 
control HUVEC cultures (media, media plus 1% DMSO) and those of compound-treated HUVECs are 
shown. The regions consisting of cells with diploid (2N), tetraploid (4N) and polyploid (>4N) DNA 
contents are indicated. (B) Dose response studies to assess compound-induced mitotic arrest in 
HUVECs. FACS analysis was performed to quantify the percentage of endothelial cells undergoing mitotic 
arrest. The percentage of cells with DNA contents of 2N, 4N and >4N, respectively are indicated. The 
data shown is compilled from three independent experiments.  
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7MN and 7CN disrupt the microtubular cytoskeleton 
Nocodazole arrests cell cycle progression by interfering with the polymerization 
of microtubules. The cells enter mitosis but cannot form metaphase spindles 
because the microtubules cannot polymerize, causing cells to arrest in 
prometaphase. Given that 7MN and 7CN cause mitotic arrest, we asked whether 
they also interfere with the polymerization of microtubules. Cultures of HUVECs 
were therefore treated with the compounds for 2 or 16 hours. Three 
concentrations (1, 3 and 10 µM) were tested. Cells were fixed and stained by 
immunofluorescence for the presence of microtubules. Figures 39 and 40 show 
examples of the stained cells after incubation for 2 and 16 hours, respectively. 
After the 2-hour treatments, the microtubular cytoskeleton of the cells treated 
with nocodazole was disrupted at all concentrations tested (Fig. 39). The cell 
shapes were rounded and there was a pronounced presence of lammelipodia. A 
similar picture was seen with 7MN. However, at the lowest concentration (1 µM), 
cells containing an intact microtubular network were occasionally seen. This was 
even more pronounced in cells treated with 1 µM 7CN, where many cells 
appeared to be normal. Incubation of cells for 16 hours with the compounds did 
not change this general picture (Figure 40). However, multinucleated cells were 
now apparent as more cells became arrested in M phase after duplicating their 
DNA. In summary, both 7MN and 7CN induced disassembly of the microtubular 
network similar to nocodazole.  
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Figure 39. Effects on the microtubular cytoskeleton of HUVECs after a 2-hour treatment with 
7MN and 7CN. HUVECs were treated for two hours with media containing either 0.1% DMSO alone or 
supplemented with 1 µM, 3 µM or 10 µM nocodazole (Noc), 7MN, or 7CN. The cells were fixed and 
stained with a monoclonal anti-α-tubulin antibody to visualize the microtubules. Nuclei were 
counterstained with DAPI. Immmunofluorescence images are shown with the microtubules stained red 
and the nuclei in blue. 
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Figure 40. Effects on the microtubular cytoskeleton of HUVECs after a 16-hour treatment with 
7MN and 7CN. HUVECs were treated for 16 hours with media containing either 0.1% DMSO alone or 
supplemented with 1 µM, 3 µM or 10 µM nocodazole (Noc), 7MN, or 7CN. The cells were fixed and 
stained with a monoclonal anti-α -tubulin antibody of visualize the microtubules. Nuclei were 
counterstained with DAPI. Immmunofluorescence images are shown with the microtubules stained red 
and the nuclei in blue.  
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In vivo identification of vascular disruptive agents 
The formation of new blood and lymph vessel is a hallmark of many pathological 
conditions, such as in cancer and inflammation. In cancer, tumor growth relies 
on attracting the growth of new blood vessel that supply with the tumor with 
oxygen and nutrients. The upregulation of angiogenesis and lymphangiogenesis 
triggers disease progression. Carcinoma cells disperse via blood and lymphatic 
vessel and they survive and grow at distant organs, where they cause 
metastases. Pathological angiogenesis and lymphangiogenesis have therefore 
become attractive targets for tumor therapy (Weis and Cheresh, 2011, Chung et 
al., 2010). The notion is that vascular disruption agents would destabilize the 
vasculature feeding the tumor, cause hypoxia and drive the cancer cells to 
necrosis (Cesca et al., 2013). The effectiveness of this approach in cancer 
therapy has been demonstrated by avastin (bevacizumab), a recombinant 
humanized monoclonal antibody that blocks angiogenesis by inhibiting VEGFA 
(Greillier et al., 2016, Shih and Lindley, 2006). Avastin was the first 
angiogenesis inhibitor to be approved for use in combination with chemotherapy 
to treat metastatic colon cancer. The widespread clinical application of 
angiogenesis inhibitors has however uncovered that tumors are able to resist 
treatment by activating VEGF-independent mechanisms to promote 
angiogenesis. This makes it necessary to develop alternative strategies to 
disrupt vessel growth. To address this need, our laboratory had developed an in 
vivo drug screening strategy using Xenopus embryos to identify small organic 
molecules that interfere with vessel formation or function (Kalin et al., 2009). 
Using edema formation as a highly predictive pathophysiological readout, 32 
compounds were identified as vascular disruptive agents, which also included 
antagonists of AR signaling. In the present thesis, we carried out extensive 
pharmacological studies to explore the specificity, efficacy, and structural 
determinants of a broad range of AR antagonists as a potential inhibitors of 
angiogenesis and lymphangiogenesis in Xenopus embryos and mammalian 
endothelial cell cultures. We found that only two compounds, 7CN and DEPX, 
and derivatives thereof were effective as vascular disruptive agents. 
Furthermore, our in vitro studies indicated that 7CN acts by disrupting the 
microtubular cytoskeleton to cause mitotic arrest.  
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Xenopus embryos as a powerful model to identify the vascular 
disruptive agents in vivo 
Chemical genetic screens to identify biochemical pathways regulating a biological 
process, such as vascular development, require three basic components (Lokey, 
2003). The first component is a chemical library of small organic molecules with 
established pharmacologies; which can include agonists and antagonists 
targeting specific receptors, kinases and other downstream signaling mediators. 
The second component is a meaningful biological assay system, which will be 
used to screen the chemical library for compounds with the desired bioactivity. 
Cell cultures, organ cultures, or whole animals, typically embryos or larvae, may 
serve as test systems. Once bioactive hits have been identified, the final step 
requires the identification and validation of the biological target(s) modulated by 
the active compounds.  
Any chemical library screen will fail, if the biological test system is inadequate to 
start with. In vitro cell culture systems have been widely used by the 
pharmaceutical industry for compound screening. More recently, the 
development of induced pluripotent stem cell technology has opened up the 
possibility of using patient-derived primary cells to develop patient-specific cell 
lines (Robinton and Daley, 2012). In general, in vitro cell cultures are easy to 
establish in multi-well plates; and thus they can be used in high-throughput 
chemical screening strategies aimed at evaluating ten thousands of chemical 
agents for specific bioactivities. In vitro cell cultures represent highly simplified 
tissue states in a well-controlled, but artificial environment. This poses a number 
of limitations. Typically, these cultures consist of a single cell type, which does 
not reflect the complexity of an entire organ. Furthermore, the cell’s behavior 
and organization in vitro can be very different from the in vivo situation, where 
different cells of an organ are interacting and communicating with each other. 
Drug candidates emerging from screens carried out with in vitro culture may 
therefore not show the same effects when tested in vivo. Furthermore, adverse 
side effects of a positive hit, such as toxicities, may not manifest in cell culture 
assays but can become a serious problem later.  
Drug screening using more complex biological systems, such whole animals, 
may offer an attractive alternative (Astashkina et al., 2012). In vivo systems 
have the advantage that the cells to be targeted by a specific drug are present 
in the correct tissue and organ context and the cellular interactions contributing 
to the pathophysiology of disease manifestation are preserved. Furthermore, 
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drug metabolism is only fully possible in animal models. These conditions are 
difficult to reproduce with in vitro systems. Finally, the recent development of 
sophisticated gene knockdown or knockout techniques, including CRISPR-Cas, 
enable now the tailoring of precise animal disease models for drug discovery and 
development (Liu et al., 2016, Schmitt et al., 2014). 
Different animal models have been used during the last fifteen years for whole 
organism-based drug screening, such as Caenorhabditis elegans, Drosophila, 
zebrafish and Xenopus (Pandey and Nichols, 2011, Liu et al., 2016, Schmitt et 
al., 2014). C. elegans and Drosophila are good model systems to address the 
genetics of basic signaling pathways, but they have their limitations when it 
comes to complex human disease processes. Drug delivery is also a problem as 
drugs do not easily penetrate into C. elegans and Drosophila larvae. 
Furthermore compound dosing is difficult due to variations in body size and the 
amount of ingested compound differ among organisms (Pandey and Nichols, 
2011). Zebrafish and Xenopus are the only vertebrate models, which are small 
enough to offer the benefit of performing high-throughput compound screening 
(Wheeler and Brandli, 2009, Schmitt et al., 2014). They have simple husbandry 
requirements, are easy to handle in the laboratory, and they generate large 
number of embryos. Importantly, the embryos and subsequent larvae are small 
enough to grow in multiwell plates, where they can be treated with thousands of 
compounds.  
From an evolutionary point of view, amphibians are evolutionary closer to 
humans than fish. This will transcend into more shared similarities at the 
genomic, histological and physiological levels. This favors the use of Xenopus 
over zebrafish. After hormone stimulation, Xenopus frogs will lay thousands of 
eggs, which can be fertilized in vitro. The embryos can be raised in a simple salt 
solution at room temperature. Test compounds can be added in bathing medium 
from which they are easily absorbed through skin of the embryos and tadpoles 
(Wheeler and Brandli, 2009, Schmitt et al., 2014). In a proof-of-principle study, 
our lab had developed successfully a high-throughput drug screening method to 
identify anti-angiogenic and/or anti-lymphangiogenic compounds using Xenopus 
embryos (Kalin et al., 2009). Furthermore, one of the identified compounds, 
7CN, was shown to suppress VEGFA-induced adult neovascularization in mice. 
Taken together these studies validate the use of Xenopus embryos for in vivo 
drug discovery purposes.  
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AR agonists fail to induce edema in Xenopus embryos  
Several studies have indicated in the past that AR agonists promote 
angiogenesis (Hasko et al., 2008, Auchampach, 2007). For example, topical 
application of A2A AR agonists increases the rate of wound healing, in part, by 
stimulating in angiogenesis in the skin using direct and indirect mechanisms 
(Montesinos et al., 1997). The proliferation of microvascular endothelial cells 
occurs either directly by stimulation of endothelial ARs, e.g. A2A and A2B, or 
indirectly via stimulation of autocrine production of VEGF, a potent angiogenic 
factor. In the chick chorioallantoic membrane model, treatment with the A1 AR 
agonist N6- cyclopentyladenosine (CPA) increases the blood vessel number by 
40% (Clark et al., 2007). Finally, the adenosine analog 5′-N-
ethylcarboxamidoadenosine (NECA), a well-known A1 AR and A2 AR agonist, 
increases blood vessel formation by stimulating VEGF release (Ryzhov et al., 
2007). This raises the question whether AR agonists would interfere with blood 
vessel development in Xenopus embryos and induce edema? 22 different AR 
agonists, including CPA and NECA, were present in the LOPAC library, which was 
screened in vivo to identify edema-inducing compounds (Kalin et al., 2009). At a 
final concentration of 20 µM, none of the 22 AR agonists induced edema 
phenotypes nor did they cause obvious changes in the morphology of Xenopus 
embryos. This is surprising as the collection of AR agonists was diverse by 
including subtype-specific AR agonists as well as those targeting multiple ARs. 
Currently, it is unclear whether AR agonist treatment had any effect on vascular 
development or function in Xenopus embryos. Such effects may first become 
visible after treatment with higher compound concentrations. This may however 
also increase the possibility of unspecific effects of compound treatment. Despite 
the absence of obvious macroscopic phenotypes, we cannot exclude the 
possibility that AR agonists stimulate endothelial cell proliferation in an orderly 
manner without disrupting normal vascular functions. Future studies will have to 
address these issues in greater detail and may possibly reveal subtle vascular 
effects of AR agonists in Xenopus embryos.  
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Pharmacological inhibition of A2A, A2B or A3 AR signaling does not affect 
vascular development 
A two-step screening protocol of the LOPAC library, which was performed 
previously in our laboratory led to the identification of two AR antagonists, 7CN 
and DEPX, with anti-angiogenic and anti-lymphangiogenic activities (Kalin et al., 
2009). The chemical treatments were performed by bathing Xenopus embryos in 
media containing single compounds at a final concentration of 20 µM. These 
findings suggested role for AR signaling in regulating vascular and lymphatic 
vessel development, which was explored in greater detail in the present study. 
AR subtype-specific antagonists for all four ARs were selected and tested for 
their ability to induce dose-dependently edema in Xenopus embryos. The 
findings were clear cut. All A1 AR-specific antagonists plus the A2A selective AR 
antagonist CGS 15943 were found to cause edema formation. Despite its ability 
to induce edema with an EC50 of 2 µM, CGS 15943 did not interfere with blood or 
lymph vessel development in Xenopus embryos. In general, antagonists specific 
for the AR subtype A2A, A2B, and A3 did not show any discernable effects on 
Xenopus embryos, even at 100 µM, the highest concentration tested. These 
findings were surprising given that our in situ hybridization analysis 
demonstrated broad and tissue-specific expression of all four AR genes in 
Xenopus embryos. Given the widespread and partially overlapping expression of 
AR genes, we reasoned that the lack of visible phenotypes may be due to 
functional redundancies. However, even combination treatments with two A2A, 
A2B, and A3 AR antagonists did not result in significant edema formation in 
Xenopus embryos for any two combinations tested. Collectively, this indicates 
that pharmacological inhibition of A2A, A2B and A3 AR signaling is not sufficient to 
disrupt embryonic vascular development or function in Xenopus. Furthermore, 
knockdown of A2A AR gene function using a translation-blocking MO failed to 
have any effect on Xenopus embryogenesis. Blood and lymph vessel 
development occurred unaffected (data not shown). Similarly, mice homozygous 
for a targeted mutation of the A2A AR gene are born viable and fertile suggesting 
that vascular development was unaffected (Ledent et al., 1997). In zebrafish 
embryos, A2B ARs are predominantly expressed in the vasculature within the 
aorta-gonad-mesonephros region and the caudal hematopoietic tissue (Boehmler 
et al., 2009, Jing et al., 2015). Knockdown of A2B ARs interfered with 
hematopoietic stem development, but did not affect general development of the 
embryos. Specifically, mutant embryos had normal heart beating and vascular 
circulation. Furthermore, vascular differentiation was unaffected and intersomitic 
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vessels were observed. Interestingly, treatment of zebrafish embryos with the 
AR antagonist CGS 15943 decreased hematopoietic stem cell emergence without 
altering vascular development and blood circulation (Jing et al., 2015). In 
summary, the pharmacological experiments in zebrafish and Xenopus 
demonstrate clearly that CGS 15943 treatment has no effect on vascular 
development in vertebrate embryos. The reasons why CGS 15943 causes edema 
in Xenopus but not in zebrafish embryos remain unknown. Finally, there is 
currently no genetic evidence suggesting a role for A3 AR signaling in the 
vasculature. According to the Zebrafish Model Organism Database (zfin.org), the 
zebrafish genome is devoid of A3 AR genes. Furthermore, A3 AR-deficient mice 
are phenotypically indistinguishable from wild-type mice (Salvatore et al., 2000). 
We conclude that genetic and pharmacological experiments in zebrafish, 
Xenopus and mouse fail to support an essential function for A2A, A2B, or A3 ARs in 
vascular development.  
A1 AR antagonists induce edema in vivo 
Out of the 14 AR antagonists tested, all four with reported selectivity for A1 ARs, 
namely 7CN, DEPX, PSB 36 and SLV 320, were found to induce in a dose-
dependent manner edema in Xenopus embryos. We therefore were able to 
confirm the edema-inducing activity of 7CN and DEPX previously reported by our 
laboratory (Kalin et al., 2009). The efficacy of these compounds was however 
unknown. On the basis of extensive in vivo dose-response studies, we report 
here the establishment of four pharmacological parameters, EC50, ECmax, LC50 
and TI (Table 18). Irrespective of the pharmacological parameter considered, 
7CN was most potent by inducing edema and lethality at submicromolar 
compound concentrations. 7CN was followed by DEPX, which was effective in the 
low micromolar range. PSB 36 and SLV 320 were very similar and they were the 
least potent compounds with activities typically above 10 µM. Except for SLV 
320 with a TI value of 11, the TI values were very similar (2.1 to 3.4) for the 
other A1 AR antagonists tested. The Ki values for A1 ARs shown in Table 18 were 
taken from the literature and they range between 0.12 and 5 µM. On this basis, 
PSB 36 and 7CN are the most potent A1 AR inhibitors followed by SLV 320 and 
then DEPX. Whereas 7CN was also the most potent edema-inducing compound, 
this was not the case for PSB 36, which was the least potent one in vivo. For a 
number of reasons, these conclusions have however to be taken with some 
caution. The Ki values of the tested compounds for Xenopus A1 ARs are currently 
unknown and the mammalian Ki values were not established identically. For 
Discussion 
 
103 
 
example, the cells used for the displacement studies were not uniform with 
regard to the species and/or tissue origin. Furthermore, it is not clear whether 
the test cells express A1 AR only, or they express other ARs. Furthermore, 
different biochemical assays were used to establish the Ki values in the different 
studies. It is therefore not surprising that widely different Ki values have been 
reported for a given antagonist depending on whether human, bovine or rat A1 
ARs were used (see Table 11). Ideally, the Ki values for a given AR antagonist 
were to be established using a competition assay, where the radiolabeled A1 AR 
antagonist would be displaced by increasing amounts of the unlabeled 
antagonist. Furthermore, these displacement experiments would have to be 
carried out using four different cell lines expressing solely one Xenopus AR 
subtype at a time, but at comparable expression levels. Using the outlined 
approach, one could establish equivocally the Ki values for each antagonist and 
its AR-subtype specificity. This was clearly out of scope for the present project.  
 
Table 18. Comparison between Ki values and selected pharmacological parameters of A1 
AR antagonists 
The Ki values were taken from the published literature (see Table 11 for references). They refer to 
bovine (b), rat (r) or human A1 ARs. The other parameters refer to Xenopus embryos and were 
established in the present thesis (see Table 12, 14 and 16).  
 
  
Compound Ki A1 (nM) EC50 (µM) ECmax (µM) LC50 (µM) TI 
7CN 0.15 (b) 0.3 0.5 0.9 3 
7MN 5.3 (b) 0.3 0.38 0.4 1.3 
DEPX 44 (r) 2.4 4.9 5.3 2.2 
DPPX 10 (r) 2.7 4.8 5.7 2.1 
PSB 36 0.12 6.7 10 23 3.4 
SLV 320 1 2 10 22 11 
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Only a subset of A1 AR antagonists affect blood and lymph vessel 
development in vivo 
Whereas all four AR antagonists with reported selectivity for A1 AR were found to 
induce edema, only 7CN and DEPX were effective in interfering with vascular 
development. Thus, PSB 36 and SLV 320 must cause edema via some other 
mechanism. Despite the robust A1 AR expression in the developing pronephric 
kidney, we did not observe any renal morphogenesis defects in compound-
treated embryos. At present, we however cannot rule out the possibility that 
edema formation by A1 AR antagonist results from interfering with vital 
pronephric kidney functions. This raises the question, whether the four 
antagonists indeed share in vivo A1 ARs as their primary target? Several pieces 
of evidence argue that this is probably not the case. First, we observed 
differences in the patterns of edema that were induced after compound 
treatment. Embryos treated with PSB 36 and SLV 320 developed ventral edema. 
By contrast, 7CN and DEPX treatment resulted in a more complex pattern of 
edema formation with fluid accumulation manifesting in close proximity to the 
developing heart, pronephric kidneys, and the blood island; described here as 
pericardial, pronephric and ventral edema. These phenotypic differences strongly 
suggest that the test compounds act at the molecular level differently in vivo. In 
fact, we had previously reported that compound treatment can cause different 
types of edema and that compounds targeting the same pathway share the 
same anatomical pattern of edema formation in Xenopus embryos (Kalin et al., 
2009). In addition, there were differences in the timing of edema induction. 
Embryos treated with 7CN and DEPX develop edema early, starting at stages 
37/38, whereas edema were first detected from stage 42 onwards in PSB 36- 
and SLV 320-treated embryos. The phenotypic differences seen in vivo between 
the two subsets of A1 AR antagonists (7CN, DEPX; PSB 36, SLV 320) are 
therefore indicative that, besides A1 ARs, they may have additional, subset-
specific targets or, alternatively, they may engage completely different 
molecular targets. Given this, we asked whether A1 ARs are at all the relevant in 
vivo targets of the four A1 AR antagonists studied here? As mentioned earlier, 
we were unable to demonstrate any significant A1 AR expression in the 
developing blood and lymphatic vasculature. Furthermore, knockdown of A1 AR 
gene function using a translation-blocking MO did not impair Xenopus 
embryogenesis, failed to induce edema, and had no effects on vascular 
morphogenesis or function (data not shown). This is consistent with findings in 
the mouse, where the loss of A1 AR gene function does not cause any apparent 
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phenotype and homozygous mutants are viable and fertile. Furthermore, 
homeostasis as well as cardiovascular and renal functions of the mutant animals 
are indistinguishable from controls (Sun et al., 2001). Collectively, these findings 
strongly suggest that neither the edema phenotypes seen with all A1 AR 
antagonists tested here nor the vascular phenotypes observed after 7CN and 
DEPX treatment of Xenopus embryos can be attributed to the inhibition of A1 ARs 
only. It is therefore likely that the different edema phenotypes observed after 
treatment of Xenopus embryos with A1 AR antagonists have to be attributed to 
the complex and presently poorly understood polypharmacologies of the 
compounds used.  
Structure-activity relationship studies reveal critical molecular 
determinants for bioactivity in vivo 
The assessment of AR antagonists in Xenopus embryos has led to the 
identification of two compounds, 7CN and DEPX, that harbor the desired anti-
angiogenic activities in vivo. Structurally, these two lead compounds have little 
in common (Table 19). Similar to caffeine, DEPX is based on a methylxanthine 
scaffold, but carries also a phenyl group. By contrast, 7CN is a naphthyridine 
derivative, with no structural resemblance to the natural AR ligands adenosine 
and caffeine. As DEPX, it carries a phenyl group substitution. Structure-activity 
relationship (SAR) studies were carried out to determine the relationship 
between key chemical structure determinants and the biological activity of the 
two lead compounds. The SAR studies were presently limited to commercially 
available derivatives of DEPX and 7CN, respectively (Table 19). The compounds 
were tested in a dose-dependent manner in Xenopus embryos.  
Three derivatives of DEPX, DMPX, DPPX and DPSPX, were tested. Interestingly, 
in vitro studies have shown that all compounds have affinities to ARs ranging 
from low to high nanomolar concentrations (see Table 14). The AR subtype 
selectivity has to date not been completely resolved for all four compounds, but 
the reported Ki values are typically lowest for A1 ARs. DMPX and DPSPX were 
previously shown to be inactive at 20 µM in Xenopus embryos (Kalin et al., 
2009). These observations were here confirmed for both compounds with test 
concentrations up 100 µM. These findings were rather surprising, particularly for 
DMPX, which is the DEPX derivative with the highest reported affinity for A1 ARs. 
By contrast, in vivo testing demonstrated that DPPX was as potent as DEPX at 
inducing edema in Xenopus embryos and it also disrupted vascular development. 
Furthermore, DPPX and DEPX share similar anatomical patterns of edema 
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induction, which suggests that they interfere via the same molecular target(s) in 
vivo. The functional equivalence is further demonstrated by nearly identical TI 
values. Structurally, DMPX, DEPX and DPPX differ only in the length of the 1,3 
substitutions of the phenylxanthine core structure. Given that DMPX was inactive 
in vivo, we can conclude that the ethyl or propyl moieties are essential for 
bioactivity. This conclusion is further supported by the fact that embryos treated 
with caffeine (1,3,7-trimethylxanthine) do not develop edema (Kalin et al., 
2009)(see also Table 10). The presence of the phenyl group is also essential for 
bioactivity of DEPX and DPPX. Theophylline, one of the primary liver metabolites 
of caffeine, is also known as 1,3-Dimethylxanthine. Thus, it lacks the phenyl 
substitution found in DEPX and DPPX. While not explicitly tested in the present 
study, it had previous been shown that theophylline does not induce edema in 
Xenopus embryos (Kalin et al., 2009) (see also Table 10). Finally, sulfonation of 
the phenyl moiety abrogates the in vivo activity of DPPX as demonstrated by the 
treatment of embryos with DPSPX.  
Regarding 7CN, two derivatives, 7MN and 7CH, were also tested in vivo. 7MN 
carries a 7-methyl substitution in place of the chloro substitution found in 7CN. 
With a Ki value of 5.3 nM, it has more than 30-fold less affinity for A1 ARs than 
7CN (Ferrarini et al., 2000) (see also Table 16). We found however that this 
substitution had no negative influence on the ability to induce edema. 
Furthermore, the pattern of edema formation and the vascular defects in 
Xenopus embryos were as with 7CN. If anything, 7MN was more toxic than 7CN 
resulting in a less favorable TI value. 7CH turned out to be devoid of any edema 
inducing activity demonstrating that the presence of a phenyl moiety is 
indispensable for bioactivity. We conclude that both DEPX and 7CN require 
phenyl substitutions to the core scaffolds for full in vivo activity, i.e. the ability to 
induce edema.  
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Table 19. Chemical properties of 7CN, DEPX, and their derivatives 
Structure Name Molecular weight XlogP 
 
Adenosine 267.24 -1.1 
 
Caffeine 194.19 -0.1 
 
Theophylline 180.16 -0.17 
 
1,3-Dimethyl-8-
phenylxanthine 
(DMPX) 
256.26 2.2 
 
1,3-Diethyl-8-
phenylxanthine 
(DEPX) 
284.31 2.9 
 
1,3-Dipropyl-8-
phenylxanthine 
(DPPX) 
312.37 4.0 
 
1,3-Dipropyl-8-(p-
sulfophenyl) 
xanthine (DPSPX) 
392.43 3.1 
 
7-Chloro-4-hydroxy-
2-phenyl-1,8-
naphthyridine (7CN) 
256.68 3.4 
 
7-Methyl-2-phenyl-
1,8-naphthyridin-
4(1H)-one (7MN) 
236.37 3.61 
 
7-Chloro-4-hydroxy-
[1,8] naphthyridine 
(7CH) 
180.59 1.8 
The chemical structures, molecular weights and the computer-predicted logP (XlogP) values of 7CN, 
DEPX, and their derivatives were taken from the ChemSpider (chemspider.com) and PubChem 
(pubchem.ncbi.nlm.nih.gov) databases. 
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Physicochemical properties and in vivo bioactivities of AR antagonists 
The central aim of SAR studies is to reveal possible connections between the 
chemical structure of a compound with its physicochemical properties (water 
solubility, molecular weight, etc.) and its biological activities, such efficacy, 
toxicity, and lethality (Lushington et al., 2013, Ritchie, 2001). Besides the 
known compounds 7CN and DEPX, two novel ones, 7MN and DPPX, emerged as 
additional compounds with largely similar in vivo properties as their parent 
compounds. All four compounds have been developed as AR antagonists with Ki 
values for A1 ARs ranging between 0.15 (for 7CN) and 44 nM (DEPX). By 
contrast, the differences in the EC50 and LC50 values obtained in vivo for the four 
compounds were less pronounced, typically not more than 10 fold. This indicates 
that there is no direct correlation between the reported in vitro affinities for A1 
ARs and the observed bioactivities of the test compounds in Xenopus embryos. 
We conclude that the anti-angiogenic activities of 7CN and DEPX cannot be 
solely attributed to the inhibition of A1 AR signaling in vivo.  
The A1 AR antagonists PSB 36 and SLV 320 induced edema, but had no anti-
angiogenic activity. Whereas the A1 AR antagonists DMPX and DPSPX had no 
edema-inducing activity at all. Interestingly, PSB 36, SLV 320 and DMPX are 
considered to be potent A1 AR antagonists with Ki values of 1 nM or less. 
Nevertheless, they have in vivo no antiangiogenic activity. The lack of bioactivity 
may be attributed to reduced absorption or penetration of these compounds into 
Xenopus embryos. Studies in zebrafish indicate that the logarithm of the 
partition ratio between octanol and water (logP) of a compound correlates well 
with a compound’s membrane permeability (Sachidanandan et al., 2008, Milan 
et al., 2003). Compounds with logP values higher than +1 were well absorbed 
and active (Wheeler and Brandli, 2009). As shown in Table 19, the computer-
predicted logP values, XlogP, were for the 7CN and DEPX derivatives in the 
range of 1.8 to 4.0. Furthermore, PSB 36 and SLV 320 had XlogP values of 4 and 
3.3, respectively. Thus, all these compounds are expected to penetrate aquatic 
larvae including Xenopus embryos. By contrast, the lack of bioactivity of caffeine 
and theophylline in Xenopus embryos could, at least in part, be attributed to 
poor penetration given that they have XlogP values below +1. With regard to 
compound size, active compounds exhibited no bias at least up to molecular 
weights of 700 Da. None of the tested compounds exceeded this empirical 
threshold (Table 19). At present, we cannot exclude the possibility that some 
compounds might have become inactive due to rapid metabolism and 
biotransformation in the embryo.  
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Endothelial cells are direct targets of 7CN and 7MN 
The described anti-angiogenic effects of a subset of A1 AR antagonists in 
Xenopus embryos raises the question whether these compounds have similar 
activities on mammalian endothelia, which is a prerequisite if they were to be 
developed as drug candidates for clinical testing. Primary human blood and 
lymphatic endothelial cell cultures were employed to assess the effects of 
compound treatment on cell proliferation and sprouting ability. It was previously 
demonstrated that 7CN blocks cell proliferation and tube formation of both blood 
and lymphatic endothelia in vitro. Furthermore, 7CN interferes with VEGFA-
induced neovascularization in adult mice (Kalin et al., 2009). Here we found that 
7CN as well as 7MN inhibited both the proliferation and sprouting of endothelial 
cells in vitro. Both compounds blocked proliferation of human blood and lymph 
endothelial cells at concentrations in the low µM range. To inhibit sprouting, 
compound concentrations as low as 0.1 µM were sufficient. Interestingly, edema 
formation and disruption of vascular development in Xenopus embryos was 
achieved at comparable compound concentrations. Taken together, 7CN and 
7MN interfered with endothelial cell functions in vitro as well as in vivo; and this 
occurred across vertebrate species ranging from Xenopus to humans. 
Furthermore, the in vitro experiments indicate that the molecular targets of 7CN 
and 7MN causing the arrest of cell proliferation and sprouting are present in 
blood and lymphatic endothelial cells.  
DEPX and DPPX exert their anti-angiogenic activities via an indirect 
mechanism 
Besides 7CN and 7MN, we have also demonstrated that DEPX and DPPX act as 
edema-inducing, anti-angiogenic compounds in Xenopus embryos. However, 
they had, at best, marginal in vitro effects on the proliferation of human blood 
and lymphatic endothelial cells. Furthermore, DEPX did not interfere with in vitro 
sprouting irrespective of the vascular cell type tested. Taken together, the 
Xenopus experiments demonstrate unequivocally that DEPX and DPPX have anti-
angionic activities in vivo, but these compounds appear to be inactive when 
tested in vitro using human endothelial cell cultures. At present, we cannot 
exclude the possibility that the vascular targets of DEPX and DPPX in Xenopus 
embryos are either not present in the mammalian vasculature or they lack 
sufficient conservation. This would imply that the anti-angiogenic effects of DEPX 
and DPPX are species-specific and limited to Xenopus or other amphibians. If 
this were indeed the case, this would of course disqualify DEPX and DPPX for 
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further pre-clinical development. Alternatively, the anti-angiogenic activities 
observed in Xenopus embryos but not in vitro using human endothelial cell 
cultures may indicate a requirement for metabolic transformation of DEPX and 
DPPX in the liver. To our knowledge, there are no reports in the literature 
describing the metabolism of DEPX or DPPX in vertebrate organisms. Future in 
vivo studies using either mice or rats will therefore be necessary to address the 
issues of species-specific bioactivities and liver metabolism of DEPX and DPPX. 
Finally, our findings could be consistent with a model, where the anti-angiogenic 
activities of DEPX and DPPX observed in vivo are of indirect nature, not involving 
endothelial targets.  
A model of paracrine stimulation of angiogenesis has been described by Clark et 
al. (2007), where adenosine-mediated activation of A1 ARs on human 
mononuclear cells (macrophages, monocytes) promotes release of VEGFA, a 
potent stimulator of angiogenesis. Treatment of the cells with the A1 AR selective 
antagonists WRC-0571 or CPX blocked the A1 AR-mediated release of VEGFA. 
These findings are consistent with the hypothesis that A1 ARs modulate 
angiogenesis through an indirect mechanism involving stimulation of 
inflammatory cells (Clark et al., 2007). It should be however noted that CPX 
treatment has no effect on Xenopus embryogenesis (Kalin et al., 2009)(see also 
Table 10). Nevertheless, it is conceivable that DEPX and DPPX treatment of 
Xenopus embryos disrupts paracrine proangiogenic signaling mechanisms. For 
example, VEGFA is highly expressed in the developing somites, where it appears 
to act as a proangiogenic factor for intersomitic vessel growth in Xenopus 
embryos (Kalin et al., 2007). Here we have demonstrated that somites express 
predominantly A2A and A2B ARs indicating that somites are responsive to 
extracellular adenosine. Whether DEPX or DPPX treatments have any effects on 
somitic VEGFA expression in Xenopus embryos is currently not known. Taken 
together, it is most likely that DEPX and DPPX elicit their vascular disruptive 
activities in vivo via an indirect mechanism, for example by inhibiting the release 
of pro-angiogenic factors from non-endothelial cells.  
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7CN and 7MN inhibit endothelial cell proliferation and sprouting by 
destabilization of the microtubular cytoskeleton 
Our findings with primary endothelial cell cultures demonstrate that 7CN and 
7MN exert their activities by directly targeting endothelial cells. Both compounds 
showed strong anti-proliferative effects on HUVEC and LEC cultures. FACS 
analysis revealed that the compound-treated cells were arrested in pro-
metaphase with tetraploid (4N) and/or polyploid (>4N) DNA contents. As 
expected, DEPX treatment did not cause any cell cycle arrest and the DNA 
content of the treated cells was 2N as with controls. These findings are 
consistent with the proposed indirect mechanism of action for DEPX (and DPPX) 
on endothelial cells in vivo. Disruption of microtubule assembly or disassembly 
both inhibits mitosis and induces excess DNA replication (Kavallaris, 2010). 
Indeed, we found that 7CN and 7MN were able to destabilize the microtubular 
cytoskeleton. Disruption of the cytoplasmic microtubules was rapid, detectable 
already two hours after compound addition to the media, and the effect was 
dose-dependent. Disassembly of the microtubular cytoskeleton was similar to 
the effects seen after treatment with nocodazole, a widely used agent to 
interfere with microtubule polymerization (Vasquez et al., 1997). Nocodazole-
treated cells do enter mitosis but cannot form metaphase spindles because the 
microtubules are no longer able to polymerize. Microtubules are composed of 
tubulin molecules, which are heterodimers, composed of αβ subunits. Both α and 
β subunits exist as numerous isotypes differing in amino acid sequence and 
encoded by different genes. High-resolution crystal structures have revealed 
that nocodazole binds to a site located deep in the β subunit of unassembled 
tubulin (Kavallaris, 2010, Zhou and Giannakakou, 2005). This binding site is 
known as the colchicine-binding site (CBS) that can be occupied by a set of 
structurally diverse inhibitors of microtubule polymerization, which includes 
colchicine, nocodazole, and plinabulin. Nocodazole binding prevents microtubule 
formation either by restricting the subdomain movements that are essential for 
structural transformation or by steric interference with the α subunit of tubulin 
(Barbier et al., 2010, Ravelli et al., 2004). Besides the CBS, most microtubule-
disrupting agents in development will target one of four other distinct binding 
sites on β-tubulin; namely the laulimalide, vinca alkaloid, taxane, or maytansine 
binding sites (Wang et al., 2016, Prota et al., 2014). At present, we do not know 
whether the observed microtubule-destabilizing activity of 7CN and 7MN is 
mediated by binding to tubulin or occurs via an indirect mechanism. 7CN and 
7MN share no structural resemblance with, nocodazole, colchicine or any of the 
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other compounds defining the five distinct binding sites on β-tubulin targeted by 
microtubule-destabilizing agents (data not shown). This fact does however not 
exclude the possibility that 7CN and 7MN directly bind to tubulin. This issue 
needs to be addressed in future studies. Alternatively, the two compounds could 
act on microtubules via an indirect mechanism. The stability of microtubules is 
regulated by proteins, which interact with the microtubular lattice, known as 
microtubule-associated proteins (MAPs). Many different MAPs, such as MAP1, 
MAP2, MAP4, and tau, have been identified in recent years and they can carry 
out a wide range of functions, which includes both stabilization and 
destabilization of microtubules (Janke and Bulinski, 2011). The activity of MAPs 
is regulated via phosphorylation, for example by the microtubule-affinity-
regulating kinase (MARK). Phosphorylation typically causes detachment of MAPs 
and followed by destabilization of microtubules (Drewes et al., 1997, Akhmanova 
and Steinmetz, 2015). Besides MAPs, many other proteins can interfere with 
microtubule function. For example, katanin is a microtubule-severing 
heterodimeric protein with an intrinsic ATPase activity (Nakamura, 2015, Sharp 
and Ross, 2012). Taken together, assembly and disassembly of microtubules is 
governed via a complex system of regulation involving many different proteins, 
whose activities are in part controlled by phosphorylation or other 
posttranslational mechanisms. Which aspect of this elaborate regulatory 
machine becomes altered after treatment with 7CN or 7MN is still a big mystery. 
The identification of the relevant intracellular targets of 7CN and 7MN should 
therefore be pursued with high priority.  
Tissue and cell-type selectivities of the active compounds  
The assessment of AR antagonists in Xenopus embryos has led to the 
identification of four compounds, 7CN, 7MN, DEPX and DPPX that harbor the 
desired anti-angiogenic activities in vivo. Our findings demonstrate that all four 
compounds disrupted blood as well as lymph vessel formation in embryos up to 
about embryonic stage 40 (2.5 days post fertilization), the last stage 
investigated. We also asked whether these compounds affect the development 
or morphogenesis of other embryonic tissues. Specifically, pronephric kidney 
morphogenesis, hemangioblast specification, erythrocyte differentiation, and the 
formation of migratory myoblasts were investigated and none of these processes 
appeared to be impaired by compound treatment. While the list of tissues and 
organs assessed is not exhaustive, it appears that compound treatment of 
embryos between stage 29/30 and stage 40 selectively interferes with functions 
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of blood and lymphatic endothelia. Furthermore, general cytotoxicity of the 
compounds can be excluded. On the basis of in vitro experiments with primary 
human endothelia cells, we found that 7CN and 7MN blocked cell proliferation by 
destabilizing microtubules to cause mitotic arrest. By contrast, DEPX and DPPX 
were essentially inactive in vitro, which suggests that both compounds exert 
their effects on the developing vasculature of Xenopus embryos via an indirect 
mechanism. The molecular nature of this mechanism, and whether it requires 
other embryonic cell types is presently unknown. We also formally cannot 
exclude the possibility that the molecular targets of DEPX and DPPX are not 
conserved between Xenopus and human endothelial cells. If this were the case, 
this would explain why DEPX and DPPX treatment does not show any significant 
effect on human endothelial cell but has profound effects in Xenopus embryos. 
Irrespective of which scenario turns out to be correct, the potential of DEPX and 
DPPX as drug candidates for therapeutic applications in patients is strongly 
diminished given the lack of compound activities in primary human endothelial 
cell cultures. 
Whereas 7MN remains poorly studied, several pieces of evidence indicate that 
the antiangiogenic and anti-proliferative effects of 7CN reported here are not 
entirely selective for endothelial cells. High-throughput screens of the LOPAC 
chemical library for compounds with inhibitory activities towards mammalian 
tumor cells in vitro led to the identification of 7CN as an active compound. This 
included mouse mammary tumor cell lines, where the IC50 values were between 
3-4 µM (Evers et al., 2010). Similarly, 7CN was cytotoxic for human breast 
cancer cell lines LM2 and MDA-MB-231 (Desmet et al., 2013). Finally, 7CN was 
active in a screen for compounds that induce excess DNA replication in both the 
human colorectal cancer cell line SW480 and in the human breast epithelial cell 
MCF10A with EC50 values ranging between 2-7 µM (Zhu et al., 2011). 9 of 15 
active compounds emerging from the screen, such as taxol, colchicine and 
nocodazole, are known to affect microtubule dynamics. This implies that 7CN 
has probably a similar destabilizing activity on microtubules, which is a 
hypothesis that was now confirmed in the present study. Collectively, these 
studies demonstrate that 7CN acts antimitotic in the low micromolar range on 
several mammalian cell lines derived from different cancer types.  
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The fact that 7CN (and 7MN) treatment selectively disrupts blood and lymph 
vessel development without apparent effects on other tissues and organs of the 
Xenopus embryo appear to be surprising at first glance. The in vivo activities of 
7CN were however also confirmed in the mouse (Kalin et al., 2009). With regard 
to Xenopus embryos, these findings may indicate that endothelial cells are the 
primary cells undergoing rapid cell proliferation between embryonic stages 29/30 
to 40, when compound treatment occurred. This hypothesis needs to be 
addressed in future studies. Importantly, 7CN was unique as none of the other 
AR antagonists present in the LOPAC library scored positive in the in vitro 
screens targeting cancer cells (Desmet et al., 2013, Zhu et al., 2011, Evers et 
al., 2010). This provides further circumstantial evidence supporting the notion 
that the antiangiogenic and anti-proliferative activities of 7CN (and 7MN) are not 
related to the known effects on AR signaling.  
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Conclusions 
The central aim of the present thesis project was to explore whether AR 
antagonists could be used as pharmacological agents to selectively disrupt blood 
and lymph vessel formation in Xenopus embryos. The project was inspired by 
the previous findings that 7CN and DEPX, two known A1 AR selective 
antagonists, caused edema formation and disrupted vascular development in 
Xenopus embryos (Kalin et al., 2009). In the present thesis, testing of a 
comprehensive panel of 14 AR subtype-selective antagonists demonstrated that 
only two compounds, 7CN and DEPX, were able to induce edema and interfere 
with vascular development in Xenopus embryos. We established that these two 
compounds exert their activities at concentrations in the high nanomolar to low 
micromolar range. The calculated therapeutic indices were between 2 to 3 
indicating a narrow therapeutic window. Structure-activity relationship studies 
identified first structural determinants important for the observed activities of 
7CN and DEPX, respectively. In vitro studies with human endothelial cell cultures 
suggest that 7CN and DEPX act via different mechanisms in vivo. 7CN acts 
directly on endothelial cells to block cell proliferation and sprouting, whereas 
DEPX appears to act indirectly without any significant effects on endothelial cells 
in culture. Whether DEPX needs to be metabolized in vivo to exert is 
antiangiogenic function or whether it targets specific cells exerting pro-
angiogenic activities remains to be determined. In Xenopus embryos, the 
activity of 7CN (and its derivative 7MN) appear to be selective for endothelia of 
the blood and lymph vasculature. However, it appears that also tumor cells 
respond to 7CN treatment. Several pieces of experimental evidence suggest that 
the antiangiogenic activities of 7CN cannot be solely attributed to its known 
biochemical activity as an A1 AR selective antagonist. No other AR antagonist 
had comparable activities in Xenopus. Furthermore, we found no significant A1 
AR gene expression in the vascular systems of Xenopus embryos. Finally, 
knockdown of A1 AR gene function did not result in edema formation or 
abnormal vascular development. Overall, this suggests that the inhibition of A1 
AR signaling by 7CN does not sufficiently explain the observed endothelial 
phenotypes. In fact, in vitro studies indicate that 7CN treatment of endothelial 
cells has a profound impact on the cytoskeleton, where it appears to interfere 
with the dynamics of microtubules. We conclude that our studies have identified 
7CN and DEPX as unique compounds with potent anti-angiogenic activities in 
vivo. They act via distinct, at present poorly understood mechanisms, to exert 
their effects on endothelial cell functions. 
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Outlook 
The present work demonstrated clearly that the treatment of Xenopus embryos 
with the AR antagonists 7CN and DEPX interferes with blood and lymph vessel 
formation in a dose-dependent manner. We also identified derivatives of 7CN 
and DEPX that have similar bioactivity in vivo. Finally, we showed that 7CN acts 
by destabilizing microtubules of endothelial cells resulting in mitotic arrest, and 
excess DNA replication. The potential of these compounds as future vascular 
disruptive agents for clinical applications remain intact. The physicochemical 
properties of 7CN and DEPX comply with Lipinski’s Rule of Five, an empirical 
measure of druglikeliness and potential of a drug candidate to become an orally 
active drug in humans (Lipinski, 2004). Importantly, both compounds have 
molecular masses less than 500 daltons and logP value not greater than 5. 
Drug-plasma protein binding is an important major determinant of drug 
distribution and elimination. High affinity of a drug for human serum albumin 
(HAS), while diminish the free drug concentration available to the site of action. 
In a high-throughput screen of the LOPAC chemical library, neither 7CN nor 
DEPX were identified as compounds with high capability of HSA binding 
(McCallum et al., 2014). Furthermore, an analysis of the LOPAC library for 
compounds capable of inducing cardiotoxicity associated with the inhibition of 
the human ether-a-go-go-related gene (hERG) channel failed to highlight 
cardiotoxic potentials for 7CN or DEPX (Titus et al., 2009). Taken together, 7CN 
and DEPX have drug-like properties warranting further development and they 
can be considered lead compounds suitable to enter the lead optimization phase 
of preclinical drug development.  
Lead optimization will require the synthesis of an array of derivatives by 
medicinal chemists with the aim of identifying variants with improved efficacy, 
higher target affinity, and reduced toxicity profiles. For example, it would be 
desirable to develop an improved version of 7CN, with an EC50 value in the low 
nanomolar range, while preserving or raising the current LC50 value well above 1 
µM. This would improve the therapeutic index significantly. Having access to the 
crystal structure of the drug target can facilitate lead optimization. As discussed 
extensively in the introduction, several crystal structures for the A2A AR have 
been determined at high resolution and in the presence of key agonists and 
antagonists. In the present case, this structural information is however of limited 
utility. First, 7CN and DEPX have significantly higher affinities for A1 than A2A ARs 
(see Table 11). Secondly, the work presented here provides compelling evidence 
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that the observed activities of 7CN and DEPX imply other targets than ARs only. 
We cannot exclude that they are the result of polypharmacology. As a first test 
of this hypothesis, it will be important to perform compound-treatment 
experiments with A1 AR knockdown embryos. If our hypothesis is correct, these 
embryos should develop edema and have vascular defects. Subsequently, it will 
be important to identify the nature of the targets that are responsible for the 
antiangiogenic effects of 7CN and DEPX in Xenopus embryos. We suspect that 
7CN and DEPX interact with different targets, as they exert their antiangiogenic 
activities via two distinct mechanisms. Target identification for DEPX will help in 
understanding how this compound acts antiangiogenic without directly targeting 
endothelial cells.  
The two-step in vivo screening strategy described by Kalin et al. (2009) that led 
to the identification of 7CN and DEPX as antiangiogenic compounds used edema 
formation as a relevant pathophysiological read out of compound-inflicted 
defects in blood and lymphatic vessel formation or function. In a second step, 
compound validation relied on whole mount in situ hybridization to identify those 
edema-inducing compounds capable of disrupting vascular development. While 
this strategy was highly successful, it does not address the issue of endothelial 
cell selectivity, which is one of the desirable features of a vascular disruptive 
agent. In fact, as discussed above 7CN not only acts antiproliferative for 
different primary human endothelial cells, but also has similar activities towards 
mammalian tumor cell lines. We would therefore propose to modify the 
screening strategy of Kalin et al. (2009) by a third step. This third step would 
screen all positive hits with antiangiogenic activity in vivo across a panel of 
human endothelial, selected non-endothelial and tumor cell lines to identify 
those that are truly selective for human endothelial cells. This third step would 
also eliminate that compounds whose antiangiogenic activities are specific to 
Xenopus. This third step relies fully on in vitro cell cultures and thus has also 
disadvantages. For example, DEPX would not score as a positive hit, since it acts 
in vivo via an indirect mechanism. Overall, however we believe that the 
proposed third screening step would provide sufficient stringency to further 
prioritize compounds for lead optimization.  
We would like to end by stressing the importance of whole animal drug 
screening to identify promising drug candidates. This is nicely illustrated by the 
discovery of DEPX and the characterization of its activities in the present study. 
DEPX and subsequently its derivative DPPX were shown to interfere selectively 
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with vascular development of Xenopus embryos. These compounds would not 
have been identified in chemical library screens performed with in vitro cultures 
of endothelial cells. They do not seem to require direct targeting of the 
vasculature in order to exert their antiangiogenic effects in vivo. In fact, a 
recently described phenotype-based in vitro screening assay designed to identify 
inhibitors of lymphangiogenesis present in the LOPAC chemical library was 
successful in identifying 7CN, but failed to detect DEPX (Schulz et al., 2012). 
Conventional cell culture screening systems typically do not adequately 
reproduce metabolic compound modifications or liver-based biotransformation 
processes that may be essential for the compound activity in vivo. We are 
therefore confident that phenotypic drug discovery in small vertebrate 
organisms, such as Xenopus or zebrafish larvae provide a much need alternative 
to conventional approaches of drug discovery.   
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Appendix
Abbreviation
7CH   7-Chloro-4-hydroxy-[1,8] naphthyridine 
7CN   7-chloro-4-hydroxy-2-phenyl-1, 8-naphthyridine 
7MN    7-Methyl-2-phenyl-1, 8-naphthyridin-4(1H)-one (7-MN) 
7 TM   7 transmembrane 
Ado   Adenosine 
ADA   Adenosine deaminase 
ADP   Adenosine diphosphate 
ADME   Absorption, distribution, metabolism, and excretion 
AGTR   Angiotensin receptors 
ALH   Anterior lymph heart 
ALS   Anterior lymph sac 
AMP   Adenosine monophosphate  
Ang   Angiopoietin 
ARs   Adenosine receptors 
ATP   Adenosine triphosphate 
AURK   Aurora kinase 
bFGF   Fibroblast factor 
cAMP   Cyclic AMP 
CBS   Colchicine-binding site 
CCR   Chemokine receptors 
CNR   Cannabinoid 
CPA   Cyclopentyladenosine 
CRD   Cysteine-rich domains 
CT   Connecting tubule 
DEPX   1, 3-Diethyl-8-phenylxanthine 
DPPX,   1, 3-Dipropyl-8- phenylxanthine 
DMPX   1, 3-Dimethyl-8-phenylxanthine 
DMSO   Dimethyl sulfoxide 
DPSPX  1, 3-Dipropyl-8-(sulfophenyl) xanthine 
DT   Distal tubule 
EC   Extracellular 
EC50   Half of effective concentration 
ECmax   Concentration with maximum effect 
ECL   Extracellular loop 
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ECD   Extracellular domains 
EDNR   Endothelin 
ENTPD1  Ectonucleoside triphosphate diphosphohydrolase 1 
ERK   Extracellular signal-regulated kinase 
FA   Formamide 
FCF   Fetal Calf serum 
FCM   Flow cytometer 
FDA   Food and Drug Administration 
FDZs   Frizzled receptors 
FGF   Fibroblast growth factor 
FSHR   Follicle stimulating hormone receptor 
GAIN   GPCR autoproteolysis-inducing domains 
G proteins   Guanosine nucleotide-binding proteins 
GEFs   Guanine-nucleotide exchange factors 
GIRK   G-protein-coupled inwardly rectifying potassium 
GPCRs  Guanylyl – nucleotide - binding protein-coupled receptors 
GRKs   GPCR kinases 
GPS   GPCR proteolytics 
GRMs   Metabotropic glutamate receptors 
HAS    Human serum albumin 
HB   Hybridization buffer 
hERG    Human ether-a-go-go-related gene 
HIF   Hypoxia-inducible factor 
Hpf   Hours post fertilization 
HUVECs  Human umbilical vein endothelial cells 
ICL   Intercellular loop 
IL   Interleukin 
IP3   Inositol-triphosphate 
IT   Intermediate tubule 
ISVs   Intersomitic veins 
JNK   C-jun N-terminal kinase 
KCl   Potassium chloride 
LC50   Half of lethal concentration 
LECs   Lymphatic endothelial cells 
MAB   Maleic Acid buffer 
MAPK   Mitogen-activated protein kinase 
MCD   Mitotic cell death 
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MCHR   Melanin-concentrating hormone receptors 
MgSO4  Magnesium sulfate 
MMR   Marc's Modified Ringers 
NaCl   Sodium chloride 
Noc   Nocodazole 
NPY   Neuropeptide 
P2Y   Purinergic receptors 
PBS   Phosphate buffered saline 
PCVs   Posterior cardinal veins 
PET   Positron emission tomography 
PDE   Phosphodiesterases 
PI   Propidium Iodide 
PI3   Phosphoinositide 3-kinase 
PIP   Phosphatidylinositol bisphosphate 
PLC   Phospholipase C 
PLVs   Posterior lymph vessels 
PT   Proximal tubule 
PTW   PBS tween 20 
RCC   Renal cell carcinoma 
RHO   Rhodopsin 
RT   Room temperature 
S1P   Sphingosine-1-phosphate 
SAR   Structure activity relationship 
SSC   Saline-sodium citrate 
SMC   Smooth muscles cell 
T2R   Taste 2 receptors 
TM   Transmembrane 
TSP   Thrombospondin 
VDA   Vascular disruption agents 
VFD   Venus fly trap domains 
VEGF   Vascular endothelial growth factor 
VVNs   Vitelline vein networks
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